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A b s t r a c t  
 
Alzheimer’s disease (AD) is a widespread pathogenic condition causing 
memory and behavior impairment mostly in elderlies because of the 
accumulation of amyloid beta peptide and tau protein in human brain. 
Current therapeutic approaches, based on the amyloid hypothesis, are 
unable to arrest the progression of the disease, hence early diagnosis is 
crucial for an effective intervention. Based on the updated criteria for AD 
probable diagnosis, and considering the limits associated with the actual 
analytical techniques, my work in this thesis was dedicated to develop 
novel strategies for AD diagnosis. The whole project focused on the 
analysis of tau protein by Surface Plasmon Resonance (SPR) biosensing. 
Such protein is well known for being relevant as neurodegenerative 
marker. In particular if the measurement of tau is associated with that of 
the amyloid beta peptide and that of the phosphorylated tau, the clinical 
specificity of this protein become significant to detect Alzheimer. Two 
aspects were studied; first of all an immunosensor was developed taking 
advantage of the well-established antigen-antibody interaction. After 
characterization of the analytical parameters of the direct assay (with 
primary antibody), a sandwich assay (using two monoclonal antibodies 
mapping on different analyte i.e. protein tau epitopes) was developed, 
allowing very low sensitivity to be obtained in artificial Cerebrospinal 
Fluid (aCSF). In particular to enhance the analytical signal Carbon Nano 
Tubes (CNTs) were used. Secondly, the research was focused on the 
selection of aptamers for tau. To this aim two SELEX (Systematic 
Evolution of Ligands by EXponential enrichment) methods were 
compared, both based on Capillary Electrophoresis (CE) for partitioning 
step of the process. Whether with CE-SELEX (first method), no 
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significant affinity improvement was measured, using the CE-Non-
SELEX (second method) affinity of the DNA library for tau protein was 
consistently improved. After isolation of a limited population of aptamer 
candidates, five sequences were chosen to be analyzed for their affinity for 
the target. Fluorescence Anisotropy (FA) measurements and SPR 
highlight similar behavior for the selected sequences, despite the detection 
principles of these techniques are significantly different. In conclusion the 
work highlight versatility of SPR technology used both for quantitative 
analysis and for new selected aptamers characterization in terms of affinity 
for the analyte tau. The above mentioned versatility is of great interest in a 
field such AD, which is rapidly expanding. Lowering the total tau levels 
has been recently identified as a new goal for therapy. Therefore many 
drug candidates are likely going to be tested in the near future. SPR 
technology is already widely used in pharmaceutical industry to 
investigate novel molecules, since it gives access to a large panel of 
information. In this panorama aptamer technology may improve the 
overall quality of the analytical data, allowing better comparison among 
drug candidates. With respect of these receptors, the thesis opened the 
door to new studies for DNA aptamers to recognize tau, with considerable 
advantages in term of the receptor stability. Moreover the whole potential 
of DNA aptamers selected in this work still remain to be explored. New 
selection methodologies, combined with fast progression of bioinformatics 
tools might give rise to affinity improvement, which will lead to 
sensitivity improvement for tau detection in the next few years. 
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O u t l i n e   
This PhD thesis is the result of a three-year project on the topic of early 
diagnosis of Alzheimer’s disease supported by Università Italo-Francese 
(UIF), Vinci project (chapter III). Thanks to the support of this Institution, 
a collaborative effort between the Biosensor laboratory, Department of 
Chemistry “Ugo Schiff”, of the University of Florence and the Department 
of Pharmacological Molecular chemistry (DPM) of the University of 
Grenoble, gave rise to an innovative approach for the detection of 
Alzheimer’s disease core biomarkers present in biological fluids. The 
work was characterized by a carefully designed step-by-step process. 
Starting from the use of a conventional antibody-based technique, we 
progressed in two main directions which will be fully clarified in the text.  
 
 
The whole project is built around tau protein (τ), which, as described in 
the introducing chapters (1 and 2), is one of currently accepted biomarker 
for Alzheimer together with Amyloid-β peptide (Aβ). In this introduction, 
in which a review published on Analytica Chimica Acta (Scarano et al., 
2016, 940, p. 21-37) is attached, a critical report of the scientific literature 
is presented. After a short description of the biochemical role and structure 
of the core biomarkers for Alzheimer’s disease, two aspects are analyzed. 
First of all novel biosensing strategies based on the well-known antibody-
antigen interaction were reported. Both label-free and label-based 
techniques were considered and compared to existing techniques used in 
clinical routine. Secondly a survey on the emerging bio-mimetic receptors 
was carried out. Finally the theoretical principles of the techniques used in 
this thesis are presented.  
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The experimental part of the thesis is organized in two main blocks, any of 
which describes different aspects of the work.  
 
Chapter 3 is focused on classical antigen-antibody interaction to develop a 
Surface Plasmon Resonance (SPR) sensor for tau protein quantification. 
This part of the thesis, published on Biosensors and Bioelectronics,(In 
Press on Special Issue of the 26
th
 International congress of Biosensors, 
doi: http://dx.doi.org/10.1016/j.bios.2016.08.078) describes the use of two 
complementary monoclonal antibodies to design a sandwich assay. Multi 
Walled Carbon Nanotubes (MWCNTs) were explored as signal enhancers 
by labeling the secondary monoclonal antibody with these large 
nanostructures, thanks to a collaboration with Prof. Stefano Cicchi, 
(Department of Chemistry “Ugo Schiff, University of Florence) who 
kindly provided the MWCNTs.  
 
In chapter 4 we investigated the possibility to obtain a new bio-mimetic 
receptor, based on single stranded DNA (ssDNA) aptamers, to compete 
with antibodies for the detection of tau protein in bioanalytical assays. As 
reported in the introduction, these receptors are usually selected in vitro by 
a process called SELEX (Systematic Evolution of Ligands by EXponential 
enrichment). The selection process starts using large DNA or RNA 
libraries and is always composed by three parts: separation, amplification 
by Polymerase Chain Reaction, and purification of amplified pool. Here 
using the same separation platform i.e. Capillary Electrophoresis (CE) two 
different selection procedures, named CE-SELEX and CE-Non-SELEX 
were tested and compared. SPR was also applied in the affinity 
determination of selected ssDNA for the target (tau).  
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Finally, in chapter 5 general conclusions and future perspectives are 
reported. Here the strong interdisciplinary character of the work was 
highlighted and appeared to be the key to obtain relevant scientific results. 
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1  S t a t e  o f  t h e  a r t  f o r  b i o a n a l y t i c a l  
a p p r o a c h e s  i n  A l z h e i m e r ’ s  d i s e a s e  
d i a g n o s i s  
Alzheimer’s disease first case was presented in Tübingen (Germany) for 
the first time at the beginning of the last century (1906) by Alois 
Alzheimer, a German physician who observed miliary bodies (amyloid 
plaques) and dense bundles of fibrils (neurofibrillary tangles) in the human 
brain of Auguste Deter [1]. Starting from that moment Alzheimer’s 
disease research made incredible progresses both in the comprehension of 
the pathogenic mechanisms eventually leading to the disease, with the 
development of amyloid hypothesis [2], and in the field of analysis of the 
biochemical markers that have been discovered along the years.  
In the analytical field main efforts ware devoted to detect the three core 
biomarkers commonly known as Alzheimer signature: Aβ (especially 
isoform of 42 amino acid residues), τ protein, and hyperphosphorylated τ 
[3]. They were included officially inn the algorithm for probable AD 
diagnosis in 2007 [4], after the criteria established 23-years earlier by the 
National Institute of Neurological Disorders and Stroke–Alzheimer 
Disease and Related Disorders (NINCDS–ADRDA) were extensively 
revised. Apart from imaging techniques, CerebroSpinal Fluid (CSF), for 
its direct contact with brain vessels, is up to now the preferred medium for 
analysis of all core biomarkers [5]. Immunochemical methods are in large 
majority both for commercial kits and for research. In parallel with 
conventional antigen-antibody assays, are reported new biomimetic 
receptors that emerged as promising for diagnosis. Nevertheless since 
considerably lower amount of works are reported for such receptors, they 
still hold great potential.  
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State of the art, including a perspective on the future improvement 
possibly desirable in the next years is reported here:  
 
“Scarano, S., Lisi, S., Ravelet, C., Peyrin, E., Minunni, M., 2016. 
Detecting Alzheimer’s disease biomarkers: From antibodies to new bio-
mimetic receptors and their application to established and emerging 
bioanalytical platforms–A critical review. Anal. Chim. Acta 940, 21–37.” 
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1.1 Generalities of Alzheimer’s disease 
Alzheimer’s disease (AD) was first described by Alois Alzheimer in 1907 
as a severe neurodegenerative disorder characterized by progressive 
memory and cognitive impairment, with evolution to dementia and death 
observed on a 50-year-old woman [1], [2]. Brain histology related to this 
new clinical condition presented two main hallmarks, i.e. distinctive 
plaques and neurofibrillary tangles (NFTs) whose composition was 
clarified only in the eighties with the discovery of the amyloid beta 
peptide (Aβ) and the tau protein as main components of amyloid plaques 
(APs) and NFTs, respectively [3]. The World Alzheimer Report 2015 
(http://www.worldalzreport2015.org) estimates that dementia syndromes 
affect over 46 million people worldwide, and approximately 60-70 % of 
them are diagnosed as AD, although the early and accurate diagnosis is 
still a challenge and a high percentage of patients are still misclassified or 
late diagnosed. [4]. Early intervention with improved accuracy of AD 
diagnosis may hence greatly increase the potential of therapeutic 
treatments as well as the assessment and validation of suitable biomarkers 
to support personalized health care. The latter area, exploiting companion 
diagnostics or theranostics, encompasses systems combining diagnosis, 
therapy, and monitoring, e.g. a test that qualifies a single patient for the 
most suitable treatment with a particular drug, at the right time and dose 
[5]. Despite huge efforts in this research field, up to now there is a lack of 
inexpensive, sensitive, and real-time detection strategies for the early 
detection and monitoring of AD biomarkers. This is due to the complex 
and partially unraveled questions regarding the production, accumulation 
and clearance patterns of assessed biomarkers under physiological and 
patho-physiological scenarios. In this framework, we feel that the design 
and development of new bioanalytical assays for AD diagnosis must be 
necessarily flanked by the definitive understanding of AD biomarkers 
State of the art for bioanalytical approaches in Alzheimer’s disease diagnosis 
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involvement in pathologic mechanisms, and their relationships. At this 
regard, functional and molecular brain imaging techniques are effectively 
improving and revising clinical diagnostic criteria of dementia-related 
neuropathologies in vivo. [6], [7], [8]. In particular, the observation of 
hippocampal atrophy and entorhinal cortex by advanced magnetic 
resonance imaging (MRI) techniques seems effective in distinguishing AD 
from healthy control subjects, whereas its utility remains unclear for 
differential diagnosis of other dementia. Molecular imaging techniques, 
such as 18F fluoro-deoxy glucose positron emission tomography (PET), 
using tracers for amyloid or tau biomarkers and invasive methods 
including  cerebrospinal fluid (CSF) analysis of amyloid β and tau protein 
are also available to support the diagnosis of AD in vivo [7]. Therefore, 
significant advances can be foreseen by coupling information from AD 
biomarkers assays to different imaging-based techniques. Their 
combination is gradually anticipating to the presymptomatic stage of AD 
sensitive and specific diagnostic tools, which give information on the 
various pathological processes underpinning the different causes of 
dementia. 
 
1.2 Overview on consolidated AD biomarkers 
Nowadays, three core biomarkers are considered for routine diagnosis of 
AD in cerebrospinal fluid (CSF): amyloid beta peptides (Aβ1-42 and     
Aβ1-40), total tau protein (t-τ), and tau protein phosphorylated on threonine 
181 (p-tau181). Such markers are involved in the well-known amyloid 
cascade hypothesis, which has been the basis of research in the field for 
the last 20 years [9, 10] (sketched in Fig. 1-1). This milestone puts tau 
aggregation downstream to amyloid deposits; however, tau pathologies are 
State of the art for bioanalytical approaches in Alzheimer’s disease diagnosis 
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also described in absence of Aβ aggregates [11], and a profound revision 
of the whole mechanism is in progress [12].  
 
 
Fig. 1-1 Schematic diagram showing the involvement of Aβ and Tau protein in the 
amyloid cascade hypothesis, freely adapted from [10]. 
 
The Alzheimer’s signature includes therefore all three biomarkers, in order 
to allow robust classification of AD patients compared to healthy subjects 
[13]. Moreover, new species such as amyloid-derived diffusible ligands 
(ADDLs) [14] or isoforms related to tau imbalance (such as four- and 
three-microtubule binding unit tau, 4R and 3R, respectively) [15], [16] 
have been recently considered as potential candidates for diagnosis.  
Although great efforts have been realized in order to separate AD subjects 
from controls, a lack of reproducibility has been recently  
highlighted, leading to a collaborative work among several laboratories in 
order to reduce the observed variability [17]. Since CSF sampling is a 
quite invasive procedure compared to blood sampling, blood biomarkers 
would be of great interest. Despite efforts made to define reliable 
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molecular patterns to discriminate AD from other dementias or from 
healthy subjects, no convincing results have been reported [2]. Eventually 
attempts in combining information from peripheral biomarkers with 
processes related to aging (such oxidative stress) have also been conducted 
[18]. However, even if this multivariate approach is promising, no 
validated pattern of blood biomarkers is available [19].  
 
1.2.1 Amyloid β peptides and derived species  
Amyloid β peptides are a family of peptides with a molecular weight 
around 4 kDa produced by the cleavage of larger amyloid precursor 
protein (APP). Among the different forms produced during this process, 
peptides constituted of 40 (Aβ1-40) and 42 (Aβ1-42) amino acidic residues 
are prevalent. The clinical meaning of Aβ1-40 and Aβ1-42 for AD diagnosis 
has been confirmed by more than 2000 CSFs’ patients analysis. Peptide 
concentration in age-matched healthy controls was found to decrease by 
50% compared to AD subjects [20]. The ratio between the two amyloid 
species, i.e. Aβ1-40 and Aβ1-42, has also been proposed as AD hallmark, on 
the base of the so-called amyloid cascade hypothesis (Fig. 1-1). In fact, in 
this model, Hardy and Selkoe reported that AD pathogenesis is stated by 
an imbalance between Aβ1-42 production and its clearance [21], giving 
good diagnostic information to distinguishing AD subjects from healthy 
population (better for early onset Alzheimer’s disease). In fact 
physiological peptide concentration usually exceeds 110 pM, while a 
consistent reduction is observed in cerebrospinal fluid of AD patients 
(table 1-1). Amyloid β monomers aggregate to the final state of mature 
fibrils, via the formation of the so-called amyloid-derived diffusible 
ligands (ADDLs). ADDLs are small aggregates displaying high toxicity 
and diffusivity into neuronal cells compared to amyloid monomers and 
neuritic plaques. The analysis of ADDLs, while challenging, seems also 
State of the art for bioanalytical approaches in Alzheimer’s disease diagnosis 
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very promising for the early AD detection [22] and would provide a 
unifying mechanism for AD, accounting not only for memory loss but also 
the major features of neuropathology (synapse loss, tau phosphorylation, 
oxidative damage, and specific cell death). 
 
table 1-1: Levels of Alzheimer's disease biomarkers and relative cut-off values, obtained 
by ELISA. Conversion is realized considering 4300 Da for Aβ1-42 and 45900 Da for tau 
protein. n.d. means not significant values for sporadic Alzheimer’s disease. 
Biomarker Healthy subject (ng L-1) AD subject (ng L-1) 
Aβ1-42 794±20 (184.3 pM) <500 (<116.3 pM) 
Total tau protein (21-50 years) 136±89 (3.0 pM) n.d. 
Total tau protein (51-70 years) 243±127 (5.3 pM) >450 (>9.8 pM) 
Total tau protein (>71 years) 341±171 (7.4 pM) >600 (>13.1 pM) 
Phosphorilated tau protein (181) 23±2 (0.5 pM) >60 (>1.3 pM) 
 
1.2.2 Tau proteins and derived isoforms 
Tau protein (50–65 kDa) belongs to microtubule associated protein family 
(MAP) and is expressed in human neurons, oligodendrocytes, and 
astrocytes within the central nervous system (CNS) and peripheral nervous 
system (PNS) [23], [24]. In axons, where it is primarily found, tau protein 
is involved in microtubules polymerization and stabilization through its 
interaction with tubulin (Fig. 1-1). The tau structure can be divided in four 
regions, i.e. the N-terminal region, the proline-rich domain, the 
microtubule-binding domain, and the C-terminal region [25]. The human 
tau gene (MAPT) contains 16 exons, with alternative splicing of exons 2, 
3, and 10, which yields six isoforms, ranging in length from 352 to 441 
amino acids. Inclusion of exon 2 results in 1N isoforms, the inclusion of 
both exons 2 and 3 produces 2N isoforms, whereas isoforms lacking both 
exons are named 0N [15]. The microtubule-binding domain is 
characterized by the presence of three (3R isoforms) or four (4R isoforms) 
repetitive units before the C-terminal region. Compared to amyloid 
peptides, tau proteins are well soluble in water and stable in the absence of 
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aggregation inducers, due to its hydrophilic primary structure, which is 
also responsible for its natively unfolded structure [26]. 
The role of tau regions in aggregation has been studied under several 
conditions. Von Bergen and colleagues discovered the minimal sequence 
able to aggregate in paired helical filaments (PHF), which eventually lead 
to tangles in AD [27]. Since interaction with microtubules is regulated 
from tau phosphorylation states, phospho-tau species have gained 
significant attention for explaining AD pathological mechanism [28]. 
Comparison among amino acid phosphorylation sites (85 potential serine 
(S), threonine (T), and tyrosine (Y)) of tau protein in normal and AD brain 
has been reported. In healthy subjects, a low level of phosphorylation 
(11.8% i.e. 10 with tau phosphorylated over 85 subjects) of analyzed 
soluble tau was found [28], [29], while in insoluble aggregated tau, 
extracted from tauopathy brain, higher phosphorylation levels, i.e. about 
50% (approximately 45 different serine, threonine, and tyrosine 
phosphorylation sites), were found [27], [30], [31], [32], [33]. 
The higher phosphorylation levels in AD patients have been considered as 
AD biomarker for the development of bioassays. In particular, attention 
has been focused on two phosphorylation sites, respectively serine 181 (p-
tau181) and threonine 231 (p-tau231) since their measurement proved to 
be informative for classifying AD from relevant differential diagnoses: p-
tau181 enhances the classification between AD and dementia with Lewy 
bodies, and p-tau231 is able to differentiate between AD and 
frontotemporal dementia (FTD) [34]. 
Along with hyperphosphorylation, other tau post-translational 
modifications have been related to tauopathies, such as glycosylation, 
glycation, prolyl-isomerization, cleavage or truncation, nitration, 
polyamination, ubiquitination, sumoylation, oxidation and aggregation 
[35]. 
State of the art for bioanalytical approaches in Alzheimer’s disease diagnosis 
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1.3  Immuno-based platforms on the market: ELISA and xMAP 
assays 
At the present time, the most widely used immunoassay platforms for CSF 
AD biomarkers detection (Aβ peptides 1-40 and 1-42, total tau (6 
isoforms), and p-tau181) are provided by Fujirebio-Innogenetics 
(Innogenetics Inc., Alpharetta, GA) and consist in a singleplex enzyme-
linked immunosorbent assay (ELISA) kit and a micro-bead based Multi-
Analyte Profile (xMAP) (also recently reviewed by Kang and colleagues 
[36]). The bioanalytical strategy of the two immunoassays benefits from 
the development of commercial monoclonal antibodies (mAbs) for each 
target molecule, working in sandwich format. No cross-reactivity between 
monoclonal antibodies has been noted [37], [38], and both immunoassays 
work in cerebrospinal fluid (CSF). If ELISA-based kit performs one 
biomarker at a time in parallel reactions on immunoplate, xMAP 
technology allows multiplexed analysis. table 1-1 shows physiological 
levels of all core biomarkers, quantified by ELISA. xMAP technology 
(Luminex
®
) indeed performs discrete assays on the surface of color coded 
beads, then read by multiple lasers or LEDs, reporting the reactions 
occurred on each individual microsphere [39]. On the basis of xMAP 
technology, Olsonn and colleagues developed a cytometry-based assay for 
the multi-analyte determination of core AD biomarkers coupling 
cytometry to the use of labeled spherical microbeads [40]. The spheres 
may be loaded with up to a hundred combinations of two selected dyes 
and then separated by flow cytometry (sketched in Fig. 1-2). Details of the 
xMAP platform and its functioning are reported in the relative caption. 
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Fig. 1-2: Sketched representation of xMAP™ technology. Each plate well (A) contains a 
10x10 microspheres set obtained by varying the ratio of two fluorophores (B), in order to 
classify each microsphere on the basis of a unique fluorescent signature. This allows for 
multiple analyte profiling in a single sample. Classification is allowed by flow cytometry 
system coupled to two lasers (C). Detector 1 (635 nm) is used to identify the interrogated 
bead. Each bead is functionalized with a primary antibody, enabling the capture of the 
analyte from complex media. Detector 2 (532 nm) excites phycoerythrin (PE), used as 
label of the secondary antibody, to quantify the binding event 
 
Absolute results obtained through this approach are similar to those 
obtained by means of ELISA. However the direct comparison of results 
obtained by ELISA and xMAP requires appropriate models to convert the 
biomarkers levels between the two platforms, as reported by several 
authors [41]. Declared ranges for calibrators of ELISA-based kits 
(lyophilized peptide solutions) are 7.8-1000 ng L
-1
 for Aβ1-40 (Limit of 
Detection (DL) not provided), 62.5-4000 ng L
-1
 for Aβ1-42                   
(DL= 65 ng L
-1
), 15.6-1000 ng L
-1
 for p-tau181 (DL= 13 ng L
-1
), and 50-
2000 ng L
-1
 for total tau (DL= 34 ng L
-1
, all six isoforms from 352 to 441 
aa). xMAP-based kit for the same CSF AD biomarkers, INNO-BIA 
AlzBio3, is furnished with a ready-to-use calibrator in solution offering 
wider calibrator ranges in a semi-automated assay platform with minimal 
intra-sample variance and limits of detection slightly lower than ELISA-
based kits. A detailed paper reporting all the operative steps and related 
expedients to minimize the variability of results has been published by 
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Kang and colleagues [42]. The same article summarizes the clinical 
performances of AD CSF biomarkers measured by xMAP-Luminex 
platform. 
Recently, Fujirebio-Innogenetics put on the market a new assay kit for 
Aβ1-40 and Aβ1-42 quantification in plasma instead of CSF. Repeatability 
for both assays showed a coefficient of variation (CV%) below 10%, with 
a limit of detection (LOD) in the pM range for all biomarkers with a 
slightly extended dynamic range and higher accuracy for xMAP 
technology, which results in an appropriate assay platform to incorporate 
diagnostic biomarkers into routine clinical practice.  
Even though conventional methods show good analytical performances, 
the lack of reference CSF matrix for calibrators and of standard reference 
materials for each biomarker is the main source of high inter-laboratory 
variability, which raises the CV% up to 30%.  This and other causes of the 
observed inter-laboratory variability are now being considered by 
Alzheimer’s biomarker standardization initiative (ABSI) members taking 
into account pre-analytical and analytical factors in large inter-laboratory 
studies. Among various sources, also batch to batch variability related 
with antibody production is considered in order to obtain harmonization of 
the results [17].  
In this framework, the availability of effective monoclonal antibodies 
targeting AD biomarkers [43] and new emerging synthetic and/or bio-
mimetic receptors have stimulated the development of alternative bio-
analytical approaches for AD biomarkers detection. Next paragraphs 
review these emerging approaches and the related analytical strategies. 
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1.4  Innovative bioanalytical platforms based on immunodetection 
 
1.4.1 Propagating Surface Plasmon Resonance (SPR) 
Several biosensors, based on various transduction principles, are reported 
in literature for AD biomarkers detection, whose performances have also 
been critically reviewed [44], [45]. Label free optical techniques, such as 
Surface Plasmon Resonance (SPR, conventional and imaging) [46], [47], 
[48] or Localized SPR (LSPR) [49], as well as electrochemical techniques, 
offer the possibility to detect biomolecular interactions with high 
sensitivity, and in real time. In table 1-2, an overview of these approaches 
based on label free biosensing is reported.  
table 1-2: Immuno-based label free methods for Alzheimer’s disease (AD) core 
biomarkers detection. (1): Technique; SPR: Surface Plasmon resonance; LSPR: 
Localized SPR; CNT-FET: carbon nanotubes-field effect transistor; SWV: square wave 
voltammetry; EIS: electrochemical impedance spectroscopy; ADDLs: amyloid-derived 
diffusible ligands; CSF: cerebrospinal fluid; mAb: monoclonal antibody. 
Transduction 
principle 
(1) 
Target LOD Medium 
Detection 
strategy 
Antibody Ref 
Optical SPR 
Aβ1-40 0.3 fM buffer sandwich 
Fragmented 
mAb 
[53] 
Aβ1-40 
Aβ1-42 
20.0 
pM 
CSF sandwich mAb [56] 
tau 
(captured) 
Aβ1-42 
(flowed) 
3.0 nM buffer sandwich mAb [58] 
Aβ1-42 0.2 µM buffer direct mAb [61] 
ADDLs 280 nM buffer sandwich mAb [62] 
ADDLs n.d. buffer direct mAb [63] 
LSPR 
ADDLs 
10.0 
pM 
human brain 
cells and 
CSF 
sandwich mAb [22] 
Tau 0.2 pM buffer direct 
mAb, protein 
G oriented 
[67] 
Electrochemical SWV Aβ1-40 
Aβ1-42 
20.0nM rat CSF direct mAb [74] 
EIS 
Aβ1-42 
0.57 
nM 
buffer direct 
mAb, protein 
G oriented 
[75] 
CNT-
FET 
Aβ1-42 2 nM serum direct mAb [76] 
 
SPR is one of the most relevant and well known analytical platforms in 
biomolecular interaction assessment, and during recent years, several 
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works in the field of AD have appeared [50], [51], [52], even if only a few 
of them are intended for biomarkers quantification. Lee and colleagues 
quantified Aβ1-40 by SPR immunosensing in a sandwich format exploiting 
gold nanoparticles (GNPs) for signal enhancement [53] (Fig. 1-3).  
 
 
Fig. 1-3: SPR-based detection of amyloid Aβ1-40/1-42 biomarkers by immunosensing 
strategies involving the use of a secondary antibody to enhance the SPR signal. The 
enhancement can be obtained by means of molecular architectures in which the 
secondary Ab is directly coupled to gold nanoparticles (I) [53], multiple site recognition 
proteins, i.e. streptavidin (II) [56], or by label-free detection exploiting the mass 
enhancement of tau/Aβ1-42 binding [58]. 
 
The low molecular weight of Aβ (about 4 kDa) limits both the SPR angle 
change and the detection limit, requiring the set-up of molecular strategies 
able to amplify the assay response.  
With GNP-enhanced SPR, the observed detection limit in buffer was 
declared at 0.2 pM (1 pg L
-1
), by using a fragmented mAb immobilized as 
receptor in an oriented fashion via gold/thiol linkage. Non-specific binding 
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or possible interferences were not considered, which is often crucial when 
dealing with fragmented Abs that suffer from non-specific interactions 
[54]. In another work, ethylene glycol was used to address this issue by 
passivating the surface of an SPR biosensor realized for the simultaneous 
detection of Aβ species [55]. Through biotinylated mAbs anchored on 
streptavidin, used both as capturing agents and signal amplifiers, Aβ 
species were detected in the buffer and CSF, with an estimated LOD of 
3.5 pM for all the species. The biosensor was fully regenerable with 
reproducibility lower than 10% (CV%). To the best of our knowledge, this 
is the only work in which SPR was used to detect analytes in real matrices 
[56] (Fig. 1-3). 
Guo and colleagues proved tau-Aβ1-42 complex formation by SPR, with a 
Kd in the low nM range [57]. On this basis, Homola’s group exploited the 
tau-Aβ1-42 complex formation through a sandwich assay in which anti-tau 
antibody was immobilized on the surface in order to capture tau-Aβ1-42 
complex from the solution [58] (Fig. 1-3). The direct signals obtained 
were then amplified by a secondary anti-Aβ1-42 antibody binding the tau-
Aβ1-42 complex. No information about regeneration was given. 
One of the major advantages of SPR is to exploit physical properties of 
metal structures or surfaces to enhance the analytical signal. If the use of 
GNPs is quite common [59], a different approach relies on the constitution 
of a bimetallic Ag/Au film. Indeed the combination of the narrower 
resonance curve of Ag (compared to Au) and very little optical leakage of 
waveguide layers are able to improve significantly signal to noise ratio 
[60]. The developed technology was used for Aβ1-42 detection in buffer at 
concentrations comparable to clinical level of the peptide in CSF (25-500 
pM, i.e. 100-2000 ng L
-1
) [61]. However, such strategy compared with the 
sandwich approach previously illustrated, could be more prone to 
interferences coming from real samples. Thus in this case, deeper 
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investigation of possible non-specific signal should be considered. Apart 
from quantitative aspects, SPR technology gives the possibility to 
investigate peculiar behaviors of the biomolecules involved in the affinity 
recognition, and this feature has been exploited also in the AD biomarkers 
field. In particular, different monoclonal antibodies against Aβ oligomers 
may highlight the existence of antibody-dependent aggregation patterns 
[62], [63]. For example, clones 82E1 and 12F4 for Aβ, when exploited on 
SPR as bioreceptors, displayed the ability to differentiate association 
patterns in Aβ oligomers growth [62], i.e. while clone 82E1 infers a single 
sigmoidal signal, a double sigmoidal trend was elicited by 12F4 clone. 
Conversely, mAb for ADDL (clone A11) together with mAb for amyloid 
fibrils (clone OC) were immobilized by Yi and colleagues to evaluate 
aggregation over time in presence of Aβ aggregation modulators such as 
copper [63]. The use of oligomers-specific antibodies could also be 
proposed to reduce sample pretreatment. Finally, in a work carried out by 
our group [51] on SPR, we exploited Aβ monomers as fibrils elongation 
triggers. This allowed to study aggregation trends in the presence or not of 
clioquinol, a proposed inhibitor of Aβ fibrils elongation, also in 
combination with piezoelectric transduction. Real time and label free 
monitoring allowed by SPR gives the exquisite chance of understanding 
and evaluating the inhibitory action of clioquinol as well as of any other 
putative active substance of interest for therapeutic purposes. 
 
1.4.2 Localized Surface Plasmon Resonance 
Surface Plasmon oscillation can occur eventually in metallic 
nanostructures, and LSPR is displayed by the characteristic wavelength of 
maximum absorbance (λmax) within the visible-near infrared range 
depending on size, shape, and material (typically gold and silver, or their 
alloys) [64]. By modifying nanostructures surface with biomolecules 
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specific for a target analyte (nucleic acids sequence, peptide, antibody, 
carbohydrate etc.) and interrogating them with light, LSPR response 
correlates with analyte concentration. It can be recorded as λmax shift of the 
extinction spectrum and it is elicited by local change of the refractive 
index, which is induced by the biomolecule film formed at nanomaterial 
surface after biorecognition. Furthermore, LSPR-based sensing presents 
reduced background noise by localizing the “sensing depth” close to the 
surface (10-20 nm), improving the detection limits as compared to 
propagating SPR (SPR and SPRimaging). This feature is of paramount 
importance since turns into a low or negligible matrix effect, one of the 
major requirements in bioanalysis on biological samples. LSPR 
measurements can be performed in solution or on planar arrays of 
nanostructures and represents a new emerging and highly performing 
optical label free-based sensing technique. 
Van Duyne’s group first exploited LSPR in the field of AD research, in 
order to assess the interaction between anti-ADDLs antibodies and 
amyloid oligomers [65] (Fig. 1-4) 
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Fig. 1-4 Reported optical techniques relied on LSPR of nanostructured metals (silver and 
gold) to transduce biomolecular interactions between antibodies and AD biomarkers. On 
the top, silver nanoprisms used for detection of amyloid-derived diffusible ligands 
(ADDLs) [65]. On the bottom, silica nanoparticles coated with thin layer of gold 
exploited for tau detection [67].  
 
ADDLs were immobilized on mono-disperse, surface-confined silver 
nanotriangles obtained by Nanosphere lithography (NSL). Polystyrene 
nanospheres, forming a hexagonal close-packed monolayer of spheres, 
served as a deposition mask. The sensor was hence exposed to various 
concentrations of anti-ADDLs antibodies. Nanoparticles anchorage was 
carried out on glass substrate avoiding the use of the classic chromium 
adhesion layer, which displayed to dramatically affect the selectivity of 
the biosensor. This effect is likely due to the higher binding affinity of Cr 
for COOH than SH groups in alkanethiols [66], leaving the thiol available 
to form disulfide bonds with cysteines of anti-ADDL molecules. Primary 
anti-ADDLs antibody was immobilized on AgNPs and then incubated 
with various oligomers concentrations. The direct signal was then 
amplified by a secondary antibody reaching LOD at a low pM level both 
in buffer, brain extract homogenates, and CSF. Moreover, models 
developed to quantify the target, revealed different classes of ADDLs with 
different binding affinity for the receptors depending on the concentration 
level (<10 pM or > 10 pM ADDLs). Such feature further demonstrates the 
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versatility of SPR biosensing as compared to conventional immuno-based 
assays [22]. More recently, tau protein was revealed by LSPR by 
Vestergaard and colleagues by immuno-based direct detection [67] (Fig. 
1-4). Here nanostructured resonating surface was achieved by growing a 
thin gold layer on a substrate of silica nanoparticles. The LSPR change 
was elicited by the binding between the monoclonal anti-tau antibody 
(clone not specified, immobilized via protein G orientation) and tau 
protein (60 KDa) in buffer solution. Despite the reported LOD was 0.167 
pM (10 ng L
-1
) tau, lower than the cut-off value of 3.5 pM (195 ng L
-1
) 
(for AD) for tau protein in CSF, the result has not been tested on real 
samples. Moreover, the specificity was tested on bovine serum albumin 
(BSA), instead of human serum albumin that is the most abundant protein 
of CSF (able to properly simulate the possible unspecific matrix effect on 
the biosensor). 
As a whole, LSPR biosensing is under fast evolution and promises 
exciting results through the fine tunability of the nanomaterial used, the 
simplicity of its signal detection, coupled to high sensitivity and 
selectivity. Moreover, LSPR biosensing is foreseen to be easily 
miniaturized for point-of-care test platforms [68], [69], so we feel that 
there will be a dramatic increase of works devoted to LSPR-based 
diagnostic methods in next years. 
 
1.4.3 Electrochemical (bio)sensors 
Label free electrochemical strategies to detect peptides and proteins can 
take advantage from intrinsic electro-active amino acids, mainly tyrosine 
and tryptophan, as exhaustively reviewed by Tamiya and colleagues [50]. 
The tyrosine residue of Aβ peptide (10th position) has been thus exploited 
for the first time by Vestergaard and colleagues in more than one work 
[71], [72], [73]. The first work dealt with the electrochemical monitoring 
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of aggregation patterns of amyloid beta peptides (Aβ1-40 and Aβ1-42) using 
three different voltammetric techniques at a glassy carbon electrode 
(GCE) [71]. The approach allowed the authors not only to evidence the 
progressive elongation of Aβ fibrils (confirmed by thioflavin T and AFM) 
by increasing the incubation time, but also to characterize that the two 
isoforms are featured by well distinguishable aggregation rates. The longer 
the amyloid beta incubation time, the lower the oxidation signal of 
tyrosine. This suggests  that the observed trend could be elicited by the 
conformational change of the peptides during the aggregation process. 
Afterwards, the same approach was exploited to investigate the 
phosphorylation degree of Aβ [72], since they found that the process 
affects the tyrosine electro-oxidation and, finally, to follow tyrosine kinase 
activity (responsible for Aβ phosphorylation in the presence of ATP) and 
its modulation in the presence of an inhibitor [73]. The reported 
approaches are sketched in Fig. 1-5. 
 
 
Fig. 1-5 Representation of label free electrochemical detection based on tyrosine 
oxidation. The Aβ1-42 elongation/aggregation induces a progressive decrease of Tyr 
signal, allowing also for the differential monitoring of aggregation patterns of Aβ species 
[71], [72], [73] 
 
Prabhulkar and colleagues developed a multiplexed, implantable 
immunosensor to detect Aβ isoforms using triple barrel carbon fiber 
microelectrodes as sensing platform [74]. Two carbon fiber 
microelectrodes were separately modified with two mAbs specific for the 
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C-terminal of the Aβ species (mHJ2 for Aβ1-40 and mHJ7.4 for Aβ1-42). 
The third one, mHJ5.1 clone, recognizes the central domain of both Aβ 
isoforms (amino acids 17–28) without detectable cross-reactivity toward 
other APP fragments. The behavior of tyrosine oxidation peak was 
monitored by square wave voltammetry (SWV) allowing simultaneous 
and label free detection of Aβ1-40 and Aβ1-42 species in rat CSF. Authors 
report that the biosensor showed non-significant interference with other 
(not specified) proteins containing Tyr residues, with an inter-electrode 
precision of 14.2% (CV%) over dilutions of analytes. The limit of 
detection for both Aβ isoforms resulted 20 nM even if calibration plots 
reported by the authors show dose-response correlation quite far from 
linearity, mainly for Aβ1-40. Despite quantitative aspects, the novelty of the 
approach among the other electrochemistry-based examples is 
undoubtedly the concept of an implantable biosensor able to detect the two 
Aβ isoforms on single triple barrel carbon microelectrodes, with 
perspectives for in vivo analyses. 
Electrochemical Impedance Spectroscopy (EIS) has been reported for the 
Aβ isoforms detection, by coupling immunosensing to disposable printed 
electrodes [75]. On impedimetric sensors, detection is based on the 
principle that any substance tethered on the electrode elicits a change of 
the measured impedance. Therefore, any change in the impedance spectra 
can be related to the change of interface properties. In a step-wise fashion, 
authors explored the detection limit enhancement by three different 
modifications of microelectrodes, before anti-amyloid antibody 
immobilization. In brief, these involve 1) direct amino coupling of the 
mAb on sensor surface; 2) growth of gold nanoparticles followed by 
amino coupling of the mAb on sensor surface; 3) growth of gold 
nanoparticles followed by protein G immobilization to obtain the most 
favored orientation of mAb on the surface. The results obtained are quite 
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expected and displayed a progressive improvement of the detection limit 
over the three methods, with the best LOD at 0.57 nM, by applying the 
method 3). At that stage of development, the authors focused the work on 
mAb immobilization strategy to improve the sensitivity of the assay of 
monomer Aβ isoforms (in standard conditions). They concluded by 
anticipating that the near future work will expand the approach also to the 
quantitative detection of oligomeric amyloid beta species. 
A different strategy was employed by Oh and colleagues [76]. A carbon 
nanotubes film-based biosensor was developed with metal semiconductor 
field effect transistor structure (CNT-MESFET). In such device, classical 
p-n junction is replaced by Schottky barrier provided by the contact 
between a metal (i.e. gold) and a semiconductor. Here the electrical 
conductance change is used as analytical signal, thus it is related to target 
concentration. Anti-Aβ1-42 antibody was oriented by using the Z domain of 
protein A displayed on the E. Coli outer membrane linked to the surface 
[77]. Using this approach, a very high sensitivity was obtained (see table 
1-2) for amyloid detection in human serum, i.e. LOD of 0.25 pM             
(1 pg mL
-1
). However, no information about other analytical figures of 
merit was reported. 
Tau misfolding during the early stage of its auto aggregation process was 
also studied by EIS and cyclic voltammetry [78]. The tau-tau binding, 
established between tau immobilized on gold electrode and tau monomers 
in solution, was investigated and compared to the behavior of p-tau181 and 
BSA, displaying specificity. A linear correlation between charge transfer 
resistance to the redox probe ([Fe(CN)6]
3-/4-
) and tau monomer 
concentration was found from 0.2 to 1.0 μM. Also in this case, the study 
provides very interesting information on tau aggregation in standard 
conditions, and could be further developed to work in real samples. 
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1.4.4 Strategies to improve the analytical performances 
Among labels employed in immuno-based detection strategies, four main 
classes can be identified in works dealing with bioassays for AD 
biomarkers detection. In particular, they consist of 1) nucleic acids 
conjugated to antibodies or immobilized on gold nanoparticles (GNPs) for 
bio-barcode assays; 2) GNPs in spectroscopic techniques such as Surface 
Enhanced Raman Spectroscopy (SERS) and Two-Photons Rayleigh 
Scattering (TPRS); 3) fluorescent dyes in fluorescence or FRET 
measurements; 4) catalytic enzymes, i.e. alkaline phosphatase, in 
electrochemical methods. Labels are generally used either as signal 
reporters and/or to improve the sensitivity of the method. table 1-3 and 
Fig. 1-6 summarize the principles of signal enhancement for the label-
based methods discussed here.  
 
table 1-3: Label-based techniques and labels used for AD diagnosis. (a) iPCR: immuno-
PCR; RLS: Resonance Light Scattering; TPRS: Two Photons Rayleigh Scattering; SERS: 
Surface Enhanced Raman Spectroscopy; FRET: Forster Resonance Electron Transfer; (b) 
GNPs: gold nanoparticles; ALP: ALkaline Phosphatase. 
Technique (a) Label (b) Role of the label References 
immuno-PCR DNA 
Antibody-DNA conjugates. DNA is amplified by PCR. 
Final DNA concentration is related to the starting 
analyte amount. 
[79], [82], 
[85], [88], [89] 
Bio-barcode 
DNA-
GNPs 
Bio-barcode DNA and antibody are both immobilized 
on GNPs. After PCR amplification, the final bio-
barcode   concentration is related to the starting analyte 
amount. 
[80], [90] 
RLS/Dot-blot 
immunoassay 
GNPs 
GNPs aggregation induces increased RLS intensity, 
which is directly related to analyte concentration 
[92] 
TPRS 
GNPs aggregation elicits changes in scattering 
properties 
[93] 
SERS 
GNPs aggregation elicits enhancement of SERS 
spectrum 
[94] 
FRET 
Fluorescent 
label 
Analyte aggregation induces proximity of labelled 
antibodies 
[95] 
Fluorescence 
intensity 
Fluorescent dye labelled to secondary antibody elicit 
signal 
[96], [97] 
Electrochemical ALP 
Catalysis of electroactive substrates to form detectable 
products 
[98], [99] 
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Fig. 1-6 Sketched representation (not to scale) of classes of labels used in bioanalytical 
methods for AD biomarkers detection discussed in the review. From top to bottom: DNA 
sequences in immuno-PCR, fluorescent probes in fluorescence-based methods, catalytic 
enzymes in electrochemical detection, and use of metallic nanoparticles in optical 
methods. All the strategies are based on the sandwich format. 
 
Nucleic acids as enhancers 
Properties of nucleic acids as labels are generally exploited on two 
different bioanalytical platforms: immuno-PCR (iPCR) [79] and bio-
barcode analyses [80]. While the first one usually requires the 
bioconjugation between an antibody and a DNA strand, the second one 
takes advantage of the immobilization of a bio-barcode DNA sequence on 
GNPs. In a typical iPCR protocol, a double-stranded DNA sequence is 
bound to an antibody addressing the target analyte similarly to classic 
immuno-based assays [81]. Afterward, if the analyte target binds to the 
Ab, the DNA reporter sequence undergoes amplification by polymerase 
chain reaction (PCR) and finally is quantitatively detected in real time 
(real-time PCR) or by means of end point PCR and gel electrophoresis 
detection, after recovery of the strands. Among AD biomarkers, Aβ1-40 
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and tau protein (total tau, 3R/4R isoforms, and phosphorylated tau) have 
been detected by iPCR while, to our best knowledge, Aβ1-42 detection 
has not been yet attempted.  
Hashimoto and colleagues detected Aβ1-40 in microdissected neurons by 
iPCR using simultaneous addition of the analyte and antibody-DNA 
conjugate to pre-coated ELISA plate [82]. Quantification was achieved 
after overnight incubation with VIC/TAMRA probe (ThermoFisher 
Scientific). LOD in buffer was 0.03 fmol per well and 100% recovery was 
found when the pre-treated matrix was fortified with known amount of the 
analyte. Since imbalance of tau isoforms in CSF has been proposed as 
promising information in AD differential diagnosis [15], [83], iPCR and 
ELISA tests for 3R and 4R tau were developed to this aim [84], [85]. 
Artificial CSF, 1:1 diluted with buffer, was used as simulated matrix, and 
anti-tau/DNA conjugate was used as secondary antibody, further amplified 
by real-time PCR. LOD of 0.2 pM was obtained in both analytes, with two 
orders of magnitude improvement versus ELISA developed by the same 
authors. Inter-assay repeatability was found to be 10-25%, with 90% 
recovery for both analytes. After optimization, the method was applied to 
human CSF samples, revealing analytical performances comparable to 
standard conditions. Phosphorylated tau species, i.e. p-tau 212, 214, 231, 
235, were analyzed after optimization of the iPCR protocol on synthetic 
peptides. While reported in the scientific literature [86], [87], such 
phosphorylation sites have still unclear role in AD diagnosis. Nonetheless, 
here again iPCR demonstrated a good sensitivity, comparable or higher 
than CSF level of the analytes (LOD 0.04 pM for all analytes), and 
allowed measurements in this matrix. The detected antibody-DNA 
conjugate in this case was against digoxigenin, used as label for secondary 
anti-tau antibody (phosphorylation specific) [88]. 
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Total tau detection was recently achieved by a different nano-iPCR 
approach [89]. Anti-tau capturing antibody was exposed to samples (tau 
calibrators in buffer solutions or undiluted CSF with unknown analyte 
amount) and incubated overnight. Then both anti-tau secondary antibody 
and DNA label sequences were immobilized on GNPs, thus no antibody-
DNA conjugate was employed. Finally, functionalized GNPs were added 
and then amplified by real-time PCR. The method demonstrated a wide 
range of linearity (0.1-500 pM in matrix, R
2
=0.99). In this asset, the 
strategy proposed by Stegurová and colleagues merges iPCR-based 
analysis with the basic concept of bio-barecode. Bio-barcode was 
introduced by Mirkin’s group in 2003 for detecting prostate specific 
antigen (PSA) [80] and defines a designed DNA strand used as specific 
code for the target of interest. Compared to iPCR, bio-barcode analysis: i) 
needs no conjugation between the antibody and the DNA strand, ii) is 
realized in a homogeneous medium, and iii) increases DNA/antibody 
ratio. Through bio-barcode analysis, ADDLs were detected for the first 
time at fM level in 30 CSF samples (LOD 0.1 fM) [90] in a sandwich like 
assay on magnetic microparticles (MMPs). The primary antibody was 
immobilized on MMPs, capturing ADDLs. Then a secondary antibody, 
conjugated to GNPs, together with a DNA strand complementary to 
biobarcode DNA, was added. Watson-Crick interactions between 
immobilized strand and bio-barcode were then removed to recover the 
latter from the solution. Finally, the bio-barcode strand was immobilized 
onto nitrocellulose membrane and recognized by GNPs functionalized 
with complementary DNA probe via DNA-DNA interactions. The 
detection was realized by scanometric analysis, in which the intensity of 
scattered light is registered and enhanced by the presence of GNPs and Ag 
reduction [91]. The above DNA-based approaches are also summarized in 
table 1-3. 
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Gold nanoparticles 
The optical properties of GNPs are widely exploited as labels, and besides 
classical spectrophotometric measurements based on LSPR, Resonance 
Light Scattering (RSL) results a very useful approach when aggregation of 
nanoparticles is under investigation. In fact, recording RLS at or near the 
absorption wavelength of the colloidal nanomaterial, e.g. gold 
nanoparticles, the aggregation trend elicits a strong enhancement of RLS, 
proportional to the analyte inducing the phenomenon. For  Aβ1-42 
detection, RLS-based method coupled to a sandwich strategy was 
developed by dot-blot immunoassay [92]. The analyte was recognized by 
two monoclonal antibodies, the secondary carrying a biotin tag to bind 
streptavidin-coated GNPs. After 30 minutes of incubation, RSL signal was 
detected. Signal enhancement depends on the size of GNPs aggregates, 
which correlates with the analyte concentration. Aβ1-42 (spiked in the 
buffer and undiluted CSF) was tested from 20 nM to 2 µM, obtaining a 
linear dose-response trend. While subnanomolar concentrations of Aβ1-42 
are usually reported in literature, the authors detected 5 nM in CSF. 
Nonetheless, such concentration is beyond calibration limits, thus a greater 
variability is possibly present. 
Tau protein was detected by Neely and colleagues [93], who 
functionalized GNPs with monoclonal anti-tau antibodies. Two-Photon 
Rayleigh Scattering (TPRS) intensity was used to detect tau in buffer from 
7.5 nM down to 0.02 pM (LOD). Signal intensity change is due to the 
increased multipolar contribution elicited by GNPs aggregation in the 
presence of tau. BSA and heme (3000 ng mL
-1
) produced negligible 
signal, demonstrating the selectivity of the method under tested 
conditions. However, the repeatability of the assay and its application in 
CSF samples were not examined. 
State of the art for bioanalytical approaches in Alzheimer’s disease diagnosis 
28 
Finally, Surface Enhanced Raman Spectroscopy (SERS) was used to 
detect tau in buffer by monitoring of 5,5-dithiobis(2-dinitrobenzoic acid) 
(DTNB) Raman spectrum [94]. A sandwich assay was established 
between a polyclonal antibody, immobilized in combination with DTNB 
on GNPs, and a monoclonal antibody immobilized on magnetic particles. 
These latter ones were used to obtain maximum recovery yield during the 
washing steps of the procedure and are potentially useful for tau extraction 
from CSF, although no real samples were evaluated in the paper. In the 
presence of the analyte GNPs undergo aggregation, and SERS spectrum 
was recorded. The peak at 1332 cm
-1
 allowed for tau quantification from 
500 nM down to 25 fM (R
2
=0.994) with no interference coming from 
BSA and IgG (host species not specified) at 500 nM. The above GNPs-
based approaches are also summarized in table 1-3. 
 
Fluorescent labels 
Fluorescent molecules were used as labels to sort ADDLs by size through 
flow cytometry coupled to Forster Resonance Electron Transfer (FRET) 
[95]. Two monoclonal antibodies (clones 4G8 and 6E10) were labeled 
with Alexafluor 488 (donor) or Alexafluor 594 (acceptor), respectively. 
Depending on the aggregation state of the analyte, the antibodies are 
sufficiently close (<10 nm) to enable the electron transfer and distinguish 
ADDLs from amyloid monomers, with a LOD of 10 pM. The assay, 
applied to 1:1 diluted CSF, displayed a CV% < 5% in all the tested 
samples. Ammar and colleagues developed an immunosensor by 
immobilizing anti Aβ1-42 antibodies onto silicon surface [96]. Analyte in 
buffer solution (0.5-1.7 µM) was detected by a sandwich immunoassay, in 
which the secondary antibody was labeled with cyanine 5 (Cy5). The 
dose-response was linear within the investigated range (R
2
=0.988), but the 
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obtained LOD resulted above the physiological levels of Aβ1-42 in human 
CSF.  
Higher sensitivity was realized by exploiting the Si/SiO2 property of 
enhancing the fluorescence intensity by modulating SiO2 layers thickness 
to have a constructive interference [97]. Aβ1-42 detection was realized in 
artificial CSF by sandwich assay in which secondary biotinylated mAbs 
bind a cyanine 3-labeled streptavidin, to give fluorescent signal. The 
method was linear (R
2
=0.993) between 0.9 nM and 20 pM, with an 
estimated LOD of 18.25 pM. Moreover, the microarray format allowed 
multiplexing determination by using only 0.4 nL of sample volume. The 
above fluorescent label-based approaches are also summarized in table 
1-3. 
 
Alkaline phosphatase 
Alkaline phosphatase (ALP) is largely exploited in bioassays as a label, in 
view of its outstanding merits. Its use by means of its catalytic activity has 
been reported also in the field of AD biomarkers detection. Two recent 
works are based on electrochemical detection of amyloid species, in which 
a competition takes place between biotinylated Aβ1-42 and the native form 
of the peptide. In the first one, Screen Printed Electrodes (SPE) were used 
by Rama and colleagues [98] to immobilize biotinylated Aβ1-42 via 
streptavidin binding on SPE surface, after its nanostructuring with gold. 
Then anti-amyloid antibodies and unlabeled antigens were incubated over 
the sensor. Finally, anti-rabbit IgG labeled with alkaline phosphatase, was 
added, together with a  mixture of 3-indoxyl phosphate with silver ions (3-
IP/Ag
+
) used as the ALP substrate. The detected signal raised from the 
reduction of silver ions a. In artificial CSF, the method gave a linear 
response in the range 0.125-125 pM (0.5-500 ng L
-1
, R
2
=0.991), with a 
LOD of 0.025 pM in buffer solutions (real samples were not tested). 
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The second example utilized the red-ox cycle of p-aminophenol (p-AP) as 
the substrate for ALP-streptavidin conjugate [99]. In presence of tris(2-
carboxyethyl)phosphine (TCEP), p-AP red-ox cycle was extended with a 
significant increase of the amperometric current, allowing for the 
simultaneous detection of total Aβ and Aβ1-42 species. Sensor response 
decreased when amyloid concentration increased, with an estimated 
detection limit of 5 pM for both species at mAb-modified electrode, tested 
in spiked artificial CSF. Both examples highlight the successful potential 
of electrochemical-based immunosensing by means of ALP-based 
enzymatic cycling leading to signal enhancement. The above ALP-based 
approaches are summarized in table 1-3. 
 
Concluding remarks 
In summary, immuno-based bioanalytical platforms such as ELISA and 
XMAP are still the gold reference for conventional AD hallmarks 
detection at clinical level, integrated to advanced functional and molecular 
brain imaging techniques. Amyloid-β monomers, i.e. Aβ1-40 and Aβ1-42, 
are still currently the major players in this field, on the basis of the 
classical interpretation of the ACH which assigns the pathogenic trigger to 
these APP sub-products. However, diagnostic meaning of Aβ1-40/Aβ1-42 
ratio and ADDLs oligomers detection are emerging as complementary 
information. Tau protein, and some of the possible phosphorylated forms 
(mainly p-tau181), flanks Aβ in AD biomarkers analyses, even if the related 
literature is still limited with respect to amyloid-based assays. Emerging 
immuno-based platforms are still restricted to research level, but their 
contribution is of utmost importance in the discovery of new biomarkers, 
creative and sensitive analytical strategies (label-free or label-based), and 
innovative analytical platforms (e.g. optical and electrochemical 
(bio)sensors). Depending on the target analyte, especially for amyloid 
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monomers and oligomers, immunoassays generally require sandwich-
based detection strategies and signal enhancers to push detection limits 
toward clinically significant values. As a whole, antibodies are still the 
bioreceptors of choice in this field, applied to established and innovative 
bioanalytical platforms. However, the following paragraphs will discuss 
the growing role of synthetic (bio)receptors as  an alternative to antibodies 
in AD biomarkers detection. 
 
1.5 Biomimetic receptors as alternative to immuno-detection 
In the last decades, great efforts have been directed toward the design and 
the selection of innovative synthetic receptors that may realize the dream 
of effective alternatives to classical antibodies. At present, several classes 
of synthetic receptors have been widely tested at research level and are 
now also available on the market. Biomimetic receptors share with their 
natural counterpart the unique feature of recognizing their target analytes 
in a specific and selective manner, being at the same time smaller in size 
and easier to be chemically modified. Moreover, their in-vitro production 
permits in general low costs and high stability of the products, which can 
be elicited toward wider panels of targetable analytes [100]. The most 
exploited biomimetic receptors for protein analysis are undoubtedly 
aptamers [101], [102], peptides or peptoids binding proteins [103], and 
molecularly imprinted polymers (MIP) [104], [105]. Surprisingly, in the 
field of biomimetic receptors for AD diagnosis, the presence of aptamers 
and MIPs is still limited. On the contrary, peptides and peptoids (unnatural 
synthetic N-substituted oligoglycines binding proteins [106], [107], [108]) 
have found major application as biomimetic receptors.  
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1.5.1 Peptides and analogues  
As shown in table 1-4, their use is prevalently found in electrochemical 
techniques based on impedance (Electrochemical Impedance 
Spectroscopy, EIS), and voltammetry (Square Wave Voltammetry (SWV) 
and Differential Pulse Voltammetry (DPV)). 
 
table 1-4 Biomimetic receptors used for AD biomarkers detection. (a): EIS, 
Electrochemical Impedance Spectroscopy; SWV, Square Wave Voltammetry; DPV, 
Differential Pulse Voltammetry.; SPRi, Surface Plasmon Resonance Imaging. (b) 
ADDLs: Amyloid-Derived Diffusible Ligands. (c) CHO: Chinese hamster ovary cells; 
CSF: cerebrospinal fluid. 
Transducer 
Technique 
(a) 
Analyte 
(b) 
Biomimetic 
receptor 
Matrix (c) LOD 
Referen
ce 
Electrochemical 
EIS ADDLs PrPc fragment CHO cells 100 pM [113] 
EIS ADDLs PrPc fragment serum 3 pM [114] 
EIS ADDLs 
Nanobodies 
(A4, A5) 
CSF n.d. [125] 
SWV ADDLs I10 peptide serum 480 pM [123] 
SWV ADDLs I10 peptide buffer 48 pM [115] 
DPV Aβ1-42 Gelsolin 
rat CSF and 
serum 
50 pM [126] 
Optical SPRi Aβ1-42 ADP3 peptoid serum 2.2 µM [118] 
 
Among synthetic peptides, Prion Protein fragment (PrP) [109], [110] and 
I10 peptide, [111] emerged over the last years as extremely promising 
synthetic receptors for ADDLs and Aβ bioassays. 
The cellular prion protein (PrP
C
) has been identified in the genome-wide 
screen as a high-affinity receptor for Aβ oligomers [110], and many 
studies have also indicated that the core region of PrP
C
 responsible for the 
AβO/PrPC interaction is PrP(95–110, THSQWNKPSKPKTNMK), which 
is located within the unstructured N-terminal region of PrP
C
. It has also 
been shown that sub-stoichiometric amounts of PrP
C
 (as small as 1/20) 
relative to Aβ strongly inhibit amyloid fibrils formation [112]. This effect 
is specific to the unstructured N-terminal domain of PrP
C
 and electron 
microscopy indicates that PrP
C
 is able to trap Aβ in an oligomeric form.  
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Rushworth and colleagues immobilized the PrP peptide via 
biotin/neutravidin interaction [113]. A polymer, polytyramine/poly-3-(4-
hydroxyphenyl propionic acid) (POPA), is used on screen-printed gold 
electrodes to minimize non-specific interactions during the analysis. The 
synthetic oligomers were incubated on the sensor surface for 20 minutes 
(1 pM to 1 µM) prior to EIS measurements; then, by increasing ADDLs 
concentration, a decrease in the charge transfer resistance was observed 
(Pearson R value = -0.991). In order to evaluate the response in real 
conditions, the ADDLs produced in Chinese Hamster Ovary (CHO) cells 
(used as a model for human oligomers) were analyzed, revealing the 
ability of the sensor to work in complex media. 
Liu and co-workers developed a sandwich-based assay in which PrPC was 
used both for capturing ADDLs and for achieving their detection by 
means of electrochemical reaction [114]. Cysteine-containing PrP(95–
110) was immobilized on a gold electrode to capture Aβ oligomers; then, 
alkaline phosphatase (ALP)-conjugated PrP(95–110) was used for the 
recognition of the captured analytes and the generation of electroactive 
species, leading to a limit of detection of 3 pM (calculated versus the 
molecular weight of the Aβ monomer). Sato and colleagues [111] 
observed that GxxxG (G=glycine) motifs play a key role as inhibitors able 
to block fibrils formation. These authors started from a general eight 
amino acid peptide, RGTFEGKF-NH2 (I1), characterized by alternated 
hydrophilic and hydrophobic amino acids. In β-strand secondary structure, 
the hydrophilic amino acids line one face of the peptide, RxTxExKx, 
whereas hydrophobic amino acids line the opposite face, xGxFxGxF. The 
alternating small and large amino acids on the hydrophobic face displayed 
a stacking activity, and among twelve peptides derived from the first, a 
number of them confirmed a binding ability in the nanomolar range. In 
particular, the linear peptide I10 showed the ability to specifically interact 
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with ADDLs by hydrophobic interactions. The dynamic properties of I10 
peptide have been exploited in a novel peptide-based sensing strategy by 
making use of the analyte-binding induced change of surface Electron 
Transfer (ET), as well as the fine-tuned Square Wave Voltammetry 
(SWV) frequency [115]. In particular, the peptide probe carrying an N-
terminal modification with 11-mercaptoundecanoic acid (MUA), and a C-
terminal modification with Ferrocene, is self-assembled on gold 
electrodes. After saturation of the surface with 9-mercapto-1-nonanol 
(MNH), the electrode was incubated (20 h at room temperature, 10 mM 
PBS, pH 7.4) with concentrations of Aβ1–42 soluble oligomer and then 
rinsed with water. Since SWV currents relative to target-free and target-
bound states result very different as the frequency of the square-wave 
pulse is altered, authors finely tuned this parameter. At 5 Hz they found 
that target binding can induce slowdown of surface ET, with consequent 
amplification of the response. Conversely, under the same conditions, the 
flexible, target-free state of I10 peptide corresponds to a suppressed signal. 
This allowed for the Aβ1–42 soluble oligomer calibration following a 
signal-on strategy down to 240 pM of the protein in buffer solution. 
Recovery was assayed in simulated serum spiked with Aβ1–42 in undiluted 
fetal bovine serum with relative errors (%) lower than 5%. In the wake of 
these first examples, the research for new and improved peptides with 
similar characteristics have been designed and tested as inhibitors [116]. It 
is easily predictable that these peptides will be soon exploited in new 
bioanalytical assays for AD markers detection. 
Similarly to peptides, peptoids are unnatural synthetic N-substituted 
oligoglycines that have been selected from the libraries and applied as 
antigen surrogates to identify and isolate target antibodies in body fluids 
[117]. This N-substitution prevents the intra-backbone (BB) hydrogen 
bonding that is seen in proteins and polypeptides, providing an 
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opportunity to explore polymer properties and folding in the absence of 
BB hydrogen bonding. Very recently, a work aimed to Aβ1-42 detection in 
serum samples by SPR imaging biosensing has been published exploiting 
the peptoid ADP3 [118]. This peptoid was first selected by Reddy and 
colleagues by a comparative screening of a peptoid library against AD and 
normal sera, searching for candidate IgG biomarkers and their relative 
capture agents based on an immunoassay method [108]. They found that 
ADP3 retains the ability to distinguish AD from healthy sera through its 
interaction with some biomolecular signature present in AD sera, i.e. Aβ1-
42 or unknown IgGs present in AD sera.  
 
1.5.2 Cucurbit[n]urils  
Another successful example are cucurbit[n]urils (n=5,6,7,8,10) [119], 
macrocylic compounds composed by glycoluril monomers linked by 
methylene bridges. Their cavities are highly symmetrical, with two 
identical openings of variable size depending on n, and have been 
extensively studied for their host-guest chemistry [120]. Their potential 
role as drug deliverers has strongly attracted researchers in supramolecular 
chemistry first [121], but recent advancements in modification and 
functionalization opened new routes for their application in several fields 
[122], including sensing. A recent, elegant example  combines the I10 
protein binding peptide cited above [111] as capturing receptor with 
cucurbit[8]uril as signal reporter [123]. Such approach was applied to 
ADDLs and Tumor Necrosis Factor (TNF) indirect detection. Depending 
on analyte concentration, after its capture by the peptide, the remaining 
free molecules are able to interact with cucurbituril and its electrochemical 
reporter. Thus an inverse relation is established between analyte 
concentration and the signal. This approach allowed for detecting ADDLs 
in buffer at a concentration of 48 pM.  
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1.5.3 Single-domain antibodies 
The use of single-domain antibodies (also called nanobodies) [124] has 
also to be mentioned in this framework. Their minimal size, great stability, 
reversible refolding and outstanding solubility in aqueous solution, is 
combined with the ability to specifically recognize unique epitopes with 
subnanomolar affinity. In the race toward new effective receptors for AD 
diagnosis, A4 nanobody [124] specific for Aβ has been immobilized over 
a printed circuit and detected by EIS [125]. A second clone, D5, specific 
for α-synuclein (Parkinson's disease biomarker), was used in parallel 
experiments and both nanoclones displayed coherent results in diluted 
CSF on AD, PD patients, or healthy controls. 
 
1.5.4 Gelsolin 
Finally, gelsolin was recently reported in two works of Yu and co-workers 
[126], [127] based on electrochemical transduction. This secretory protein 
is known to selectively bind soluble Aβ monomers (both Aβ1–40 and        
Aβ1–42) in a concentration-dependent manner, but not their oligomeric and 
fibril forms [128]. Gelsolin is therefore a promising alternative receptor 
for the detection of total soluble Aβ1–40/1-42 in CSF, even if it does not 
allow for the differentiation between the two forms. Both the cited works 
use screen-printed carbon electrodes (SPCEs) as electrode surface, which 
undergo modification with multi-walled carbon nanotubes and gold 
nanoparticles (GNPs) to facilitate the electron transfer on the film. 
Gelsolin is then immobilized by amino-coupling and the remaining film 
surface is finally blocked through bovine serum albumin (BSA) 
incubation. The direct assay is performed by addition of Aβ1–40/1-42 on the 
sensor surface. To realize the sandwich assay, GNPs in solution are 
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functionalized with gelsolin and thionine [126], or Horseradish peroxidase 
(HRP) [127] and added to Aβ1–40/1-42 molecules already bound to the 
electrode. The secondary recognition is allowed since gelsolin displays 
multiple site recognition ability on Aβ1–40/1-42 species. By monitoring 
thionine reduction signal, a linear relationship was found between 0.1 and 
50 nM of Aβ monomers, with a LOD of 50 pM. The inclusion of HRP 
enzymatic reaction in the detection strategy further improved the 
sensitivity down to 28 pM. Both methods allowed the differentiation 
between healthy and AD rat’ CSFs, and high selectivity against potential 
sources of interference, i.e. Aβ oligomers, fibrils and protofibrils, was also 
demonstrated.  
 
1.5.5 State of art on aptamers and MIPs for AD diagnosis 
Aptamers are usually selected in vitro by Systematic Evolution of Ligands 
by Exponential enrichment (SELEX), fully reviewed elsewhere [129]. 
Compared to antibodies, they show no immunogenicity, smaller size, and 
can be labeled with multiple fluorophores to ensure multi modal 
recognition [130]. Since the 1990's, with two seminal works in this field, 
references [101], [102], a huge number of aptamers for therapeutic and/or 
diagnostic purposes have been selected and tested, two among all the 
thrombin [131], [132], [133] and TAT protein aptamers [134], [135]. 
Despite aptamers have stimulated wide interest in clinical diagnostics and 
therapeutic applications, up to now only few attempts have been directed 
toward their selection for AD biomarkers detection. An aptamer for Aβ1-40 
was developed by Ylera and colleagues, who immobilized the target on an 
affinity chromatography separation column [136]. After eight rounds of 
selection, several sequences were isolated with apparent dissociation 
constants (Kd) spanning from 29 to 48 nM. The lowest Kd was obtained 
for β55 oligonucleotide, which interacted only with amyloid fibrils. Such 
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feature was due to the specific interaction of the aptamer with β-sheets 
assumed by the target during aggregation. Such hypothesis was also 
supported by Rahimi and colleagues [137], who used covalently stabilized 
Aβ1-42 trimers as target for the aptamer selection. After 12 rounds of 
selection based on filter binding partitioning technique, 33 clones were 
selected. Surprisingly, no interaction with trimers was found for the two 
best candidates (KM33, KM41). Otherwise, the aptamers showed affinity 
toward several kinds of amyloid fibrils, either formed by Aβ peptides or 
by other amyloidogenic molecules such as lysozyme, prion peptide etc. 
Despite the scarce specificity showed as receptors, aptamers could find 
use in replacing amyloidogenic marker (thioflavine) to detect early β-
sheets structures. This suggestion was exploited for ex vivo application of 
β55 aptamer on natural amyloid plaques [130]. From this point of view, 
aptamers showed better features compared to antibodies because of the 
ease of labeling (by inserting fluorescent nucleotides) and delivery into 
living cells. Nonetheless, the absence of analytical applications and the 
observed cross-reactivity, suggest the need for further efforts in the 
aptamer selection for AD biomarkers detection. In this framework, also 
aptamers against whole tau protein have not yet been developed and 
proposed. A pioneering selection was recently carried out by Flu-Mag 
SELEX [138], against a peptide corresponding to amino acids 226-240 of 
the tau protein, in which the target analyte is bound to magnetic beads 
allowing for their easy separation. Thirteen rounds of selection were 
performed obtaining 47 clones with the best binding affinity of Kd=76 nM. 
To note, preliminary experiments have been reported by joint work by 
Minunni and Peyrin groups for the capillary electrophoresis-SELEX based 
selection of DNA aptamers against whole protein tau [139], and a very 
recent work has also been reported [140]. 
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Finally, MIPs development for large biomolecule binding, e.g. proteins, is 
an emerging field that only in the last years has found some innovative 
strategy to obtain reliable results applicable to bioassays [141]. One of the 
most promising approaches is undoubtedly the so called 'epitope 
imprinting', which differs from past strategies by substituting the classical 
whole molecule imprinting method with a smart and effective imprinting 
of short (≥ 9 aa) and surface epitopes [142] of the protein. To do this, 
synthetic peptides are exploited to mimic the epitope, and tailored 
mixtures of monomers and cross linkers (depending on the amino acids 
composition) are used through different methods to synthesize MIPs, even 
at nanoscale [143].  
Epitope imprinting has been therefore attempted for the imprinting of the 
C-termini of Aβ1-40 and Aβ1-42 corresponding to the sequences Aβ33-40 and 
Aβ33-42. MIPs were synthesized using two hexapeptides as templates 
[144], and their binding properties were evaluated comparing MIP affinity 
with non-imprinted polymers (NIPs) after incubation for 24 h of polymer 
particles with the analyte under denaturing conditions. The most 
promising polymers were immobilized on solid phase extraction cartridges 
used to enrich serum samples spiked both with 625 nM (2.5 mg L
-1
) of the 
templates and full length Aβ1-40 (5 µg L
-1) or Aβ1-42 (1 µg L
-1
). Eluted 
fractions were analyzed by HPLC showing linear dependence (R
2
=0.999) 
between 0.125-12.5 μM (0.5-50 mg L-1). Recoveries at spiked levels were 
also analyzed by SDS-PAGE of eluted fractions. Interestingly, MIPs 
presented similar performances both for templates and for full-length 
species. This attempt, the first at our best knowledge, shows that MIPs are 
promising new biosynthetic receptors with encouraging perspective, both 
in fundamental studies of peptide aggregation and AD diagnostics. 
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1.5.6 Concluding remarks 
In summary, new routes are opening toward the application of biomimetic 
receptors in the field of AD biomarkers detection, mainly peptides and 
peptoids. The advantages offered by their unique characteristics (mainly 
ease of production, modification, and improved stability compared to 
antibodies) can be effectively exploited to transduce electrochemical or 
optical signals. Great efforts are still needed to expand their applicability, 
mainly aimed to explore and control their specificity toward target 
analytes in real matrices. Sensing platforms, from electrochemical to 
optical ones, find room to host synthetic bioreceptors with high versatility 
and potentialities, but new sensitive and assessed detection strategies are 
still required. In this panorama, the selection of aptamers and the synthesis 
of molecularly imprinted polymers (MIPs) targeting AD biomarkers could 
further enrich the possibilities given by biosynthetic receptors in rivaling 
antibodies. However, much work is still needed in this direction, and the 
overall feeling is that results strictly depend on the elucidation of the 
physiopathological mechanisms of AD, under continuous revision, and the 
identification of effective biomarkers. 
 
1.6  Conclusions and future outlooks  
This review provides a critical viewpoint on bioanalytical approaches to 
CSF AD biomarkers detection, moving from conventional assays based on 
antibodies as bioreceptors (ELISA and xMAP) toward innovative 
approaches both in terms of bioanalytical platforms and synthetic 
receptors. Conventional methods are still the best choice for routine 
diagnosis, while more likely emerging techniques are going to play a role 
in the study of marker levels variability and aggregation patterns. Among 
currently investigated AD biomarkers, we focused the discussion on the 
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most validated core biomarkers, i.e. Aβ1-40/1-42, total-τ, and p-tau181. At 
present, the majority of the works is related to the investigation of amyloid 
species, while only few focused on the tau protein detection. A similar 
trend is found considering the capturing probes, i.e. antibody-based assays 
are predominant compared to the exploration of new receptors for AD 
detection.  
Signal amplification based on labeled or unlabeled strategies showed to be 
effective to achieve adequate sensitivity, but related protocols are usually 
more complex with possible analyte loss over steps. Moreover, 
conjugation of antibodies to labels is a delicate step which may result in 
reproducibility loss and increase of analysis costs. Concerning the choice 
of selective and sensitive bioreceptors as an alternative to antibodies, a 
number of encouraging examples are emerging in the literature. Most of 
these synthetic receptors are peptides or related species, while aptamers 
and MIPs still found very few applications to biomarker quantification. As 
a whole, their employment as synthetic receptors is still in its germinal 
stage, but promising results have already been obtained. 
Some aspects related to AD biomarkers detection, besides those covered 
here, deserve to be mentioned in conclusion. In particular, the 
identification of alternative sampling matrices and new hallmarks has 
undoubtedly a relevant role in the near future of AD diagnosis [145]. CSF 
is still considered the elective source for biomarker detection, as it is in 
direct contact with the extracellular space of the brain and can reflect 
biochemical changes that occur inside the brain. However, alternative 
matrices are currently under consideration for conventional biomarkers 
detection, i.e. serum/plasma, urine, saliva [146], [147], [148]. At the same 
time, alternative matrices are of great interest also in the identification of 
new AD biomarkers [149]. To our best knowledge, despite the obvious 
advantages non-invasive and peripheral sampling, to date controversial 
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and limited results have been reported in literature [150], and a clinical 
applicability is far from reality. Brain derived proteins exist in much 
smaller concentrations in peripheral blood or urine than in CSF, due to the 
function of the blood–brain barrier and the large total volume of blood and 
urine in which they are diluted; further complications include significant 
binding of many proteins of interest and rapid clearance from the blood, 
which may make many conventional assays insufficiently sensitive [151]. 
This may change with the development of more sensitive metabolomic 
and proteomic approaches being used for biomarker discovery. 
The route toward early and effective AD diagnosis is still a challenge, but 
the perspective of achieving reliable, sensitive and hopefully predictive 
bioassays is mandatory. Several technical aspects such as sampling, 
handling and storage of CSF samples are related to inter-laboratory 
variability, which results significant even if tested on validated 
commercial platforms. Moreover, the complexity of AD pathogenesis, far 
from being unraveled, results in the production of several related 
biomarker species (i.e. monomers, oligomers, fibrils, etc.). This reflects 
and could eventually elicit the currently investigated inter-laboratory 
variability, thus going deeper into the research in this field is necessary. 
Behind these considerations related to ex vivo analysis, the role of in vivo 
imaging approaches, which achieved important results in the field, should 
be finally considered, believing that joint efforts interesting progresses in 
AD anticipated diagnostic may come in the next future. 
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2  B a s i c  P r i n c i p l e s  o f  b i o s e n s i n g  a n d  
s e l e c t i o n  t e c h n i q u e  
Beyond the issues presented in the review, few words are worthy to be 
said on the theoretical principles of the techniques which are the basis for 
this work. In the next two paragraphs basics of the biosensing technique, 
i.e. SPR and on aptamer selection based on capillary electrophoresis as 
partitioning technique are reported.  
 
2.1 Principle of SPR biosensors 
IUPAC (International Union of Pure and Applied Chemistry) [1] define a 
biosensor as:  
 
“A device that uses specific biochemical reactions mediated by 
isolated enzymes, immunosystems, tissues, organelles or whole 
cells to detect chemical compounds usually by electrical, 
thermal or optical signals.” 
 
Such devices can be distinguished in Affinity Based biosensors (ABB) or 
catalytic biosensors which differs from the nature of the signal measured 
after the interaction take place. Despite the most successful example of 
commercial biosensors is represented by catalytic biosensor for glucose 
monitoring [2], growing applications of ABB are reported in scientific 
literature. Several transducers and various receptors of different nature 
exist to convert the biological interaction to a readable analytical signal 
(Fig. 2-1). 
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Fig. 2-1: Biosensor general scheme. 
 
Among existing transducers, Surface Plasmon Resonance (SPR) sensors 
are widely applied in clinical diagnosis and many other research field (e.g. 
in drug discovery for reducing in vivo tests) [3–5]. The basic principle that 
allows the transduction is related with the generation of Surface Plasmon-
Polaritons (SPPs), which are electromagnetic waves that propagates at the 
interface between a semi-infinite metal and a semi-infinite dielectric. SPPs 
have a magnetic vector parallel to the plane defined by the interface and 
are characterized by a propagation constant (βSP) dependent on 
permittivity of both materials (equation 1).  
 
𝛽𝑆𝑃 = 𝑘√
𝜀𝑑 𝜀𝑚
𝜀𝑑+𝜀𝑚
  eq. (1) 
 
Such equation describes SPPs only if real part of permittivity for metal 
(εm) is negative and that of dielectric (εd) is positive (εm < - εd). When 
visible or near-infrared light waves are used, silver and gold are among 
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those metals able to fulfill the criteria to generate SPPs, with a propagation 
depth of 100 – 500 nm, for a dielectric with a refractive index (η) of 1.32. 
Intensity of the magnetic field decays exponentially into both media, 
however the majority of the field is concentrated on the dielectric. Because 
of that when SPPs are excited and investigated with a light wave, 
refractive index (related to permittivity) variations in the dielectric 
medium are detected with extreme sensitivity [4,6,7]. However the direct 
interaction of the wave vector with metal films does not allow SPPs to be 
excited. Hence in the SPR instrument described in the experimental part of 
the thesis, as in many other apparatus, a prism (made of BK7 glass, 
ηp~1.52) is used as coupler in order to allow the component of the wave 
vector parallel to the interface, to match that of the SPPs. The light wave 
(λ) must pass through the prism in Krescthmann configuration of 
attenuated total reflection (ATR), generating an evanescent wave 
penetrating the metal film. In matching conditions, depending from the 
incident angle (θ) of light, the propagation constant of the evanescent 
wave can be adjusted to match that of the SPPs and part of the energy of 
the wave vector is transferred to the SPPs (equation 2). 
 
2𝜋
𝜆
𝜂𝑝 sin(𝜃) = 𝑅𝑒{𝛽𝑆𝑃} eq. 2 
 
Using thin metal films (~50 nm thickness) the evanescent wave reaches 
the opposite boundary of the film itself, hence it serves as a probe to 
investigate the events involving the superior dielectric layer (within the 
limit of the magnetic field) [8]. Under coupling conditions, change in the 
propagation constant (i.e.: due to analyte-receptor interaction) affects the 
properties of the incident light wave (i.e.: change of SPR angle, change of 
intensity, and change of the phase), that can be detected label-free and in 
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real time by a photomultiplier detector (in our case) to produce the 
analytical signal.  
Absence of labeling processes is one of the main feature of the SPR, 
especially when the technique is compared with ELISA (Enzyme Linked 
ImmunoSorbent Assay). Moreover time of analysis, multiplexing 
capability [9] and multiple usage of a single biochip [10] can be also 
mentioned as three of the main benefits available for SPR sensors. 
Technologic developments and coupling between SPR biochip and now 
widely available smartphones opened the route for Point-of-Care (POC) 
testing by surface plasmon resonance based sensors, although further 
improvements need to be done (i.e. temperature control) [11,12].  
Similarly to ELISAs, several assay format can be designed for SPR. 
Sandwiches are widely used for proteins or (more generally) those 
molecules presenting at least two epitopes that are recognized by a 
primary and a secondary antibody [3]. Despite the success of this 
approach, the low levels of some proteins in biological fluids, as is the 
case for Alzheimer’s biomarkers, require further efforts to enhance 
sensitivity. Several works reported the use of gold or silver nanoparticles 
(GNPs or AgNPs) as label for the secondary antibody, to greatly increase 
the sensitivity of SPR thanks to mass due to NP size and to the coupling 
occurring between the plasmons on the sensor surface and those of the 
NPs [13–15]. Other approaches allowing significant gain in sensitivity 
consist in nanostructuring the sensor surface using metal nanoparticles 
[15,16], or with single- or multiple graphene layers [17].  
Apart from the very high sensitivity in quantitative analysis, SPR also 
holds the ability to monitor biomolecular interaction in real time, 
elucidating the kinetic and thermodynamic parameters that drive the 
formation of affinity complex. Absence of a label for monitoring kinetic 
interactions, greatly facilitated many tasks such as a comparison among 
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different species and drug-target interactions. Nevertheless determination 
of kinetic association and dissociation constants require carefully designed 
experiments to avoid misleading interpretation of SPR data. Several are, 
indeed, the events that might negatively affect the correct determination of 
kinetic (and thermodynamic) parameters associated with a biochemical 
interaction. Some of them, such as mass transport effect, might be easily 
interpreted and corrected simply by using the proper mathematical model 
to fit the SPR sensorgram, whether it is more difficult to correctly interpret 
biphasic interaction. A complete survey of the amount of information 
derivable from SPR data is reported by Rich and Myszaka [18]. 
In this work, SPR was used both for its excellent sensitivity properties and 
for the above mentioned capability in monitoring biomolecular 
interactions in real time, giving access to kinetic information about the 
binding that are usually more difficult to be obtained with labeled 
approaches. 
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2.2 SELEX and Non-SELEX: advantages and drawbacks compared 
to other existing separation techniques 
In this section basic principles of Capillary Electrophoresis SELEX and 
Non-SELEX (CE-SELEX and CE-Non- SELEX respectively) are 
reported. Since 1990 when aptamers were firstly selected [19,20], the 
selection process has been extensively modified. Many excellent reviews 
summarized the advances made in aptamer selection technologies [21,22]  
which is still evolving nowadays, with the growing application made by 
bioinformatics tools [23].  
Despite its fast evolution, main steps of selection process can be easily 
represented and are summarized in Fig. 2-2 
 
Fig. 2-2: General representation of Systematic Evolution of Ligands by EXponential 
enrichment (SELEX). 
 
After the chemical synthesis (step 1) of a DNA or RNA library, usually 
containing ~10
15
 molecules, this large, heterogeneous pool of sequences is 
put in contact with the molecule for which one wants to select the aptamer 
(step 2). A separation technique is then used to select only the single 
strands DNA (ssDNA) or RNA sequences able to bind the target, 
enriching the library with most affine molecules. After the enrichment, 
Polymerase Chain Reaction (PCR) (step 3) is exploited for their properties 
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to greatly amplify the selected sequences by generating double-strand 
DNA molecules (dsDNA) which are finally purified (step 4) to re-start the 
cycle. For conventional selection methodologies indeed up to 15 cycles 
are needed to obtain potential aptamer candidates, making the process 
laborious and time-consuming. With respect of separation methods they 
are well described by Gopinath [24] and reported in table 2-1. 
 
table 2-1: Separation methodologies used for aptamer selection 
Separation 
technique 
Small 
molecules/Proteins 
Advantage Drawback Reference 
Nitrocellulose 
membrane 
- /+  easy to use 
 high number of 
selection cycles 
 poor binding for 
small molecules 
and peptide 
[19] 
Affinity based 
surface 
+/+ 
 used for 
protein and 
small 
molecules 
 need of target 
specificity or tags 
for 
immobilization on 
the support 
[25] 
Surface Plasmon 
Resonance 
+/++ 
 determination 
of Kd during 
SELEX 
 possible surface 
degradation along 
rounds 
[26] 
Gel shift - /++ 
 no need of 
expensive 
instrument 
 slow 
 low separation 
efficiency 
[27,28] 
Affinity 
Chromatography 
++/+  very common 
 high target 
amount 
 difficile elution of 
best binders 
[29,30] 
Magnetic Beads - /++ 
 no need to 
expensive 
instrument 
 [31,32] 
Flow Cytometry For cell-Selex 
 allows direct 
affinity 
evaluation 
 expensive, require 
high-specialized 
operator 
[33] 
Capillary 
Electrophoresis 
- /++ 
 homogeneous 
 high 
separation 
efficiency 
 need of 
electrophoretic 
mobility 
difference 
[34,35] 
 
The efficiency of the partitioning step is crucial, since the maximum 
affinity improvement per round is closely related to that [32]. As reported 
by Irvine et al., in any partitioning process some parasite sequences 
interacts with the target molecule and migrates with the sequences 
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presenting lower Kd, although the affinity of these parasite sequences is 
not as good as that of the best binder in the pool [36].  
Any method has advantages and drawbacks, but as a general rule they all 
require immobilization of the target on a support. One of the few 
methodology that does not require target immobilization is based on the 
properties of nitrocellulose membranes, which were used to separate RNA 
molecules from protein [37] prior to be applied to selection [19]. 
However, because of the low efficiency of separation technique, several 
rounds were needed to complete the selection. Reducing the number of 
selection rounds is not only necessary in order to rapidly obtain aptamers, 
but also to i) avoid loss of rare (but highly affine) sequences [38], ii) 
reduce errors introduced by PCR along rounds [39,40], and iii) limit 
parasite species enrichment. 
Capillary Electrophoresis-SELEX was introduced by Bowser’s group 
[34,35] to overcome some of the limitations of selection procedures. In 
particular, thanks to separation efficiency of CE, the selection rounds were 
significantly reduced from usual 8-15 to only 2. Secondly, using CE the 
target-DNA (or RNA) complexes are formed in free solution, thus they are 
fully accessible during the separation. Finally, because the process takes 
place in homogeneous solution, the negative selection rounds that serve to 
eliminate the sequences directed to the immobilization support are no 
more required in this approach.  
A lower amount of sequences is generally introduced in the capillaries for 
electrophoretic separation (10
12
 versus 10
15
), though a very high diversity 
is usually recovered from the analysis of selection results. Thus the 
number of independent aptamers available might be greatly increased 
compared to conventional selection techniques. Perhaps one of the major 
inconvenient associated with CE-SELEX is related to the principle that 
allows the separation between DNA and the target. In fact, the 
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electrophoretic mobility of the species depends on the charge/mass ratio, 
thus aptamers against small molecules (i.e.: MW<500 Da) are more 
difficult to select.  
Due to its ability to monitor affinity of the affinity complex, CE responds 
to all characteristics one needs during aptamer selection: i) monitor 
separation efficiency between target and the library; ii) determine kinetic 
and thermodynamic parameters of the interaction; iii) select aptamers with 
pre-defined binding ability [41]. 
To evaluate affinity of target-DNA complex, the species are combined to 
form an equilibrium mixture (EM). Then a plug of the mixture is injected 
in the capillary and undergoes separation in non-equilibrium conditions. 
Ideally the following electropherogram should be obtained (Fig. 2-3). 
 
 
Fig. 2-3: Electropherogram of the Equilibrium Mixture (EM). Upper panel represents 
peak migration times of stable target-DNA complex (target@DNA), dissociating 
complex, and free DNA respectively (from left to right). Lower panel shows position of 
the species in the capillary tube during separation in normal polarity.  
 
DNA molecules which form stable complex (low Kd) with the target 
usually migrate faster than DNA sequences with lower affinity, and free 
DNA. Since libraries are usually fluorescently labeled, all these species 
might be identified with high sensitivity by Laser Induced Fluorescence 
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(LIF) detector [41]. During the selection protocol, the various zones of the 
electropherogram are separated by collecting fractions at different time. 
The user defines the amplitude of collection window (containing 
sequences that are later amplified by PCR) which generally starts from the 
migration time of the affinity complex, and finish when the peak of free 
DNA starts to exit from the capillary. Modification of collection window 
amplitude affects significantly the stringency of the selection. In fact using 
short-time collection windows (end of collection immediately after the 
affinity complex peak) only stable DNA-target complex are selected, 
whether with long-time windows more diversity is maintained within the 
library. Negative selection is carried out simultaneously, by eliminating 
the fraction representing free DNA alone. Evaluation of affinity 
improvement  is realized by estimating the areas under the curve (AUC) of 
each species detected by LIF. 
The concept of CE-Non-SELEX was introduced later in two works 
[42,43]. The process was characterized by absence of amplification steps 
between the partitioning steps. As major advantage, CE-Non-SELEX 
allows to select aptamers considerably faster than any other selection 
methodology. For example, aptamers for h-Ras (a protein involved in cell 
proliferation) were obtained after only three rounds of selection in only 
few working hours according to the authors. Moreover the absence (or 
reduction) of PCR amplification steps, allows rare, very affine sequences, 
to be selected by maintaining the initial high diversity of the library [22]. 
On the other end, for the same reason, data issued of CE-Non-SELEX 
might be difficult to be interpreted without using some data analysis 
technique. In chapter 3 of the thesis the results of CE-SELEX and CE- 
Non-SELEX are compared to the selection of aptamers for tau protein, in 
view of aptamer applications to diagnosis of Alzheimer’s disease.  
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3  I m m u n o s e n s i n g  f o r  p r o t e i n  t a u :  c a r b o n  
n a n o t u b e s  f o r  s i g n a l  a m p l i f i c a t i o n  
As described in the introducing chapter (chapter 1), detection of tau 
protein is usually carried by using time-consuming (i.e.: ELISA) or with 
highly expensive instrumental apparatus. These techniques, despite their 
consolidated applicability need to take advantage from labelling molecules 
(a chromophore or a fluorophore) for the detection of the target.  
Starting from the well-established affinity and selectivity properties of 
commercially available antibodies against tau protein, here we explored 
the use of Surface Plasmon Resonance (SPR) to develop a label-free, 
regenerable biosensor to detect tau.  
First step in this sense was devoted to the investigation of the analytical 
performances of SPR immunosensor developed with a monoclonal 
antibody, mapping the central region of the analyte, immobilized onto the 
gold surface by simple amino-coupling approach. Here we demonstrated 
that, by this method, tau was easily detected with good repeatability 
(below 10% average CV) both in buffer and in simulated matrix solution, 
developed to reproduce the saline, and protein composition of 
CerebroSpinal Fluid (CSF). In the latter, the analytical signal of protein 
tau was maintained for a longer period compared to buffer, suggesting a 
role of dissolving medium composition tau preservation.  
From this first approach the use of an amplification strategy seemed 
mandatory to significantly improve the sensitivity toward pM levels (cut-
off for Alzheimer’s probable diagnosis). To this aim a sandwich assay was 
developed, using of a secondary antibody directed to the N-terminal part 
of tau. The signal was increased, but further amplification was needed. 
Therefore, although label-free feature was lost, Multi-walled Carbon 
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Nanotubes (MWCNTs) were employed to fulfill the sensitivity 
requirement for tau.  
Experimental Limit of Detection at pM level was obtained, and total 
amount of secondary antibody necessary for the analysis was also 
decreased. Regeneration of the sensor became more complicated, if 
compared with previous experiments. Successful removal of carbon 
nanotubes from the surface was achieved by considering the length 
dispersion associated with these nanostructures. As demonstrated here, 
and in previous works, oxidized nanotubes lengths span from                 
0.2 to 2.0 µm. Because of that, to restore the regeneration process 
antibody-MWCNTs conjugate injection in SPR was preceded by a mild 
centrifugation step aimed to keep low- size nanotubes only. Despite this 
could negatively affect signal enhancement this was not observed in this 
case, with a global increase in sensitivity of about two orders of magnitude 
compared to the initial direct assay, set up with the primary antibody only. 
Further studies might allow to improve the LOD in the near future. Better 
size-selection protocol for MWCNTs can be conceived, to improve 
sensitivity as well as repeatability. Since MWCNT length is easily 
monitored by Transmission Electron Microscopy (TEM), accurate 
measurement of this parameter can be considered to evaluate sample 
dispersion. Total antibody amount fixed at the nanotube surface could also 
be controlled either by thermogravimetric analysis or Atomic Force 
Microscopy (AFM). Nevertheless the intrinsic complexity of the 
nanostructures might lead to difficile data interpretation and need 
therefore to be studied in depth prior to be applied.  
 
The results of this work are reported in Biosensor and Bioelectronics, 
special issue of the 26
th
 international congress of Biosensors, in the form 
of Short communication (doi: 10.1016/j.bios.2016.08.078) 
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Abstract 
Interest on Tau protein is fast increasing in Alzheimer’s disease (AD) 
diagnosis. There is the urgent need of highly sensitive and specific 
diagnostic platforms for its quantification, also in combination with the 
other AD hallmarks. Up to now, SPR has been poorly exploited for tau 
detection by immunosensing, due to sensitivity limits at nanomolar level, 
whereas the clinical requirement is in the picomolar range. Molecular 
architectures built in a layer-by-layer fashion, biomolecules and 
nanostructures (metallic or not) may amplify the SPR signal and improve 
the limit of detection to the desired sensitivity. Mostly gold nanostructures 
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are widely employed to this aim, but great interest is also emerging in 
Multi Walled Carbon Nanotubes (MWCNTs). Here MWCNTs are 
modified and then decorated with the secondary antibody for tau protein. 
Eventually we took advantage from MWCNTs-antibody conjugate to 
obtain a sandwich-based bioassay with the capability to increase the SPR 
signal of about 10
2
 folds compared to direct detection and conventional 
unconjugated sandwich. With respect to these results, we hope to give a 
strong impulse for further investigation on studying possible roles of 
carbon nanotubes in optical-based biosensing. 
 
Keywords: Carbon nanotubes; tau protein; Alzheimer’s disease; Surface 
Plasmon Resonance; signal amplification. 
 
3.1 Introduction 
Tau protein is one of the validated biomarkers for Alzheimer’s disease 
(AD) and tauopathies diagnosis in general [1–3]. Sensing and biosensing 
approaches to the detection of AD biomarkers were recently reviewed 
[4,5], highlighting how majority of works in AD research is directed 
toward other biomarkers, i.e. amyloid beta monomers and derived species. 
Despite SPR is described in routine diagnostics for clinical analyses [6,7], 
SPR-based tau biosensing was attempted only by few works [8–10], and 
none of them approaches the detection of tau in real matrix, i.e. 
CerebroSpinal Fluid (CSF). In this framework, we developed an SPR 
immunosensor to detect tau protein at nanomolar concentration, both in 
buffer and artificial CSF (aCSF) by direct and sandwich-based detection. 
Since the use of metallic nanostructures emerged in the last years for SPR 
signal amplification [11,12], we recently exploited gold nanoparticles-
DNA conjugates to this aim, in DNA sandwich-like detection strategies 
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[13,14]. Herein, we combine the enhancing properties given by Multi-
Walled Carbon Nano Tubes (MWCNTs) [15,16] to a classic immuno-
based sandwich format for tau detection. Such nanostructures have been 
reported in biosensing [17] however their use in SPR is still scarcely 
described [15]. Being inspired by these approaches, and considering that 
significant clinical levels of tau protein are in the range of pM [18], we 
developed a sandwich strategy in which the secondary monoclonal 
antibody (mAb2) is coupled to MWCNTs (MWCNTs-mAb2) via amino-
coupling reaction. These nanostructured amplifiers were successfully 
exploited for signal amplification, obtaining a gain of more than two 
orders of magnitude respect to the unlabeled strategy.  
 
3.2  Materials and methods 
3.2.1 Materials and methods 
List of chemicals, SPR instrumentation, biochip modification, MWCNTs 
characterization by TEM and elemental analysis, together with the 
oxidation and functionalization protocols are all reported in 
Supplementary material (Section 3.5.1). 
 
3.2.2 Analysis 
Three assays were designed (Fig. 3-1) and compared: a) a direct assay on 
the primary mAb (39E10 clone, hereafter mAb1), b) a sandwich assay by 
adding the secondary mAb (tau 12 clone, hereafter mAb2) after the direct 
assay and c), a sandwich assay in which mAb2 is covalently coupled to 
MWCNTs (MWCNTs-mAb2). 
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Fig. 3-1: Design of SPR assays for tau quantification. A) direct approach. Antibody 
immobilized by amino-coupling interacted with tau. Injection of the analyte is followed 
by the injection of secondary mAb2 (Tau12, panel B) to amplify the signal. C) Tau12 
coupled to MWCNTs in a sandwich-like format to obtain signal amplification. 
 
Tau protein (diluted in 1X HBS-EP or aCSF) was injected at different 
concentrations, ranging from 125 pM-250 nM. Interaction with mAb1 
lasted 4 minutes for measurements performed in 1X HBS-EP buffer and 5 
minutes in aCSF. The sandwich approach was carried out using mAb2 at 
10 mg L
-1 
for 6 minutes of contact time, when used unconjugated, while 
injection lasted 6 or 15 minutes in presence of MWCNT-mAb2 conjugates. 
HSA at 100 mg L
-1 
(the most abundant protein in CSF) [19], mAb2 
(Tau12) in absence of tau, and MWCNTs-mAb2 (on non-functionalized 
cell) were tested as negative controls to check possible non specific 
contributions. All measurements were realized at 5 µL min
-1 
flow rate, 
using 1X HBS-EP as running buffer. 
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3.3 Results and discussion 
 
3.3.1 Direct assay  
A pre-concentration test was realized to optimize pH conditions during 
immobilization of mAb1, finding the best accumulation effect at pH 4.0 
(2440.7 RU, see Fig. S3-1).  
After immobilization, the biosensor was calibrated in 1X HBS-EP buffer 
and aCSF on tau concentration spanning from 7 nM to 250 nM, showing 
different behaviors in the two media (Fig. S3-2 and Fig. S3-3). Limit of 
detection (LOD) in both media resulted similar (7.8 nM and 15.0 nM 
respectively), but tau showed positive properties when dissolved in 
simulated matrix than buffer. In particular, an extended linearity (125.0 
nM versus 31.2 nM) and an improved repeatability, as demonstrated by a 
lower coefficient of variation in aCSF (5.8%) than in buffer (7.8%), were 
obtained. LOD observed in our experiments resulted similar to that 
reported by Homola’s group, who used a 2-D Self Assembled Monolayer 
(SAM) to build a sandwich strategy to detect tau-amyloid complex 
formation [9]. In our case, nM range was reached by direct approach, 
probably thank to the 3-D character of dextran surface which allows to 
obtain a higher mAb surface density [6,20]. More than 30 measurements 
were realized over the same chip, after regeneration of the surface 
injecting short pulses of NaOH (Fig. S3-4), which did not damage the 
sensor as demonstrated by the absolute RU variation of the baseline 
between two consecutive cycles (±2.2 RU) (data not shown). As negative 
control, aCSF containing physiological HSA levels was tested, displaying 
negligible signal in the absence of tau (3.2 ± 2.2 RU). Investigations on 
tau protein preservation (62.5 nM) in the two tested media revealed about 
89% (45.5±3.1 RU) recovery for tau protein kept overnight at 4 °C in 
aCSF, while only about 42% (16.6±5.1 RU) in 1X HBS-EP buffer under 
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the same conditions (Fig. S3-5). In analytical perspective, these results 
support the need for stable Certified Standard Materials (CRMs) to 
validate methods for AD clinical diagnosis. Such materials, because of 
their validated composition, could help in reducing the interlaboratory 
variability associated with AD biomarker measurements [21,22]. 
 
3.3.2 Sandwich assay 
The sandwich approach, performed by injecting mAb2 after tau binding on 
mAb1 allowed to enhance the analytical signal through mass enhancement 
in a time dependent manner, as demonstrated by increasing tau-mAb2 
incubation time from 2 to 6 minutes (Fig. S3-6, upper panel). The 
maximum enhancement of the analytical signal was obtained by using 10 
mg L
-1
 of mAb2, displaying a concentration dependent response which 
indicates the specific binding between tau and mAb2 (Fig. S3-6, lower 
panel). The absence of non-specific interaction of mAb2 with mAb1 
immobilized on the chip surface was assessed. As negative control, HSA 
at physiological concentration (e.g. 100 mg L
-1
) was tested giving 
negligible signal (Fig. 3-2A). 
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Fig. 3-2: Sandwich assay for tau protein. A) mAb2 injection in absence of tau protein. 
Arrows indicate beginning of injection and end of signal monitoring. B) signal obtained 
for four tau levels. Blue bars represent the results for direct assay, while red bars take into 
account amplification with the secondary antibody (mAb2). 
 
Under these conditions, tau protein was calibrated in aCSF between 1 and 
25 nM (Fig. 3-2B), obtaining a significant enhancement of the SPR signal 
respect to direct detection, with a slope increment of about six folds (from 
0.579 to 3.179) and a linear correlation (R
2
) of 0.995. The estimated LOD 
for tau protein was consequently lowered to 2 nM (vs 15 nM by direct 
detection). Despite the sandwich assay improved the sensitivity, this result 
is still far from the pM range needed for detecting tau protein in clinical 
samples [2]. Therefore, we investigated the use of nanostructures to 
further amplify the signal. 
 
3.3.3 Coupling mAb2 to MWCNTs as signal enhancers for SPR analysis 
MWCNTs were exploited as mass enhancers after their conjugation to the 
secondary antibody to elicit SPR signal amplification. In fact, mAb2 
carrying these nanostructures (Fig. S3-7) at the sensing interface should 
provide a consistent refractive index change, as already reported for the 
detection of erythropoietin by SPR [15]. To use these nanostructures 
overcoming hydrophobic nature associated with their pristine structure is 
mandatory. Dispersibility of pristine nanotubes is in fact very low in 
aqueous solutions [23], which are the ideal media for protein analysis. The 
oxidation of the original material was hence performed both to obtain 
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stable suspensions in aqueous solutions and to provide carboxylic groups 
on MWCNTs surface to covalently link mAb2. Activation of the 
functional groups was verified by IR spectroscopy and elemental analysis 
demonstrating the increase of nitrogen amount on MWCNTs surface (Fig. 
S3-8). To effectively bind mAb2 MWCNTs, a fine optimization of the 
whole protocol was necessary, i.e. sonication time, coupling medium 
composition, and mAb2 concentration, as discussed in section 3.5.2 of 
supplementary material. These parameters resulted crucial to minimize 
inter-particles aggregation and the desired functionalization of MWCNTs 
with mAb2. After a preliminary 1:10 dilution, the conjugates were initially 
tested (in 1X HBS-EP buffer) on 7 nM tau previously bound on mAb1, 
obtaining an enhancement of the SPR signal of about two orders of 
magnitude respect to the signal recorded by direct assay (from 5 RU to 
567 RU) (Fig. 3-3A). However, despite this huge amplification, the 
regeneration of sensor surface under these conditions resulted impossible, 
probably because of the presence of MWCNTs-mAb2 in the micrometers 
range of size, more prone to aggregate at the sensor surface than shorter 
structures.  
 
 
Fig. 3-3: Signal amplification with MWCNTs-mAb2. A) Comparison of SPR 
sensorgrams obtained by unconjugated mAb2 (top) and MWCNT- mAb2 (bottom), 
displaying the marked enhancement achieved at 7 nM tau. B) MWCNTs- mAb2 / tau 
dependence. Blue bars represent the results for direct assay; red bars reported RU values 
after interaction of tau-mAb1 complex with MWCNTs-mAb2. 
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To overcome this limitation, a final centrifugation step was performed to 
select the low-size fraction of NTs [24], and only the supernatant was then 
used for the injection. By this approach we successfully achieved the 
enhancement of the SPR signal in a dose-response manner, together with 
the good regeneration of the tau-MWCNTs-mAb2 adduct after each 
measurement. Under the optimized conditions, tau concentration from 125 
to 1000 pM were assayed in aCSF, clearly showing a dose-response trend 
(Fig. 3-3B), which displays an exponential shape. In fact, we observed that 
the increase of tau bound to mAb1 induces a deviation from linearity, 
probably due to local packing of nanostructures at the surface. This likely 
reflects the complexity of tau-MWCNTs-mAb2 interactions at the sensor 
surface, and suggests a key role of the protein in bundles deformation 
process [25]. This process eventually might favor nanotube-nanotube 
interactions and produce both deviation from linearity and difficulties in 
regenerating the biochip, especially for tau concentration higher than         
1 nM. As negative control, MWCNTs-mAb2 were tested on the non-
functionalized CM5 surface, showing low absorption (21.20 RU ± 5.27 
RU) compared to the signal obtained in the presence of the analyte. 
Conversely, when MWCNTs-mAb2 are injected on mAb1 in absence of 
tau, valuable adsorption of about 60 RU is recorded, therefore an 
experimental detection limit of 125 pM is obtained. The variability among 
different MWCNTs injections (n=6) was estimated by relative error (Er), 
resulting about 14% probably due to the complexity of the nanostructures, 
both in controlling their size distribution and their reproducible 
functionalization. Although some room for improvement is still possible to 
effectively apply the present approach to reusable biosensing platforms 
such as SPR, our results are easily transferable to disposable devices for 
AD biomarkers detection in CSF, e.g. for point-of-care testing, on which 
regeneration aspects would be of minor importance.  
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3.4 Conclusions  
Interest on Tau protein is fast increasing in CSF AD biomarkers detection, 
and there is the urgent need of highly sensitive and specific diagnostic 
platforms for its quantification, also in combination with the other AD 
hallmarks. SPR is still poorly exploited for tau detection by 
immunosensing, displaying sensitivity limits at nM concentration, whereas 
the clinical requirement is in the pM range. Herein we report the 
successful use of MWCNTs as mass enhancers in a classic sandwich assay 
carried out by SPR biosensing. The analytical performances of direct, 
classic sandwich, and MWCNTs-based amplification strategies are here 
tested and compared. As a whole, a significant amplification capability 
(two orders of magnitude) was obtained at the detection limit of the direct 
assay likely due to both the mass of nanostructures and their large surface 
area that makes mAb2 more available for binding. An investigation on 
dose-response dependence at pM tau concentration seems to highlight that 
several contributions are involved in the amplification trend, especially 
increasing tau concentration up to the nanomolar range. Effective 
regeneration of the biochip surface is achievable in the picomolar range of 
the analyte only if nanotubes are well dispersed and bundles formation is 
minimized. Once injected on the sensor surface, the establishment of 
interactions among MWCNTs and tau strongly influences the overall 
behavior of the analytical response, and different optimized conditions 
should be likely adopted to calibrate tau in the nanomolar range. The 
preparation and use of MWCNTs-mAb2 conjugates are here optimized to 
work within the tau picomolar range, and in these conditions the bioassay 
resulted reversible and with an estimated batch-to-batch variability of 
14%. As a whole, in this paper we report the preliminary but encouraging 
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results on the use of MWCNTs-antibody conjugation for the improvement 
of the analytical performances of SPR sensing for tau detection in the 
picomolar range, and may open new roads for innovative and sensitive 
SPR-based methods. 
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3.5 Supplementary material 
 
3 . 5 . 1  Chemicals and procedures 
Reagents and buffers 
Human tau protein (isoform 2N4R) was purchased from Enzo Life 
Sciences (Lyon, France). Primary antibody (mAb1, monoclonal, clone 
39E10 produced in mouse) was from Biolegend (San Diego, U.S.A). It 
recognizes tau protein in its middle domain (amino acids 189-195), a 
region shared by all isoforms. Secondary monoclonal antibody (mAb2, 
monoclonal, clone Tau12, produced in mouse) was purchased from Merck 
(Daarmstaad, Germany) and recognizes tau in N terminus part (aa 9-18). 
Bovine and Human Serum Albumin (BSA and HSA), MWCNTs were 
purchased from Sigma Aldrich (Milan, Italy). HEPES, EDTA, N-Hydroxy 
succinimide (NHS), 1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide 
(EDAC), ethanolamine (EA) and all the other reagents for surface 
modification or buffer preparation were commercially available and 
purified at analytical grade. Buffers and solutions used in the works are 
listed below: 
Running buffer (1X HBS-EP): 10 mM HEPES, 150 mM NaCl, 3 mM 
EDTA with 0.005% Tween20; pH 7.4.  
Immobilization buffer: 10 mM CH3COONa 3 H2O; pH 4.0.  
Artificial CerebroSpinal Fluid (aCSF):150 mM NaCl, 3 mM KCl, 1.4 mM 
CaCl2 2H2O, 0.8 mM MgCl2 2H2O, 1.0 NaH2PO4 H2O with 100 mg L
-1
 
HSA, pH 7.3) [1]. 
Conjugation buffer (0.5X HBS-EP): 5 mM HEPES, 75 mM NaCl, 1.5 mM 
EDTA with 0.005 % Tween20, pH 7.4. 
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SPR instrumentation and biochips modification  
All measurements were performed on a BiacoreX™ provided by GE 
Healthcare (Uppsala, Sweden) The system consists in a liquid delivery and 
an optical system, both thermoinsulated and maintained at 
T=25.00±0.01°C. Optical system was arranged in classical Kretschmann 
configuration [2] (Kretschmann, Raether; 1968). In this configuration the 
diode array (at 632.5 nm wavelength) of the instrument interacts with a 
metal film (i.e. gold of about 50 nm thick) vaporized over a glass prism 
which serves as wavelength coupler. Commercially available CM5 chips 
(GE Healthcare, Uppsala, Sweden) are provided with 100 nm layer of 
carboxymethylated dextran to allow covalent linkage for biomolecules. 
Primary mAb (mAb1) was attached to CM5 surface using the following 
procedure: carboxymethylated dextran surface was activated with 50/200 
mM NHS/EDAC aqueous solution (50 μL, 10 min). 200 mg L-1 mAb1 (75 
μL, 15 min) were prepared in immobilization buffer and let react with the 
surface on flow cell 1 (fc1) of BiacoreX™. Residual active sites of the 
surface were finally de-activated with 1 M EA solution (pH 8.5) (75 μL, 
15 min, 2X). Flow cell 2 (fc2) underwent the same protocol except for 
antibody injection and is used as negative reference. The reagents required 
for all steps were injected manually in the SPR system, and transferred to 
biochip cells using running buffer as carrier. Reproducible sample volume 
was insured by the Integrated µ-Fluidic Cartridge (IFC) of the instrument. 
An external compressor and an automatic syringe pump provided a 
constant flow rate, maintained at 5 µL min-1for all functionalization steps. 
SPR signals were expressed as difference of resonance units (ΔRU) with 
respect of the absolute baseline RU value.  
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MWCNTs characterization 
Carbon nanostructures have been characterized by Transmission Electron 
Microscopy (TEM), IR spectroscopy and Elemental Analysis (Elem. 
Anal.). TEM analysis was performed on a Philips STEM CM12 at room 
temperature, IR spectra were recorded, under nitrogen at room 
temperature, on a Perkin Elmer FT-IR 881 spectrophotometer, in KBr 
(pellets). Elemental analysis was carried out on a Perkin Elmer 240, 
C/H/N analyzer.  
 
Carbon-Nanotubes oxidation and activation process 
Commercially available Multi-Walled Carbon Nanotubes (MWCNTs) 
(507 mg) (CAS: 308068-56-6, Sigma-Aldrich, product code: 724769, lot. 
MKBH7743V, O.D. x L. = 6-9 nm x 5 µm, carbon>95%) were stirred in 
sulphonitric mixture (20 mL), (H2SO4 96% and HNO3 65%, 3:1) at 100°C 
for 30 min. The suspension was then diluted with cold water and filtered 
on Teflon filter (Wathmann, pore size 0.2 μm). The residue was washed 
with water to neutral pH. Finally, the solid was dried under vacuum for 12 
h affording a black powder (382 mg). Activation of Ox-MWCNTs was 
performed with NHS/EDAC as described by Jiang and colleagues [3]. 
 
Coupling Carbon nanotubes with mAb2 
Oxidized and activated MWCNTs (1 mg) were dispersed in 1 mL of 0.5X 
HBS-EP and sonicated for 30 min. Afterward, 1 mg L
-1
 mAb2 was added 
and incubated under stirring, overnight at room temperature. A 
centrifugation step (14000 g, 10 min, 2X) was realized to remove unbound 
mAb2 by discarding the obtained supernatant. Then MWCNT-mAb2 
conjugates were passivated with aqueous 1 M EA solution (pH 8.5) for 2 h 
at RT. A final centrifugation step (14000 g, 10 min) followed by re-
suspension in coupling buffer, was performed to wash EA after 
Immunosensing for protein tau: carbon nanotubes for signal amplification 
87 
passivation. Finally a mild centrifugation step was realized (2000 g, 90 
seconds) in order to remove evident aggregates from the solution. Only the 
supernatant was injected in the SPR system to interact with the analyte. 
 
 
Fig. S3-1: Pre-concentration test for mAb1. The test was performed dissolving 10 mg L
-1
 
mAb1 in 10 mM CH3COONa·3H2O at pH 4.0, 4.5, and 5.0, as indicated in figure. 
Antibody solutions were injected for two minutes on non-functionalized CM5 sensor chip 
to perform the test. Running buffer was maintained at constant flow rate of 10 μL min-1. 
 
 
 
Fig. S3-2: Calibration of the immunosensor for tau protein in 1X HBS-EP. Limit of 
detection is estimated by the linear plot considering 3σ=6 RU. 
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Fig. S3-3: Calibration of the immunosensor in artificial cerebrospinal fluid (aCSF). Limit 
of detection is estimated by the linear plot considering 3σ=6 RU. 
 
 
Fig. S3-4: Regeneration of the sensor during three sequential cycles. NaOH injections (10 
mM, 24 s) are indicated by arrows. 
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Fig. S3-5: Reflectivity changes inferred from 62.5 nM of tau protein in 1X HBS-EP 
(buffer) or aCSF (matrix). Grey bars represent fresh tau aliquots injected immediately 
after preparation, while white bars represent tau protein preserved overnight at 4°C. 
Measurements were performed in triplicates. 
 
 
 
Fig. S3-6: Upper panel: variation of tau-mAb2 interaction time  at constant antibody 
concentration. 2 and 6 minutes were tested respectively. Lower panel: variation of mAb2 
concentration (20 mg L
-1
 versus 10 mg L
-1
) at optimal contact time of six minutes. 
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Fig. S3-7: TEM image of oxidized CNT. 
 
Elemental analysis: 
a) oxidized MWCNT: IR (KBr): 3422, 2918, 2851, 1696, 1621, 1546, 
1211, cm
-1
.  
Elem. Anal. C, 81.34; N, 0.19; H, 0.65. (Oxidized MWCNT) 
b) activated O-Succinimide-Ox-MWCNT: IR (KBr): 3446, 3020, 2958, 
1699, 1553, 1330 cm
-1
 
Elem. Anal (activated OSu Ox MWCNT): C, 75.80; N, 5.49, H, 2.70. 
 
 
Fig. S3-8: IR spectra of pristine (black line, top), oxidized (red line, middle), and 
activated with O-succinimide groups (blue line, bottom) nanotube obtained in KBr. 
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3.5.2 Optimization of parameters for MWCNTs-mAb2 coupling 
The behavior of activated-MWCNTs in solution, initially studied on BSA 
as model system, resulted highly dependent from the sonication pre-
treatment performed, in agreement with previous observation of two 
different physical states for these nanostructures by using different 
sonication times [4]. The suspension was more stable after 30 minutes 
sonication in 0.5X HBS-EP, while a thick deposit was observed for 
MWCNTs sonicated in the same medium for 10 minutes (Fig. S3-9:  Steps 
carried out to optimize CNTs functionalization by varying the sonication 
time on non-functionalized MWCNTs (1), the immobilization medium 
used for MWCNT-mAb2 conjugation (2), and the MWCNTs/mAb2 ratio 
(3).  
 
 
Fig. S3-9:  Steps carried out to optimize CNTs functionalization by varying the 
sonication time on non-functionalized MWCNTs (1), the immobilization medium used 
for MWCNT-mAb2 conjugation (2), and the MWCNTs/mAb2 ratio (3). 
 
Buffer composition and pH strongly affect the handling of MWCNTs 
during their conjugation to mAb2. Despite acetate buffer (10 mM, pH 5.0, 
under mAb2 isoelectric point) was the first choice to perform amino-
coupling reaction and mAb2 conjugation, we observed a massive 
aggregation under this condition, probably due to the protonation of 
carboxyl sites over the nanotubes surface (Fig. S3-9, panel 2, left). On the 
contrary, the use of HBS-EP buffer (0.5 X, pH 7.4) used for binding 
assays provided very homogeneous and stable dispersion of MWCNTs 
(Fig. S3-9, panel 2, right) and was selected for conjugation. Finally, also 
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the mAb2 concentration strongly affects the stability of MWCNTs 
suspension. In particular, MWCNTs/mAb2 ratios higher than 50:1 led to 
the rapid aggregation of nanostructures (Fig. S3-9, panel 3), whereas by 
scaling down the ratio of 100:1 the aggregation can be successfully 
avoided and it was hence chosen for bioconjugation. 
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4  A p t a m e r  s e l e c t i o n  f o r  p r o t e i n  t a u  
After demonstrating the suitability of Surface Plasmon Resonance in 
quantification of tau protein by well-known antigen-antibody interaction, 
the second part of the work was dedicated to the development of the 
aptamer against tau protein. Two different aptamer selection strategies 
were designed and compared, both based on Capillary Electrophoresis 
(CE) as a separation technique. The first approach was based on the 
conventional CE- SELEX approach, in which separation and amplification 
by Polymerase Chain Reaction (PCR) were carried out in each selection 
round, whether the second was instead inspired to the CE-Non-SELEX 
method. Here the amplification by PCR was realized only once, after all 
partitioning rounds, on the pool of sequences that showed the highest 
affinity for the target.. Only CE-Non-SELEX resulted suitable for affinity 
improvement, possibly because of the non-amplification of the PCR by 
products, with little affinity for tau protein. Pooled sequences issued of the 
third round of CE-Non-SELEX, were sequenced by Next Generation 
Sequencing (NGS) based on the ion-torrent machine. Thanks to this, 
thousands of potential aptamers were obtained, thus data were further 
analyzed by bioinformatics tools before choosing the isolated sequences 
for experimental screening. After this step five isolated DNA strands, were 
collected and their affinity for tau was evaluated by Fluorescence 
Anisotropy (FA) and SPR. Both seemed to confirm that three aptamers 
presented higher affinity for the target, compared to the initial library. As a 
whole in this part of the work we concluded that CE-Non-SELEX was 
superior to SELEX in selecting aptamers for tau protein. The large pool of 
sequences obtained, despite promising, seem only very partially explored, 
thus more in depth analysis of the pool may give access to aptamer that 
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would be more potent than those analyzed experimentally during this 
work, leaving great room for improving the technology.  
 
A manuscript from the results reported here is in preparation with the 
following title:  
 
“CE-SELEX and CE-Non-SELEX comparison for the selection of an 
aptamer directed against the tau protein.”-Manuscript in preparation 
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4.1 Introduction 
After the first selection in 1990 [1,2], aptamers have been widely 
employed either for therapeutic purposes, or for bioanalytical devices. 
Such shorts single stranded DNA (ssDNA) or RNA sequences have 
properties that make them suitable for competing with the most popular 
class of receptors i.e. antibodies [3,4]. For instance, one of their major 
advantages is related to the production process, which is carried out in 
vitro by the so-called SELEX (from Systematic Evolution of Ligands by 
EXponential enrichment), with reduced batch-to-batch variability [5]. 
Among SELEX methodologies, capillary electrophoresis- SELEX (CE-
SELEX) [6–8] presents some significant advantages, such as very low 
sample consumption, no need of target immobilization, and absence of 
negative selection steps [6]. A slightly modified version of CE-SELEX is 
also reported and named CE-Non-SELEX. While in conventional SELEX 
each round is followed by Polymerase Chain Reaction (PCR) 
amplification, in CE-Non-SELEX selection cycles are carried out without 
amplification steps between them. After separation, the recovered DNA is 
incubated with a new amount of the target and immediately re-injected 
into the separation system, considerably speeding-up the selection process, 
and leading to the aptamer selection in about 1 h [9]. Despite the above-
mentioned advantages, to the best of our knowledge very few examples of 
aptamer selection by CE-Non-SELEX are reported [10,11].  
With this in mind, the selection of aptamers against tau protein was 
approached by both methodologies, in order to compare the outcomes of 
the two processes. Human tau, together with amyloid beta peptide, is one 
of the currently accepted biomarker in CerebroSpinal Fluid (CSF) for 
Alzheimer’s disease (AD) early diagnosis [12]. Up to now majority of 
works that investigated interaction among tau and nucleic acids reported 
ability of the protein to interact with double strands DNA or RNA only 
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[13,14]. However more recently ssDNA-tau affinity complex was 
highlighted, making tau a potential candidate for aptamer selection 
[15,16]. After the most affine ssDNA sequence described by Krylova and 
colleagues [16] was used as capturing agent for a mixed DNA-antibody 
assay on SPR [17], Kim and colleagues described a selection process for 
anti-tau aptamer, in 12 selection rounds. [18]. Here is reported the 
selection of aptamer candidates for tau protein after only three rounds of 
CE-Non-SELEX. Two techniques were used to evaluate the affinity of 
isolated sequences: Fluorescence Anisotropy (FA), and Surface Plasmon 
Resonance [19,20]. A critical comparison between the CE-SELEX and 
CE-Non-SELEX methods showed some weakness and strengths of the 
two selection approaches, leaving room for possible improvement in the 
near future. 
 
4.2 Materials and Methods 
 
4.2.1 Materials 
Human tau protein longest isoform (tau441) was purchased from Enzo 
Life Science (Lyon, France), supplied lyophilized and reconstituted as 
recommended by the seller. The linear peptide, LinR3 (representing amino 
acid G271-G323 of tau441) was kindly provided by I2BM group. Human 
Serum Albumin (HSA), mesityloxide (MO), trizima base (tris), glycin 
(gly) and all the reagents for acrylamide gel preparation were from Sigma 
Aldrich (St Quentin Fallavier, France). N-hydroxysuccinimide (NHS) was 
from Fluka (Milan, Italy); sodium acetate was from Carlo Erba reagents 
(Milan, Italy);1-ethyl-3-(dimethylaminopropyl) carbodiimide (EDAC) was 
fromMerck (Darmstadt, Germany); 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES), ethylenediaminetetraacetic acid(EDTA), 
Aptamer selection for protein tau 
97 
ethanolamine hydrochloride (EA) used for SPR experiments were all from 
Sigma Aldrich (Milan, Italy). Other chemicals for buffer preparation were 
commercially available and purified at analytical grade. The 77-nucleotide 
(77-nt) fluorescently labeled single-stranded DNA (ssDNA) library (5’-
carboxy fluorescein (FAM)-GCCTGTTGTGAGCCTCCTGTCGAA-30 
random nucleotides-TTGAGCGTTTATTCTTGTCTCCC-3’), unlabeled 
reverse primer, (5’-ACTGACTGACTGACTGACTA-6C3-GGGAG 
ACAAGAATAAACGCCAA and isolated aptamers were from Eurofins 
Genomics (Ebersberg, Germany). Labeled (5’-FAM-) and unlabeled 
forward primer (5’-GCCTGTTGTGAGCCTCCTGTCGAA) were from 
Eurogentec (Liege, Belgium).GeneAmp 10X PCR buffer II, AmpliTaq 
Gold DNA polymerase and SYBR
®
 green PCR Kit were provided were 
from Applied Biosystems(Foster city, California, USA).  
 
Capillary Electrophoresis apparatus – All separations were carried out 
using Beckman Coulter P/ACE MDQ system (Fullerton, California, USA) 
with exchangeable UV absorbance and laser-induced fluorescence (LIF) 
detectors (λex 488 nm and λem 520 nm) equipped with a fused silica 
capillary for all experiments. The sample was injected applying 0.7 psi 
pressure at the inlet of the capillary and injection times varied depending 
on the experiment. The fused-silica capillaries were conditioned by 
performing the following washing steps at 20 psi: 1 M NaOH for 5 min, 
water for 5 min and migration buffer (which composition varies depending 
on the experiment) for 30 min. Further washing process was performed 
between each run at 20 psi with 1 M NaOH (2 min), water (2 min) and 
migration buffer (5 min) to improve repeatability of peak migration time. 
The voltage applied during separation was 20 kV for all experiments. 
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4.2.2 Preliminary steps 
Tau protein mobility identification- Tau protein (15 µM) was dissolved in 
three different buffers (table s4-1) varying pH values (7.4; 5.5; 3.0) to 
verify electrophoretic mobility (µ±) under different conditions. 
ElectroOsmotic Flow (EOF) was monitored using a 1 % (w/w) 
mesityloxide (MO) solution. Since ionic strength, temperature and 
migration voltage significantly affect the separation [21], all these 
parameters remained unchanged during the analysis. Electrophoretic runs 
were performed on a bare silica capillary of 60 cm (total length) with an 
internal diameter of 50 µm (Polymicro Technologies Inc., Phoenix, 
Arizona, USA). Inlet was positively charged (normal polarity) and the 
distance from the detecting window was 50 cm. Protein was detected by 
UV at 200 nm wavelength. Electrophoretic mobility of the species was 
calculated according to equation 1 to 3 (in supplementary materials) 
 
Quantitative PCR (qPCR) or RT-PCR (real time PCR) - Experiments were 
carried out on collected samples, issued from CE separation, using 
Applied Biosystem StepOne™ Real Time - PCR instrument (Applied 
Biosystem, Foster city, California, USA). Amplification was carried out 
following previously published protocol [22]. Briefly 2 µL of collected 
ssDNA were mixed with 18 µL of SYBR
®
 green PCR Kit (final volume 
20 µL). Unlabeled forward primer and reverse primer were kept at 10
-5 
M. 
Thermal cycle consists in initial denaturation at 95 °C (10 minutes), 
followed by 36 amplification cycles during which 15 seconds at 90 °C 
were alternated with 30 seconds annealing step at 60 °C. Threshold cycles 
(Ct) were determined for each sample, and averaged on three independent 
measurements. 
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4.2.3 Aptamer selection for tau protein 
CE-SELEX - Separation was optimized using TGK as migration buffer (25 
mM Tris, 192 mM glycine, 5 mM K2HPO4, pH 8.34). DNA library was 
heated at 80°C for 5 minutes and left at room temperature for 10 minutes 
prior to tau addition. After 20 minutes incubation, at room temperature, in 
TGK buffer with 1 mM MgCl2, circa 30 nL (calculated by Poiseuille 
equation) of the mixture (total volume 30 µL) were injected. The capillary 
used for conventional selection was 60 cm length from inlet to the bottom 
(effective length from inlet to detector was 50 cm) with an inner diameter 
of 50 µm and an outer diameter of 360 μm (Polymicro Technologies Inc., 
Phoenix, Arizona, USA). Six rounds were carried out, during which the 
sample was collected repeatedly (up to 8 times) in 100 µL of migration 
buffer. Concentration of tau protein and library ratio were modified along 
rounds as reported in table 4-1, and finally amplified by PCR.  
 
table 4-1: tau and DNA concentration along CE-SELEX rounds. 
round [tau]nM 
[ssDNA] 
µM 
DNA/ tau 
ratio 
1 7.50 40 5 
2 0.25 1.25 5 
3 0.13 1.25 10 
4 0.13 1.25 10 
5 0.06 1.20 20 
6 0.04 1.10 30 
 
CE-Non-SELEX - The capillary for electrophoretic separation was 80 cm 
in length (70 cm from inlet to detection window) with an inner diameter of 
75 μm (Polymicro Technologies Inc., Phoenix, Arizona, USA).The DNA 
library (40 µM) was heated at 80°C for 5 min and left at room temperature 
for 10 min. Tau (7.50 µM) was then added to the library for the first round 
of selection. The mixture was incubated at room temperature for 20 
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minutes in incubation buffer (10 mM Tris, 20 mM NaCl, 1 mM MgCl2; 
pH 8.34). For each selection round, DNA sequences, target protein and 
incubation buffer were combined in 40 μL total volume. Tau 
concentrations were 750 nM and 75 nM for rounds 2, and 3, respectively. 
The equilibrated sample was injected for 40 seconds and detected using 
UV to monitor the separation. During a selection round, the eluate was 
collected into 30 μL migration buffer (50 mM Tris, pH 8.34) until the 
unbound DNA peak began to elute. During the first round approximately 
187 nL were injected, containing 10
12 
sequences of ssDNA. Subsequent 
rounds of selection used collected DNA, from the previous round as the 
input DNA. Immediately after migration, the collected mixture was 
incubated with a new aliquot of the target and injected again for the new 
selection cycle. Only the last round is amplified by PCR and sequenced.  
 
PCR amplification and ssDNA recovery - ssDNA candidates were 
generated using a reverse primer and a 5’-FAM-labeled forward primer 
during each round of the selection procedure. The reverse primer is made 
heavier with a succession of six C3 links extended with a 5’ DNA stretch 
of 20 nucleotides. During PCR, this six C3 region and the 20-nucleotide 
stretch cannot be amplified by the Taq DNA polymerase. A PCR product 
with two strands of unequal length is consequently synthesized. Each 
strand is then easily purified on a denaturing polyacrylamide gel. All PCR 
were performed using a Biometra cycler from Labgene (Archamps, 
France). Master mix was made by combining 886 μL nuclease-free water, 
64 μL deoxyribonucleotide triphosphate (dNTPs) (25 mM of each) 
(Invitrogen, Cergy-Pontoise, France), 200 μL each of forward and heavier 
reverse primers (10
-5
 M), 240 μL MgCl2 (25 mM), and 200 μL GeneAmp 
10X PCR buffer II (500 mM KCl and 100 mM Tris-HCl, pH 8.3). After 
mixing, 10 µL (5 U/µL) of the AmpliTaq Gold DNA polymerase was 
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added. To finish, 200 µL of DNA collected during selection were added. 
This mixed solution was divided equally over thin-walled tubes that were 
subjected to PCR. The thermal cycling regime was: initial denaturation for 
10 min at 95°C, and then cycling for 60 s at 95°C, 60 s at 60°C and 90s at 
72°C for 14 cycles. After a Nanosep
®
 3K purification (Pall, Washington, 
New York, USA), the samples, which contained different amounts of 
amplified products, were resolved on a 12% acrylamide gel (see 
supplementary material for preparation and apparatus) at an applied 
voltage of 300 V. The band corresponding to the selected aptamers 
migrates with the same velocity of the library (used as a witness) and was 
visualized by UV-shadow method at 254 nm. After that, it was cut and 
eluted for 1 hour at 65°C and 1 hour at 4°C, in 1 mL of the extraction 
buffer (100 mM Tris-HCl, 500 mM NaCl, 1 mM EDTA, pH 7.4). To 
remove acrylamide, the extracted product was transferred into a Nanosep
®
 
3K device, the retention membrane was replaced by glass wool and the 
system was centrifuged during 10 min at 14,000 rpm with MIKRO 220R 
centrifuge (r=87 mm) (Hettic centrifuges, Tuttlingen, Germany). Filtrate 
was removed, transferred in another native Nanosep
® 
3K device and 
centrifuged for 90 min at 5,000 rpm at 15°C. The material retained on top 
of the porous membrane was washed with 100 µL of water and 
centrifuged again. Finally ssDNA amount was quantified by UV 
absorbance at 260 nm.  
 
4.2.4 High Throughput Sequencing 
After purifying PCR products with MinElute PCR Purification Kit Qiagen 
(70 bp to 4 kb) and elution in very small volumes (10 μL), Next 
Generation Sequencing (NGS) was used to determine aptamers sequences. 
According to the protocol, DNA concentrations were adjusted to 200nM 
(Qubit
®
 dsDNA BR Assay Kit and Qubit
®
 2.0 Fluorometer) and a library 
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was built using AB Library Builder System and Ion Xpress Barcode. 
Clonal amplification was performed using the Ion One Touch 2 system 
and the Ion PGM Template OT2 200 kit (all materials were from Life 
Technologies SAS, Saint Aubain, France). 
The sequencing step was performed using the Ion PGM™ Sequencing 200 
Kit v2, the Ion 316 Chip and the PGM instrument, Personal Genome 
Machine (PGM™) System (Life Technologies SAS, Saint Aubin, France). 
The PGM technology is based on the detection of releasing hydrogen ion 
during nucleotide incorporation in DNA template sequences [23]. In case 
of all chip micro-wells, the incorporated dNTP and the release of a proton 
triggers an ion sensor and an electrical signal indicates that a reaction has 
occurred. Automated read datasets were provided by Ion Torrent software 
7.0.3 as FASTQ format. Obtained sequences were further analyzed by two 
software: PATTERNITY-seq (v 1.0) and MEME (Multiple Em for Motif 
Elicitation, where Em stand for the algorithm used for motif discovery) 
open source suite for motif discovery [24,25]. 
 
4.2.5 Affinity analysis of DNA sequences 
CE-LIF - affinity study was carried out on pooled ssDNA to evaluate 
evolution of selection approaches. To this aim, areas under the curve 
(AUC) of the species in the electropherogram was calculated. Depending 
on the selection process, 60 cm or 80 cm length (from the inlet to the end) 
fused silica capillaries were used (internal diameter 50 or 75 µm 
respectively). Migration and incubation buffers were the same of CE-
SELEX or CE-Non- SELEX. Equilibrium mixture (EM) was composed of 
100 nM 5’-FAM-ssDNA (original library or selected pools), heated for 5 
minutes at 80 °C prior to be incubated with tau protein (3 to 9 µM) for 30 
minutes. EM was injected by applying 0.7 psi pressure at the inlet of the 
capillary for 20 s. Detection of the species was insured by LIF detector.  
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FA - Fluorescence Anisotropy (FA) measurements were performed on 
Tecan Infinite F500 microplates reader (Männedorf, Switzerland). 384-
wells black microplates (Grenier Bio-One, Courtaboeuf, France) were 
used for the minimal sample volume required for the analysis (10 µL). 10 
nM of 5’-FAM-ssDNA (library or isolated sequences) were dissolved in 
incubation buffer (10 mM Tris, 20 mM NaCl, 1 mM MgCl2; pH 8.34) and 
underwent the same treatment carried out during selection. After 30 
minutes at room temperature, tau protein (20 - 700 nM) or LinR3 peptide 
(0.4 – 14 µM only for selected aptamers) were added to the DNA solution 
and immediately analyzed. Excitation was set up at 485 ± 20 nm and 
emitted light was collected at 525 ± 25 nm. Fluorescence anisotropy was 
directly calculated by the instrument software, and the signal was 
expressed as difference (Δr=r-r0) between that obtained in presence of the 
target (r) and that of the fluorescently labeled ssDNA alone (r0).  
 
SPR – BIAcore X™ (GE Healthcare, Uppsala, Sweden) was used for all 
experiments. Tau protein was immobilized on a CM5 sensor chip (GE 
Healthcare, Uppsala, Sweden) by amino-coupling reaction [26]. To this 
aim, the chip surface was activated by the injection of 50 mM/200 mM 
solution of NHS/EDAC (10 minutes, 5 µL min
-1
), followed by the 
injection (30 minutes, 2 µL min
-1
) of 100 mg L
-1
 tau protein dissolved in 
10 mM acetate buffer (pH 4.0). In the end EA (1 M, pH 8.5) was used to 
block residual active sites (15 minutes, 5 µL min
-1
). The five selected 
aptamers (unlabeled, sequences listed in the next section) were injected for 
5 minutes in the system at concentrations ranging from 1 to 10 µM, and 
resulting sensorgrams were analyzed by BIAevaluation 3.1 software. 
During the analysis HBS-EP (10 mM HEPES, 150 mM NaCl, 3 mM 
EDTA, with 0.005% Tween 20; pH 7.4) was used both as running buffer 
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and for aptamer dilutions. The flow rate was maintained at 5 µL min
-1
 and 
temperature at 25 °C. 
 
4.3 Results and discussion 
 
4.3.1 Preliminary steps for optimization of selection conditions 
Electrophoretic tau mobility determination 
Aptamer selection by CE-SELEX or CE-Non-SELEX requires optimal 
electrophoretic separation among the target and the ssDNA library [27]. 
To this aim identification of tau protein was necessary, however at 200 nm 
wavelength several peaks were detected in the electropherogram (Fig. 
S4-1). Usually proteins are specifically detected at 280 nm wavelength 
(Soret’s band), however tau absorbance in this region is very low because 
of the little amount of aromatic amino acid residues which leads to low 
molar absorptivity coefficient (7450 cm
-1
) [28,29]. 
Using small-diameter capillary tubes, no tau was detected, thus monitoring 
of electrophoretic mobility (µeff) of peak 1 and 2 (Fig. S4-1, panel a and b) 
was chosen as criteria to identify tau. Peak 2, showing higher absorption at 
200 nm, showed an electrophoretic mobility value strongly dependent 
from the pH of the buffer solution (µ𝑒𝑓𝑓
𝑝𝐻 3.0
= 9.47 x 10
-9
; µ𝑒𝑓𝑓
𝑝𝐻 5.5
= 1.52 x 
10
-10
; µ𝑒𝑓𝑓
𝑝𝐻 7.4
= -5.93 x 10
-10 
m
2
 x V
-1
 x s
-1
). This behavior is consistent with 
protein properties, since the net charge depends on their isoelectric point. 
Unlike species represented by peak 2, peak 1 showed a constant 
electrophoretic mobility, and eventually disappeared at pH 3.0, probably 
because fully undissociated under these conditions (Fig. S4-1, panel c). 
Once the peak of tau protein was identified, the separation conditions both 
for CE-SELEX and CE-Non-SELEX were optimized and the collection 
windows were defined (Fig. 4-1). 
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Fig. 4-1: Collection window for CE-SELEX (panel a) and CE-Non-SELEX (panel b). 
Tau protein peak (dashed line) migrated before the beginning of collection window, 
while the ssDNA library (solid line) was outside the boundaries of collected sample. Both 
electropherograms were recorded at 20 kV, T 25°C and detected by UV at 200 nm. 
 
4.3.2 Optimization of PCR rounds and target concentration 
Starting target concentration is one of the key points for successful 
selection. As a rule of thumb the target should be incubated with the 
library at concentration two orders of magnitude lower than initial Kd [27] 
but, in this case, little amount of stable affinity complex was observed 
when 750 nM of tau were injected. A more in depth analysis to evaluate 
presence of DNA-tau complex was realized by qPCR, carried out after CE 
separation under optimized conditions. A higher amount of dsDNA is 
recovered from PCR if the DNA-tau adduct is present. Nevertheless, at 
750 nM tau concentration, Ct (threshold cycles) for control (library alone) 
and positive sample were the same (Fig. 4-2, solid line versus dashed-dot-
line respectively). 
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Fig. 4-2: Comparison of qPCR experiments realized after capillary electrophoretic 
separation of 750 nM tau-ssDNA (red, dashed-dot line) and 7.5µM tau-ssDNA (green, 
dashed line). 40 µM of ssDNA were used for all experiments. Library alone was also 
amplified by qPCR as control (blue, solid line). 
 
To overcome this limit, the increase of tau concentration during the CE 
separation was considered. To this aim, two strategies were tested. The 
first one consisted in increasing the number of collections and the injected 
volume for each separation, while in the second approach tau 
concentration, incubated with the library, was increased from 750 nM to 
7.50 µM. Using the first approach, electrophoretic migration time of tau 
protein and library showed poor repeatability after few collections (data 
not shown). The second approach showed only little influence on the 
migration time of the species and, more importantly, Ct were significantly 
lowered as compared with previous experimental set-up (6.26 ± 0.04 
versus 17.57 ± 0.44). These operative conditions revealed a significantly 
higher amount of tau-ssDNA complex, and were therefore chosen for 
selection. 
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4.3.3 Aptamer selection: CE-SELEX versus CE- Non -SELEX 
After optimization of the initial conditions, the selection was carried out. 
The affinity of the selected pool was constantly monitored by measuring 
the area under the curves (AUC) in the electropherogram, using LIF 
detector. Only CE-Non-SELEX approach showed significant increase of 
AUC of the affinity complex (Fig. 4-3a), whether no evolution was found 
for CE-SELEX (Fig. 4-3b) .  
 
 
Fig. 4-3: Affinity complex of the two selection methods. a) CE-Non-SELEX; stable 
affinity complex of the three rounds (indicated in the inset) is collected at 9.8 minutes 
migration time. Areas under the curves of library and first selection round were closely 
related, thus only the latter is reported. b) CE-SELEX showed no evolution; stable 
complex formation (in the inset) is better for library (dotted line) than after two rounds of 
conventional selection (solid line). 
 
The reasons leading to affinity improvement by CE-Non-SELEX might be 
related to the absence of the amplification step. Indeed, for the CE-SELEX 
approach, the presence of PCR by-products was suggested by two 
different experiments. A significant shift of melt temperature (Tm) was 
observed by qPCR after six rounds of selection by CE-SELEX, showing a 
Tm of 68°C which was considerably lower than that observed for the initial 
library (Tm = 75°C) (Fig. S4-1). Even though such shift may be addressed 
to the increased structural homogeneity of the selected pool compared to 
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initial library, this possibility seemed to be remote. Schütze and colleagues 
reported an increment of Tm as long as the selection proceeded [30]. Here 
Tm reduction could most likely be addressed with the formation of PCR 
by-products due to primers dimerization, primer-primer (forward with 
reverse) interactions, or to the presence of impurities in the original library 
[31,32]. Presence of PCR by-products was also suggested from the 
amplification of a negative control sample in which the library was 
injected alone into the capillary and collected in the same conditions of 
CE-SELEX. No ssDNA should have been recovered from the collection 
window, however a broad peak, running with same migration time of the 
library, was observed in the electropherogram (Fig. S4-3). By- products 
formation is a well-known problem of SELEX. The use of CE for 
separation might even worsen such issue because, when compared with 
other approaches, lower amount of ssDNA is injected into the capillary, 
requiring very high efficiency of the amplification step. When the 
accumulation of the desired amplicons is over, presence of primer excess 
in solution could significantly reduce efficiency, resulting in the undesired 
amplification of secondary products [33,34].  
 
4.3.4 Sequencing results 
After selection, the ion torrent sequencing gave rise to 4792 DNA strands 
which are all possible aptamer candidates. PATTERNITY-Seq, developed 
by Ducongé’s group, was used for identification of most abundant families 
within the whole DNA pool. This in-house developed software, was 
designed to highlight DNA families by finding similarities among DNA 
sequences using Levenshtein distance [35]. The tool was conceived for 
screening the sequences of any selection round, in order to highlight the 
presence of DNA similarities along cycles. Nevertheless the software can 
be used also to analyze the data of a single round of selection. Here only 
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round three was analyzed, since the affinity test showed the best binders 
were in that pool. High diversity of the sequence space was revealed, with 
the most abundant family representing only 0.09% of the whole pool. 
Such lack of enrichment might be explained by a multitude of factors. 
First of all the homogenous nature of CE separation used for selection 
greatly increased the degree of freedom for tau-ssDNA interaction. 
Usually considered as an advantage of the technique, in this case this 
feature could have contributed to the diversity obtained during the 
sequencing. Secondly, CE-Non-SELEX also limited the enrichment of the 
pool because of the lack of repeated PCR amplifications.  
Together with this method, a more traditional approach was used to obtain 
a limited amount of sequences for experimental screening of the affinity. 
The entire DNA set was screened again using MEME-suite software, 
based on a different algorithm to seek for conserved motifs. Considering 
the limitations of this online open source utility, only a limited amount of 
DNA strands was uploaded on the website (in FASTA format), after the 
removal of constant region, and elimination of sequences shorter than 30nt 
(random region). MEME confirmed the results obtained previously, since 
no highly conserved motifs were found. Nevertheless five different blocks 
were isolated by grouping the aptamers depending on the number of single 
nucleotides (counting number of A,G etc.) present within each sequence. 
From each one of this block, five oligonucleotides were chosen for affinity 
determination (table 4-2) 
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table 4-2: Isolated ssDNA strands selected as possible anti-tau aptamer candidates. Only 
random region is reported. 
Aptamer 
identifier 
Truncated primer Aptamer sequence Features 
3146 CCTTTGGGGTGGCTTGACGAAGAAAGTAGT Majority of G 
3914 CGGTTCTTAAGGCGTCCGTCTTCATTTGTT 
T with G and C; 
Stem-loop at 5’-end 
4133 CCTGTCAGGTCTTTGACGAGGCTTTTCTTC 
T with G and C; 
linear 5’-end 
4618 CATGTTAATATTCCATCACCGACTTCTTTC Majority of T 
433 GGTGTCGACACCAGCCTTTAACCCTGTGTC 
Equal distribution of all 
nucleotides 
 
4.3.5 Affinity results of isolated sequences 
Fluorescence Anisotropy 
For affinity evaluation of the five isolated aptamers (including primer-
binding regions) we initially chose an homogeneous signaling method to 
replicate the condition of selection process. Among tested sequences, three 
aptamers (sequences 4133, 3146, 433) showed higher affinity than the 
library for the target, whether low binding capabilities were found for 
sequences 3914 and 4618 (Fig. 4-4, panel a and b). 
 
 
Fig. 4-4: Fluorescence anisotropy variations for aptamers 3146 (red triangles, panel a), 
4618 (white squares, panel a) and the library (blue circles, panel a) incubated with tau 
protein (0.02 – 0.7 µM). Panel b shows same data for two concentrations of the target: 
0.04 µM (low level) and 400 µM (high level).  
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All selected aptamers showed similar affinity for tau protein model 
(peptide LinR3, data not shown), revealing a role in improving selectivity 
for the amino  acid residues present in the whole protein and absent in the 
LinR3 model. Human Serum albumin, chosen as negative control, did not 
interact with any of the selected aptamers, showing good specificity 
toward physiological proteins.  
 
SPR 
Tau protein immobilization was carried out at surprisingly acidic pH (4.0) 
with respect to the isoelectric point reported in literature (pI 8.6) [28]. 
Such immobilization pH was chosen with the help of preconcentration test 
(Fig. S4-4) carried to maximize amino-coupling efficiency, which gave 
rise to an average signal of 5190 ± 2 RU. The five aptamers, including the 
primer-binding regions, were then injected at same concentration level    
(1 µM) to compare affinity with tau under the same conditions. In Fig. 4-5 
sensorgrams of the five sequences are reported. 
 
 
Fig. 4-5: Sensorgrams of five isolated sequences injected at 1 µM. 
 
Despite the results reported here are only preliminary, they seemed to 
confirm those obtained by fluorescence anisotropy experiments. Aptamers 
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3146, 433, and 4133 showed higher signal as compared to the other two 
sequences. Aptamer 3146 was chosen for kinetic experiments. A 10 µM 
solution of DNA was initially injected and seemed able to saturate whole 
active sites present on the sensor surface. Recovered signal (2570 ± 2 RU) 
was indeed compatible with theoretical Rmax (2720). Since Rmax value 
might be obtained at species concentration equal to 100 Kd, we could 
expect affinity values for the aptamer is in the nM region. However some 
experimental problems were highlighted. After few injections the 
repeatability of the signal was significantly worsened, resulting in difficult 
interpretation of the sensorgrams recorded at low aptamer concentrations.  
 
4.4 Conclusion 
In this paper, we reported a fast method for selecting aptamer for tau 
protein. Since the initial results obtained by conventional CE-SELEX were 
disappointing, an analysis of the factors leading to the lack of evolution 
was made. In the end amplification step results as a major obstacle to 
allow affinity to be improved. Reducing PCR steps in CE-Non-SELEX led 
to significant affinity increase in only three rounds, and at the same time, 
it considerably reduced the time demanded to realize the whole process. 
Despite highly stable DNA-tau complex was obtained with this approach, 
a very high diversity of the selected pool was highlighted  by the 
bioinformatics tool developed by Ducongé’s group. Absence of highly 
predominant families was obtained from PATTERNITY-Seq, revealing a 
lack of exponential enrichment using only one PCR step. To overcome 
this limitation, some strategies such as emulsion PCR has been reported to 
improve amplification efficiency [34], and might be considered for future 
development. Nevertheless the affinity of five isolated aptamers was tested 
by Fluorescence Anisotropy (FA) and Surface Plasmon Resonance (SPR), 
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showing similar results. The Aptamers 3146, 4133, and 433 clearly 
showed affinity improvements compared to the initial library, with a 
dissociation constant estimated around nM range by SPR. In conclusion, 
here we highlighted the importance of PCR in amplification when highly 
heterogeneous libraries are used as is the case aptamer selection. CE-Non-
SELEX clearly improved the selection of anti-tau aptamers, revealing 
affinity in nM range, similarly to several aptamers present in scientific 
literature. Despite tau concentration is in pM range in Cerebrospinal fluid, 
the work seems promising to highlight critical areas for future 
improvement, leading to aptamers application to AD diagnosis.  
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4.5 Supplementary materials 
 Protocols 
 Results 
 Equations 
 
4.5.1 Acrylamide gel preparation protocol 
Gel for single strand-DNA recovery after PCR amplification was prepared 
as follows: 31.5 mL of 10X TBE buffer (1X: 44.5mMTris-Borate, 1mM 
EDTA; pH 8.3) was mixed with 13.5 mL of 40% acrylamide solution 
(final volume 45 mL). 21.6 g Urea were then added to the solution (final 
concentration 8M) and served as denaturing agent for dsDNA issued of 
PCR [1]. After Urea was completely dissolved, 450 µL of 10 % 
ammonium persulfate solution (APS) and 45 µL of 1,2-
Bis(dimethylamino)ethane (TEMED) were added. The mixture was 
immediately poured within two glass plates and a comb was placed on top 
of the plates, serving as a mold for the wells in which the samples were 
deposited. Polymerization lasted 45 minutes, after which 300 V were 
applied for 10 minutes using ENDURO™ power supplies (Labnet 
International, Edison, USA). 40 to 80 µL of DNA (dsDNA from PCR, 
primer mixture, and original library) were then mixed with equal volume 
of gel loading and added on the well. Separation lasted at least one hour 
after which the species were revealed by UV detection (254 nm). All 
reagents used for gel electrophoresis separation were from Sigma (St. 
Quentin Fallavier, France) 
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4.5.2 Results 
Electrophoretic mobility of tau protein 
Electrophoretic mobility of tau protein was evaluated in the three different 
buffers reported in table s4-1 
 
table s4-1: buffer composition for protein tau mobility test. 
pH Composition Ionic strength 
7.4 50 mM Tris, 50 mM NaCl 
92 mM 5.5. 92 mM CH3COOK 
3.0 63 mM K2HPO4, 28 mM NaCl 
 
Electropherograms of the tau protein are reported in Fig. S4-1. 
 
 
Fig. S4-1: UV absorption of tau protein (15 µM) at pH 7.4 (panel a), pH 5.5 (panel b), 
and pH 3.0 (panel c). Solid line represents tau samples, while dashed line is for reference 
compound (mesytiloxide) 
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Analysis of melt temperature  
 
 
Fig. S4-2: Melt Curves of the DNA pool after round 6 of CE-SELEX process (left panel) 
compared with original library (right panel). In left panel two populations seemed to be 
present. 
 
Electrophoretic migration of library and control sample. 
 
 
 
Fig. S4-3: Electropherograms of ssDNA library (100 nM, panel a) and control sample, 
recovered after PCR amplification, in absence of target (estimated concentration, 655 
nM, panel b). Intensity of both electropherograms were normalized on the peak at 12 min 
(migration time). TGK was used as background electrolyte, temperature was kept at 
25°C. 
.  
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Surface Plasmon Resonance: pre-concentration test 
 
 
 
Fig. S4-4: Pre concentration test for tau protein immobilization. For all samples tau was 
dissolved at 10 mg L
-1
 in acetate buffer (10 mM). 
 
4.5.3 Theoretical models 
Electrophoretic mobility calculation 
The equations below (equation 1 - 3) were used to evaluate the mobility of 
tau protein in the conditions reported in section 3.1.1 of the paper. 
µ𝑎𝑝𝑝± =  
𝐿𝑑/𝑡±
𝑉/𝐿𝑡
  eq (1) 
µ𝑒𝑜 =  
𝐿𝑑/𝑡𝑛𝑒𝑢𝑡𝑟𝑎𝑙
𝑉/𝐿𝑡
  eq. (2) 
µ± =  µ𝑎𝑝𝑝± −  µ𝑒𝑜  eq (3) 
 
Where µ identified electrophoretic mobility of charged species (µ±) or 
neutral electroosmotic flow marker (µeo), Lt, Ld are total length of the 
capillary and lentgh from inlet to detection window respectively (Here 60 
cm, and 50 cm), and V is the separation voltge (20 kV). 
 
 
 
 
Aptamer selection for protein tau 
121 
References  
[1] C. Simard, R. Lemieux, S. Cote, Urea substitutes toxic formamide as destabilizing 
agent in nucleic acid hybridizations with RNA probes., Electrophoresis. 22 (2001) 
2679–2683.  
 

 123 
5  G e n e r a l  C o n c l u s i o n s  a n d  f u t u r e  
p e r s p e c t i v e s  
In this thesis tau protein detection was faced from two different aspects. 
Initially commercially available antibodies were employed to develop the 
immunoassay, then, using advanced separation and sequencing 
technologies, selection of novel aptamer receptors was realized. In both 
these aspects versatility of Surface Plasmon Resonance (SPR) results 
crucial both for quantification of tau and to monitor affinity of the selected 
aptamers toward the target.  
In immunosensing approach the use of a primary antibody only (direct 
assay) did not allow to detect the analyte at pM levels usually founds in 
Cerebrospinal fluid of healthy subjects and those affected by Alzheimer’s 
disease. Nevertheless sensor was able to work both in buffer solution and 
in simulated matrix, encouraging further developments. Hence 
amplification strategy based on multi walled carbon nanotubes 
(MWCNTs) was developed. Such nanostructures were used as label for a 
secondary monoclonal antibody to develop a sandwich-like assay. Using 
MWCNTs pM levels were reached, and the sensor surface was easily 
regenerated in this concentration range. Since Carbon nanotubes can 
interact among them forming bundles, we addressed the regeneration and 
repeatability worsening observed at nM tau level to non-covalent 
interaction between tubes. Possible improvement of both regeneration and 
repeatability issues may come from reducing length-dispersion commonly 
associated with MWCNTs [1], by selecting mono-disperse (or at least less 
disperse) fractions of the nanostructures prior to antibody conjugation.  
Otherwise, nanotubes could be fixed onto the sensing surface of the SPR. 
In fact graphene sheets have been recently reported as SPR signal 
enhancers for the exceptional electrons mobility associated with the planar 
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hybridization of carbon atoms [2,3]. Even though carbon nanotubes are 
oxidized (thus they hold defects that decrease total conductivity) to 
provide functional groups for biomolecules attachment, some properties of 
graphene retained. Moreover increasing superficial area of the sensor 
could greatly improve sensitivity by providing additional capturing 
capability to the sensing elements (i.e. antibodies, aptamers etc.). 
With respect of aptamer selection, despite Kim and colleagues [4] isolated 
few aptamer candidates against tau, the selection they set up was 
characterized by a higher number of selection rounds (12) compared to the 
method developed in this thesis. Here we reported the selection in only 
three rounds of CE-Non-SELEX, which allowed the affinity to be 
significantly improved, compared with initial library. The sample was 
enriched by carrying out a single PCR amplification step on the sequences 
resulting from the third round of selection. Since little sample volumes are 
used during CE, the PCR amplification steps needs to be very efficient to 
avoid amplification of by-products, that are detrimental for affinity 
improvement. Although here the elimination of PCR among different 
selection rounds allowed the aptamers to be selected, further development 
are desirable for the optimization of the amplification step. Next 
Generation Sequencing (NGS), was chosen instead of conventional 
cloning-sequencing process to keep maximum amount of information 
about the selected sequences. This results in the identification of 
thousands aptamers, all potentially good for binding the target. Although 
this might be seen as a limitation because of the difficult interpretation of 
the data, the high information content stored in the dataset could be also 
interpreted as one of the main strength of the aptamer technology. 
Commercially available antibodies have, in fact, limited room for 
improvement with respect of enhancing affinity of the receptor, and they 
can be considered as a mature technology. With the advent of NGS, an 
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enormous amount of sequences can be investigated simultaneously and 
even rare, highly potent aptamers can be selected [5]. Recently the 
importance of sequence-specific interaction with the target was also 
questioned by applying Quantitative Structure Activity Relationship 
(QSAR) model to aptamer for influenza virus [6]. 
As a whole despite immunochemistry still play the most important role in 
diagnostic, the great potential that bioinformatics analysis enable leave 
margin for improving aptamer selection toward protein tau and in many 
other cases. 
In conclusion, in the next years significant advances in nanotechnology 
can be foreseen to improve detection by conventional immunoassays, 
whether growing applications of bioinformatics tool are likely to 
associated with aptamer technology, to extend the possibility over the use 
of such receptors in all the field in which they could rival with antibodies. 
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A p p e n d i x  I .  R i a s s u n t o  t e s i  d o t t o r a t o  -  
I t a l i a n o  
Introduzione 
La malattia di Alzheimer (AD) è stata scoperta da Alois Alzheimer nel 
1906, grazie all’osservazione di placche amiloidi e aggregati 
neurofibrillari localizzati nell’encefalo di August Deter, donna di 50 anni 
che è il primo caso accertato di AD. Secondo il World Alzheimer Report, 
circa 46 milioni di individui sono affetti da demenza a livello globale tra i 
quali si stima una prevalenza dei casi di Alzheimer che si attestano a circa 
il 60-70% dei soggetti totali. Nel corso degli anni numerosi studi hanno 
delucidato la composizione delle placche amiloidi e degli aggregati 
neurofibrillari. In particolare, per quanto riguarda le prime, la loro 
composizione è stata svelata nel 1985, rivelando alte concentrazioni di 
peptide Aβ, mentre per gli aggregati neurofibrillari (1986), la loro 
composizione ha mostrato essenzialmente la presenza di proteina tau. Allo 
stato attuale, nessuna metodica diagnostica tra quelle esistenti si è rivelata 
efficace per una diagnosi precoce della malattia di Alzheimer (che sarebbe 
fondamentale per poter produrre un intervento nelle prime fasi della 
patologia). Tra le varie tecniche che possono supportare la diagnosi in vivo 
possiamo elencare: le tecniche di imaging come la risonanza magnetica 
per immagini (MRI dall’acronimo inglese), la tomografia ad emissione 
positronica (PET) o le tecniche basate su saggi immunochimici.  
Questi ultimi si basano sulla variazione dei livelli (riportati in Tabella 1) 
dei biomarcatori di core nel liquido cerebrospinale (CSF usando 
l’acronimo inglese), che allo stato attuale sono: il peptide Aβ, la proteina 
tau (il totale delle isoforme) e la proteina tau fosforilata.  
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Tabella 1: Livelli di concentrazione e relativi cut-off, ottenuti mediante saggio ELISA, 
per i biomarcatori di core dell’Alzheimer. 
 
 
Essi derivano dalla cosiddetta Amyloide cascade hypothesis (rappresentata 
in Figura 1), sviluppata tra gli anni novanta e 2002 e che pone 
l’aggregazione dell’Aβ precedente quello della proteina tau.  
 
 
Figura 1: Schema rappresentante il pattern e il coinvolgimento seguiti da proteina tau e 
peptide amiloide secondo l’ipotesi della cascata amiloide. 
 
Successivi sviluppi nello studio dei biomarcatori hanno poi descritto 
l’esistenza di specie oligomeriche che, data la loro maggiore diffusibilità, 
sembrano notevolmente più tossiche degli aggregati.  
Nonostante alcuni lavori abbiano descritto l’analisi di queste o altre specie 
in CSF od in altre matrici biologiche, le attuali tecniche immunochimiche 
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di routine sono basate sul dosaggio multiplo in CSF dei biomarcatori di 
core (Aβ, tau-totale e tau iperfosforilata). L’utilizzo di questa 
combinazione di biomarcatori ha dimostrato un’elevata sensibilità clinica 
e specificità nel discriminare tra soggetti sani e soggetti affetti da 
patologia di Alzheimer, mentre minori performances sono state riscontrate 
nella discriminazione tra i diversi tipi di demenza. Nelle sezioni 
successive le caratteristiche delle tecniche immunochimiche convenzionali 
e non, e quelle basate su recettori innovativi, saranno presentate.  
 
Tecniche immunochimiche adottate in analisi di routine 
Sviluppati in seguito all’introduzione degli anticorpi commerciali diretti 
contro i biomarcatori di core e utilizzati lungamente nella ricerca 
biomedica, il saggio ELISA (Enzyme Linked Immunosorbent Assay) e il 
saggio xMAP, sono ormai adottati nella pratica ospedaliera (dopo 
l’introduzione nel 2007 delle linee guida pubblicate dal NINCDS-
ADRDA
1
) allo scopo di supportare la diagnosi di probabile malattia di 
Alzheimer. Nonostante gli elevatissimi standard raggiunti in termini di 
ripetibilità analitica e le ottime prestazioni in termini di sensibilità, con 
limiti di rivelabilità (LOD) nell’ordine del picomolare, queste due tecniche 
presentano ancora diversi limiti.  
La variabilità interlaboratorio può infatti raggiungere valori elevati, 
espressi attraverso il coefficiente di variazione (CV%), che possono 
raggiungere il 30%. Inoltre, l’utilizzo di marcatori fluorescenti o 
colorimetrici e di recettori come gli anticorpi (affidabili, ma soggetti ad 
una variabilità intrinseca dovuta al sistema di produzione dei vari lotti) 
                                                 
 
1 NINCDS-ADRDA:  National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer's Disease and Related Disorders Association. 
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può fortemente limitare l’applicazione dei saggi nella routine. Per questo 
sono state sviluppate tecniche alternative, basate, ad esempio, sull’uso di 
biosensori.  
 
Biosensori di affinità per la diagnosi della malattia di Alzheimer 
I principali biosensori di affinità (il cui principio sarà elucidato nella 
sezione successiva), che sfruttano anticorpi mono- o poli- clonali, 
utilizzati per la diagnosi label-free dell’Alzheimer, sono elencati in 
Tabella 2. 
 
Tabella 2: Tecniche immunochimiche innovative per la diagnosi label-free della malattia 
di Alzheimer. Abbreviazioni: SPR: risonanza plasmonica di superficie; LSPR: SPR 
localizzata; SWV: voltammetria con potenziale ad onda quadra; EIS: spettrometria di 
impedenza; CNT-FET: transistor basati sull’utilizzo di nanotubi di carbonio; ADDL: 
oligomeri derivanti dal peptide amiloide; mAb: anticorpo monoclonale. 
 
 
Senza entrare nel dettaglio delle tecniche sviluppate, esse, come riassunto 
in tabella, permettono l’ottenimento di limiti di rivelabilità comparabili o 
superiori rispetto alle tecniche di routine. L’assenza di marcatore e la 
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possibilità di leggere l’interazione in tempo reale (nella maggioranza delle 
tecniche presentate) ne aumentano la versatilità di utilizzo, semplificando 
anche l’interpretazione del dato ottenuto. Possibilità di miniaturizzazione 
strumentale elevate sono inoltre associate all’utilizzo di tecniche come 
LSPR, e le tecniche elettrochimiche, rendendo entrambe altamente 
adattabili ad un utilizzo su campo (nel caso di analisi su matrici il cui 
prelievo sia meno invasivo rispetto al CSF).  
La sensibilità delle tecniche immunochimiche può essere enormemente 
migliorata attraverso l’utilizzo di approcci tipo sandwich e grazie 
all’utilizzo di marcatori di varia natura (schematizzati in Figura 2). 
 
 
Figura 2: Rappresentazione (non in scala dimensionale) delle classi di marcatori usati nei 
saggi bioanalitici per l’analisi dei marcatori di core dell’Alzheimer. Dall’alto verso il 
basso: DNA, fluorofori, enzimi catalitici e nanoparticelle metalliche.  
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Nel caso del DNA, questo ha trovato applicazione nei metodi che 
permettono la sua amplificazione attraverso Reazione Polimerasica a 
Catena (PCR dall’inglese) o che sfruttano la possibilità di predirne gli 
appaiamenti tra le basi. La prima proprietà viene utilizzata ad esempio 
nell’immuno-PCR, in cui uno degli anticorpi usati per il riconoscimento 
dell’analita viene marcato con una sequenza oligonucleotdica, sottoposta a 
PCR per aumentare la sensibilità del saggio. Elegante esempio 
dell’abbinamento tra le capacità del DNA e nanoparticelle metalliche 
viene riportato nel saggio definito biobarcode, grazie al quale la sensibilità 
dell’analisi si è spinta fino a determinare gli oligomeri del peptide 
amiloide a livelli nell’ordine dell’attomolare.  
In altri esempi le nanoparticelle metalliche hanno trovato applicazione 
nell’amplificazione di fenomeni come la diffusione Raman o in altri 
metodi ottici, mentre i fluorofori organici sono stati sfruttati per lo studio 
di risonanza Foster (FRET) o per misure tradizionali dell’intensità di 
fluorescenza.  
I label enzimatici, come la fosfatasi alcalina, sono più adatti ad un utilizzo 
nei metodi elettrochimici (elettrodi convenzionali o stampati SPE
2
), di cui 
si trovano però un numero inferiore di esempi in letteratura.  
In conclusione, per le tecniche emergenti una maggiore attenzione allo 
sviluppo di metodiche che prevedano l’utilizzo in matrice biologica 
sembra necessario. L’utilizzo di un marcatore o perlomeno lo sviluppo di 
saggi di tipo sandwich sembra favorito e, allo stato attuale, la maggioranza 
dei metodi è rivolta verso l’analisi di specie derivanti dall’APP3 (ADDLs, 
Aβ). Da quest’ultima considerazione si può comprendere come sia 
auspicabile uno sviluppo di tecniche per il dosaggio della proteina tau. 
                                                 
 
2
 SPE: Screen Printed Electrode 
3
 APP: amyloid precursor protein 
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Recettori biomimetici 
Alla famiglia dei recettori biomimetici vengono catalogati tutti quei 
recettori che hanno proprietà simili (o in alcuni casi migliori) dei recettori 
di tipo biologico (anticorpi, enzimi, ecc.) e che provengono da un processo 
di sintesi chimica effettuato in vitro e che ne permetta la produzione 
controllata e riproducibile. In linea generale, gli aptameri, i peptidi, i 
peptoidi (N-sostituite oligo-glicine) e i MIP
4
 sono sicuramente i recettori 
sintetici più usati per la rilevazione di target proteici.  
Nel campo della diagnostica molecolare della malattia di Alzheimer (AD) 
sono numerosi gli esempi di peptidi utilizzati per la diagnosi, in particolare 
grazie alla loro intrinseca maggior flessibilità rispetto a recettori proteici 
strutturati, come ad esempio gli anticorpi. Questa caratteristica è stata 
utilizzata nei metodi di impedenza, che sfruttano il processo di 
trasferimento di carica dal peptide (marcato con un mediatore 
elettrochimico, come ad esempio il ferrocene) alla superficie 
dell’elettrodo. Nel momento dell’interazione analita-recettore, la 
conformazione del peptide varia, e allo stesso tempo si osserva una 
variazione del segnale analitico. 
Per quanto riguarda gli aptameri ed i MIP, ad oggi non si riportano 
applicazioni diagnostiche per questi recettori, anche se un crescente 
sviluppo viene registrato a partire dal 2002. Entrambi le classi di recettori 
sono note per garantire un riconoscimento selettivo dei target attraverso la 
particolare struttura tridimensionale assunta nell’interagire con la 
molecola d’interesse. Alcuni autori hanno descritto, per gli aptameri, una 
sostanziale mancanza di selettività verso le specie accomunate da un 
processo aggregativo guidato dalla formazione di foglietti beta (proteine 
                                                 
 
4
 MIP: Molecularly imprinted polymer 
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prioniche, sinucleina-alfa, peptide amiloide, tau ecc.). Tuttavia come 
descritto nelle successive sezioni della tesi, i risultati ottenuti nel corso di 
questo lavoro mostrano un significativo miglioramento dell’affinità delle 
sequenze isolate rispetto a quella misurata per il pool di sequenze iniziale, 
suggerendo perciò un meccanismo di selettività verso il target. 
Altri recettori sintetici sono stati sviluppati e utilizzati in saggi di tipo 
elettrochimico garantendo limiti di rivelabilità nell’ordine del picomolare.  
In conclusione, lo stato dell’arte indica come, nonostante la strada verso 
una diagnosi precoce dell’AD resti ancora una sfida difficile da affrontare, 
gli sviluppi in varie aree della sensoristica e della bioanalitica possano 
offrire soluzioni in questo senso. La strada però non passerà solamente 
dallo sviluppo analitico in quanto miglioramenti delle tecniche di 
campionamento, lo sviluppo di matrici di riferimento, l’adozione di 
protocolli standardizzati e, non ultima, l’aumento di conoscenza degli 
aspetti biochimici associati con lo sviluppo della patologia, ricopriranno 
sicuramente un ruolo chiave verso la diagnosi e la cura dell’Alzheimer. 
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Principi di Risonanza Plasmonica di superficie e di selezione degli 
aptameri 
In questo lavoro la risonanza plasmonica di superficie (SPR) e 
l’elettroforesi capillare (CE) hanno rivestito un ruolo importante per 
ottenere i risultati sperimentali descritti a partire dalla successiva sezione.  
Qui ne vengono descritti i principi fondamentali, facendo riferimento alla 
fisica legata allo sfruttamento delle caratteristiche dell’SPR e alle tecniche 
di selezione sviluppate partendo dalla CE come tecnica separativa. 
 
Principi di risonanza plasmonica di superficie 
La risonanza plasmonica di superficie (SPR) è uno dei fenomeni fisici più 
sfruttati per la costruzione di biosensori di affinità. In generale un 
biosensore viene definito come uno strumento capace di trasdurre 
l’interazione di tipo biologico, in un segnale elettrico, ottico o termico, 
analiticamente rilevabile. Nonostante in letteratura siano riportati diversi 
esempi di biosensori sviluppati in soluzione omogenea, la configurazione 
standard dei biosensori prevede un contatto fisico tra un recettore e una 
superficie come mostrato in Figura 3. 
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Figura 3: Principi ed elementi principali di un biosensore. 
 
La trasduzione attraverso SPR è garantita dall’accoppiamento tra i 
polaritoni di superficie all’interfaccia tra un dielettrico e un metallo, e una 
radiazione a lunghezza d’onda tale da essere messa in risonanza con gli 
elettroni del metallo. 
Sotto particolari condizioni, dipendenti dai materiali utilizzati e dalla 
configurazione spaziale degli elementi componenti il sensore (prisma, 
sorgente della radiazione, spessore del film metallico all’interfaccia), gli 
elettroni vengono eccitati collettivamente dando luogo ad un’onda 
evanescente che penetra il metallo raggiungendone la faccia a contatto con 
il dielettrico. Grazie a ciò gli eventi che interessano il dielettrico stesso, 
provocando la variazione dell’indice di rifrazione, sono rilevati con 
estrema sensibilità in una profondità di campo di circa 500 nm nel caso in 
cui il film metallico sia l’oro. 
La trasduzione in tempo reale permette numerosi vantaggi rispetto ai saggi 
ELISA, come ad esempio: a) la possibilità di monitoraggio delle proprietà 
cinetiche (e termodinamiche) dell’interazione biomolecolare; b) 
l’esistenza di procedure di rigenerazione, che permettono il riutilizzo del 
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sensore per numerosi cicli; c) la possibilità di amplificare il segnale 
attraverso l’utilizzo di nanostrutture che permettano l’accoppiamento 
plasmonico tra la superficie e le nanostrutture stesse. 
Nei paragrafi successivi le proprietà dell’SPR utilizzate nel lavoro saranno 
riportate dettagliatamente, mettendo in mostra la versatilità della tecnica 
nei diversi ambiti della bioanalitica. 
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SELEX e Non-SELEX: vantaggi e inconvenienti delle tecniche per la 
selezione degli aptameri 
La tecnica del SELEX
5
 è stata sviluppata nel 1990 da due lavori 
indipendenti. I principali step della selezione sono la sintesi chimica della 
library di sequenze a DNA (singolo filamento) o RNA (step 1), a cui fa 
seguito l’incubazione con il target d’interesse (step 2). Grazie all’utilizzo 
di diverse tecniche di separazione, solo le sequenze affini vengono isolate 
e amplificate attraverso PCR (step 3). Dopo la rimozione dello strand 
complementare (step 4), le sequenze affini vengono ri-iniettate in modo 
che il ciclo possa ricominciare. In funzione delle condizioni di selezione e 
delle metodiche di separazione, il numero di cicli di selezione può 
raggiungere i 15 rounds. La Figura 4 riassume i passaggi descritti 
precedentemente.  
 
 
Figura 4: Passaggi principali della tecnica SELEX per l’identificazione di aptameri. 
  
                                                 
 
5
 SELEX: Systematic Evolution of Ligands by EXponential enrichement 
Appendix I. Riassunto tesi dottorato - Italiano 
139 
 
In questo lavoro si è sfruttato l’utilizzo della CE per la sua elevata 
efficienza separativa. A differenza di altre tecniche separative, nel 
cosiddetto CE-SELEX l’immobilizzazione del target non è necessaria, 
rendendo quest’ultimo completamente accessibile da parte della library 
durante il processo di riconoscimento molecolare. Inoltre grazie alla CE, è 
possibile osservare, utilizzando una sola tecnica, l’evoluzione dei vari cicli 
di selezione, in quanto è possibile stimare l’affinità dei pool selezionati, 
misurando l’area sottesa ai picchi presenti nell’elettroferogramma.  
Tali considerazioni sono altresì valide per la tecnica che prende il nome di 
CE-Non-SELEX, in cui i vari cicli di partizione non sono intervallati da 
amplificazione PCR, che viene invece realizzata solo sull’ultimo pool 
selezionato. Ciò riduce notevolmente i tempi di lavoro, da alcune 
settimane a poche ore. Tuttavia il campione risulta poco arricchito, 
diventando di più difficile interpretazione a causa di una popolazione di 
sequenze di DNA altamente variegata. 
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Scopo del lavoro 
 
Scopo di questo lavoro è quello di studiare lo sviluppo di un metodo 
analitico basato su SPR per il rilevamento della proteina tau. Inizialmente 
lo sviluppo ha riguardato l’utilizzo di anticorpi commerciali, che sono poi 
stati marcati con nanostrutture per incrementare il segnale analitico. 
 
Parallelamente, recettori di concezione innovativa sono stati selezionati 
attraverso elettroforesi capillare. Due diversi metodi di selezione sono stati 
confrontati (CE-SELEX e CE-Non-SELEX) in modo da comprendere 
quale dei due si adatti meglio allo sviluppo di aptameri per la proteina tau. 
In questo caso l’SPR è stato ideale per connettere entrambi gli aspetti del 
lavoro, che ha dimostrato, una volta di più, le potenzialità della tecnica in 
tutti i campi della bioanalitica. 
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Immunosensore per la proteina tau 
L’immunosensore per l’analisi della proteina tau è stato sviluppato grazie 
ad una collaborazione con il gruppo del prof. Cicchi, che ha fornito i 
nanotubi di carbonio utilizzati per l’amplificazione del segnale (Figura 5) 
 
 
Figura 5: Schema del saggio immunochimico. Step 1: saggio diretto in cui l’anticorpo 
primario è immobilizzato sulla superficie dà il riconoscimento molecolare necessario per 
la cattura del target. Step 2: iniezione dell’anticorpo secondario, con nanotubi di carbonio 
come amplificatori del segnale. 
 
L’utilizzo di queste nanostrutture per l’amplificazione del segnale SPR è 
stato precedentemente riportato per l’analisi dell’EPO6, risultando come 
efficace per l’aumento della sensibilità verso livelli fisiologici di tale 
analita. Queste strutture possono essere proposte come alternativa alle 
nanostrutture metalliche, più comunemente usate in SPR. Tra le 
caratteristiche che permettono l’amplificazione del segnale si possono 
annoverare un aumento dell’area superficiale a disposizione dell’anticorpo 
secondario e analita per interagire tra loro, nonché un forte spostamento 
dell’indice di rifrazione causato dalla particolare geometria delle 
nanostrutture. 
                                                 
 
6
 EPO: eritropoietina, ormone proteico di 34 KDa coinvolto nel processo di ematopoiesi. 
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Risultati e discussione 
La proteina tau è stata iniettata ad una concentrazione compresa tra 125 
pM e 250 nM. In prima istanza lo sviluppo ha riguardato l’analisi 
utilizzando un anticorpo primario, capace di mappare l’analita nell’epitopo 
compreso tra il residuo amino acidico 189 e quello 195 (clone 39E10, 
monoclonale). Questo recettore è stato immobilizzato attraverso un 
processo di amino-coupling che ha richiesto l’ottimizzazione del pH di 
immobilizzazione attraverso un saggio di pre-concentrazione. In 
particolare l’utilizzo di tampone acetato (10 mM) a pH 4.0 ha dato i 
migliori risultati, permettendo l’immobilizzazione sulla superficie 
destranica di un chip CM5 commerciale. Grazie a questo saggio, la 
sensibilità ottenuta sia in buffer che in liquido cerebro spinale simulato 
(aCSF) è stata nell’ordine del nM. Migliori sono state le performances in 
aCSF in termini di ripetibilità e estensione del range lineare del saggio 
sviluppato (Figura 6). 
 
Figura 6: Saggio diretto con il solo anticorpo primario, in matrice simulata.  
 
Questo risultato, a confronto con altri metodi SPR presenti in letteratura, è 
decisamente buono, in quanto ottenuto utilizzando un singolo anticorpo 
per la quantificazione. Ciò è dovuto probabilmente all’utilizzo di una 
superficie che, grazie alle sue proprietà, riesce ad incrementare la cattura 
di analita. L’analisi in aCSF ben si sposa con le necessità di applicazione 
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nella pratica clinica, supportando la necessità dello sviluppo di un 
materiale di riferimento certificato (CRM) per migliorare le performances 
dei metodi di routine nella diagnosi precoce della malattia di Alzheimer.  
Il sandwich è stato sviluppato a partire dal saggio diretto, utilizzando un 
anticorpo secondario (clone tau12) che lega la proteina tau nella sua parte 
N-terminale. Le performances del metodo in aCSF sono state migliorate, 
fino a raggiungere un limite di rivelabilità due volte migliore rispetto a 
quello precedentemente osservato (Figura 7B). 
 
 
Figura 7: A) Assenza di interazione non specifica dell’anticorpo secondario sulla 
superficie del sensore, in assenza di analita. B) contributo del segnale ottenuto per una 
concentrazione di tau tra 1 e 25 nM grazie al saggio diretto e al sandwich. 
 
In assenza di analita non è stata osservata interazione non specifica tra gli 
anticorpi (Figura 7B) o in presenza di albumina sierica umana (HSA). 
Per poter raggiungere livelli dell’ordine del pM, il gruppo del professor 
Cicchi ha realizzato l’ossidazione e la seguente attivazione dei nanotubi, 
in modo da consentire sia la loro dispersione nei mezzi acquosi, sia di 
fornire i siti attivi per la formazione del legame covalente con gli 
anticorpi. Tale processo viene facilitato grazie alla presenza di gruppi O-
succinimmide, la cui presenza è stata verificata attraverso spettroscopia IR 
e analisi elementare. Dopodiché tre parametri sono stati presi in 
considerazione per rendere più efficace la bioconiugazione. In particolare 
il tempo di sonicazione (in assenza di anticorpo), il tampone di 
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coniugazione e la concentrazione totale di anticorpo (Figura 8) si sono 
rivelati fondamentali nel mantenimento di una dispersione stabile.  
 
Figura 8: Ottimizzazione della coniugazione dell’anticorpo secondario. 1) tempo di 
sonicazione; 2) mezzo di immobilizzazione; 3) rapporto tra la concentrazione di CNT e 
quella di anticorpo.  
 
In queste condizioni una prima prova di concetto in buffer è stata 
effettuata, dando luogo ad una amplificazione di segnale significativa 
(Figura 9A). Tuttavia la rigenerazione del sensore, che nella 
configurazione precedente era effettuata grazie a brevi iniezioni di NaOH 
(10 mM - 50 mM; 24 – 48’’), risultava impossibile.  
 
 
Figura 9: A) amplificazione segnale in buffer grazie all’utilizzo di nanotubi in cella 
confrontata con il segnale ottenuto utilizzando una concentrazione equivalente di 
anticorpo secondario; B) investigazione dell’amplificazione ottenuta con nanotubi 
“selezionati”, a concentrazioni pM di proteina tau.  
 
Tra le varie ragioni che possono spiegare quanto osservato, l’ampia 
dispersione delle lunghezze dei nanotubi sembra la più probabile. È infatti 
noto che i CNTs sono composti da frazioni la cui lunghezza varia 
notevolmente, fino a raggiungere valori nell’ordine dei µm. Questi ultimi 
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hanno una tendenza elevata ad interagire fra loro, e possono dunque 
produrre uno spesso strato di CNTs, inaccessibile alla soluzione 
rigenerante. Riducendo questa frazione attraverso un passaggio di 
centrifugazione blando (3000 rcf, 3’), la capacità rigenerante è stata 
ripristinata con successo, permettendo l’investigazione del range pM 
(Figura 9B) con un solo sensore. In questo range di concentrazione si è 
osservata una chiara correlazione della dose di analita con il segnale 
ottenuto a seguito dell’iniezione del coniugato anticorpo-nanotubi. Tale 
curva era descritta da una funzione esponenziale che deviava dalla 
linearità a concentrazioni di analita che si approssimano al nM, 
probabilmente a causa di un maggior impaccamento dei CNT dovuto alla 
loro maggiore concentrazione locale in cella. 
 
Conclusioni-immunosensore 
In questa prima parte del lavoro l’utilizzo di CNT per la rilevazione di 
proteina tau ha mostrato interessanti proprietà, lasciando intravedere 
possibili applicazioni nella diagnosi dell’Alzheimer. L’amplificazione del 
segnale, di circa 2 ordini di grandezza rispetto al saggio diretto, ha 
permesso l’ottenimento di un limite di rivelabilità sperimentale vicino ai 
valori fisiologici del target e buone prestazioni in termini di ripetibilità 
sono state ottenute (CV 14%) usando diversi lotti di nanotubi 
funzionalizzati. Queste prestazioni possono essere ulteriormente 
migliorate soprattutto grazie ad una selezione più fine delle lunghezze 
delle nanostrutture coinvolte, ma anche allo stato attuale, i CNT possono 
essere considerati come una nuova frontiera per l’uso di SPR nella 
diagnosi dell’Alzheimer. 
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Selezione di un recettore a base aptamerica per la rivelazione della 
proteina tau 
La seconda parte del lavoro è stata condotta grazie alla collaborazione con 
l’Università di Grenoble al dipartimento di farmacologica chimica 
molecolare. Come già accennato, scopo di questa seconda parte era lo 
sviluppo di un recettore per la proteina tau, con proprietà diverse da quelle 
degli anticorpi, in particolar modo in termini di stabilità e riproducibilità di 
sintesi dei vari lotti. I recettori aptamerici sono noti in letteratura per 
rispondere a queste necessità, e sono stati usati in diversi campi applicativi 
dal momento del loro sviluppo. Essi vengono selezionati in vitro usando di 
solito la tecnologia SELEX, che prevede diversi passaggi, ma che è 
essenzialmente basata su un’alternanza di step separativi e di 
amplificazione tramite PCR. In questo lavoro una strategia di selezione 
alternativa è stata sviluppata e prende il nome di CE-Non-SELEX, in cui a 
seguito di vari passaggi separativi, una singola amplificazione PCR viene 
realizzata. L’aumento di affinità per le sequenze isolate è stato analizzato 
interpolando la dipendenza tra concentrazione di tau e segnale attraverso 
due tecniche: Anisotropia di Fluorescenza (FA) e SPR. Grazie all’SPR le 
sequenze più affini sono state identificate. 
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Risultati e discussione 
In primo luogo la separazione tra target e pool di sequenze a DNA 
(marcata con fluoresceina modificata, e composta da 77 nucleotidi, 30 dei 
quali disposti in posizione casuale per la composizione del pool) si è resa 
necessaria per poter identificare la finestra di collezione da cui poi si 
sarebbero ricavate le sequenze più affini per la proteina tau. Per ottenere 
questo obiettivo uno dei primi ostacoli da superare ha riguardato 
l’identificazione del tempo di migrazione del target, data la molteplicità 
dei picchi presenti nell’elettroferogramma. Questo è stato fatto misurando 
la mobilità elettroforetica della proteina (dipendente dal pH del tampone di 
corsa) a tre diversi pH (3,0; 5,5; 7,4). Identificando il picco la cui mobilità 
fosse dipendente da questo parametro, si è potuta definire la zona di 
separazione per entrambe le metodiche (SELEX e Non- SELEX) usate in 
questo lavoro (Figura 10). 
 
 
Figura 10: a) finestra di collezione per CE-SELEX e b) CE-Non-SELEX. Il picco della 
proteina tau (linea tratteggiata) migra più rapidamente rispetto alla library (linea 
continua), che viene esclusa dalla frazione collezionata. Entrambi gli elettroferogrammi 
sono ottenuti a 20 kV, 25°C e la rivelazione è effettuata grazie alla misura 
dell’assorbimento a 200 nm. 
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Dopodiché, l’analisi con PCR quantitativa (qPCR) ha permesso di mettere 
a punto la concentrazione iniziale di proteina tau necessaria e il numero di 
cicli di amplificazione, in modo da evitare amplificazione dei sottoprodotti 
(dimeri dei primer). Infatti, per quanto riguarda il primo aspetto, la 
concentrazione di proteina tau da incubare nel primo round di selezione 
con il DNA deve essere 2 ordini di grandezza inferiore rispetto al valore 
della costante termodinamica di dissociazione (nel nostro caso 0,750 µM). 
Tuttavia l’analisi qPCR ha rivelato una debole quantità di complesso di 
affinità in queste condizioni, che non permettevano perciò 
l’amplificazione selettiva delle sequenze più affini. Aumentando la 
concentrazione di tau fino a 7,5 µM, la qPCR ha mostrato la formazione di 
un complesso di affinità, mettendo in evidenza come il numero di cicli 
soglia (Ct) della frazione in presenza dell’analita fosse sensibilmente 
inferiore a quello della frazione in assenza del target. Data la relazione di 
proporzionalità inversa che lega il numero di ampliconi al numero dei Ct, 
tale analisi ci ha permesso di identificare le condizioni di partenza per la 
selezione. 
Nonostante ciò la selezione con CE-SELEX non ha portato evoluzione 
positiva, che invece è stata realizzata attraverso l’utilizzo del CE-Non-
SELEX (Figura 11). 
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Figura 11: Complesso di affinità derivante dai due processi di selezione. a) CE-Non-
SELEX; aumento delle aree rappresentanti il complesso di affinità stabile (osservato ad 
un tempo di 9,8 minuti) nei tre round di selezione. Vista la sostanziale uguaglianza tra le 
aree del complesso formatosi in presenza della library e del primo round di selezione, 
solo quest’ultima è riportata. b) CE-SELEX; aree del complesso in presenza della library 
(linea tratteggiata) e in presenza del pool selezionato dopo il round 2 (linea continua). 
 
Tra le ragioni che possono aver impedito la selezione attraverso CE-
SELEX, c’è sicuramente la formazione di sottoprodotti della PCR, 
evidenziati attraverso misure della temperatura di denaturazione (Tm) del 
doppio filamento, associate con una probabile amplificazione di sequenze 
di acido nucleico più corte rispetto all’originale.  
Il campione di sequenze selezionate per via CE-Non-SELEX è stato 
sottoposto a sequenziamento con un processo diverso da quello 
convenzionale in cui è previsto l’uso di un plasmide per l’identificazione 
del motivo consenso. In particolare l’applicazione di un processo di NGS7 
ha permesso l’ottenimento di un numero molto elevato di sequenze 
(4792), tutte potenzialmente valide per legare selettivamente il target, la 
cui analisi è stata effettuata attraverso software bioinformatici. Nel primo 
caso l’uso di PATTERNITY- Seq (software che permette l’analisi della 
similarità tra le sequenze secondo un parametro detto distanza di 
                                                 
 
7
 NGS: next generation sequencing 
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Levenshtein) non ha mostrato un arricchimento del pool in poche famiglie, 
ma ha invece evidenziato un’elevata variabilità delle sequenze selezionate.  
L’analisi con MEME8 ha sostanzialmente mostrato una situazione simile, 
sebbene, grazie ad esso, una classificazione secondo lunghezza dei motivi 
presenti ha permesso la scelta di cinque sequenze isolate, la cui affinità è 
stata caratterizzata sperimentalmente (FA e SPR).  
La caratterizzazione con FA è stata scelta poiché permette l’utilizzo di 
ridotti volumi di campione (10 µL) e allo stesso tempo riflette in maniera 
fedele le condizioni di selezione (vale a dire omogeneità della soluzione, 
presenza della sonda fluorescente). Grazie a questa tecnica le sequenze 
4133, 3146 e 433 hanno mostrato una affinità doppia rispetto alla library 
iniziale (Figura 12a e b). 
 
 
Figura 12: a) Variazioni di anisotropia di fluorescenza per gli aptameri 3146 (triangoli), 
4618 (quadrati) e per la library (cerchi) in presenza di concentrazioni di tau comprese tra 
0.02 e 0.7 µM. b) valori per le stesse sequenze a bassa concentrazione (0.04 µM) e alta 
concentrazione (0.3 µM) di analita. 
 
L’immobilizzazione di tau, attraverso amino-coupling su un sensore CM5 
commerciale ha permesso l’analisi SPR delle sequenze in condizioni 
label-free, a differenza di quanto accade in FA. Il sensorgramma delle 
sequenze è riportato in Figura 13. 
                                                 
 
8
 MEME: Multiple Em for Motifs Elicitation 
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Figura 13: sensorgrammi delle sequenze isolate analizzate attraverso SPR. 
 
Questa seconda analisi ha mostrato risultati simili a quanto riportato per la 
FA, pur basandosi su un principio fisico completamente diverso e su un 
diverso assetto strumentale, in cui l’analita era immobilizzato rispetto alle 
sequenze. In questo approccio la Kd stimata iniettando le sequenze a 
concentrazione costante sul sensore (1 µM) è risultata nel range del nM 
per la sequenza 3146, considerando il suo segnale come pari al valore di 
riflettività massimo (Rmax), che può essere approssimato a 100 Kd. Il 
superamento dei problemi strumentali legati alla stabilità della proteina tau 
immobilizzata sul sensore potrà in futuro permettere una delucidazione più 
completa di quanto osservato.  
 
Conclusioni  
In questo lavoro è stata riportata la selezione rapida di aptameri per 
proteina tau. Se l’approccio convenzionale si è dimostrato inefficace per 
ottenere un’evoluzione positiva delle affinità, la CE-Non-SELEX ha 
permesso di ottenere gli scopi prefissi. Una riduzione sostanziale dei cicli 
di selezione è stata osservata, in particolar modo in confronto con gli 
aptameri contro la proteina tau selezionati in letteratura.  
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Sebbene grazie alla riduzione dei cicli di amplificazione sia stato possibile 
superare i limiti osservati, una elevata variabilità delle sequenze è stata 
riscontrata e l’uso di tecniche bioinformatiche per l’analisi dei dati 
(PATTERNITY-Seq e MEME) si è reso necessario. Pur considerando 
l’elevata variabilità vantaggiosa in termini di potenzialità ancora 
inesplorate per la tecnologia degli aptameri, questo ha reso molto 
complessa l’analisi dei dati. Alcune soluzioni sperimentali possono essere 
prese in esame per migliorare il processo di selezione, come ad esempio 
l’uso di diversi tipi di PCR. 
Tra gli aptameri selezionati, cinque sequenze sono state analizzate 
attraverso SPR e anisotropia di fluorescenza, dando risultati confrontabili.  
In conclusione la selezione grazie al CE-Non-SELEX ha permesso di 
ottenere numerosi candidati. Allo stato attuale l’affinità sembra 
insufficiente per un’applicazione diretta in diagnostica molecolare, tuttavia 
l’elevato numero di sequenze ottenuto e l’analisi critica dei vari step di 
selezione suggeriscono ampi margini di miglioramento in questo senso.  
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Conclusioni Generali 
In questa tesi la rivelazione della proteina tau a scopo diagnostico è stata 
affrontata considerando due diversi aspetti. In primo luogo, il lavoro ha 
riguardato lo sviluppo di un saggio immunochimico sfruttando anticorpi 
monoclonali commerciali, mentre secondariamente è stato sviluppato un 
metodo di selezione per ottenere uno o più potenziali aptameri specifici 
per la proteina tau.  
In entrambi gli approcci l’utilizzo della tecnica SPR è stato fondamentale, 
grazie alle sue proprietà e versatilità, per quantificare il target (grazie agli 
anticorpi) o per stimare le potenzialità di legame dei recettori selezionati. 
Lo sforzo maggiore durante lo sviluppo dell’immunosensore ha riguardato 
la concezione di strategie di amplificazione innovative per raggiungere i 
livelli di proteina tau (pM) generalmente presenti nel liquido 
cerebrospinale, sia nei soggetti sani che nei soggetti affetti da demenza. 
Per raggiungere gli scopi prefissi, l’utilizzo di nanostrutture di carbonio 
(CNTs), come marcatori per un anticorpo secondario, ha permesso lo 
sviluppo di un saggio sandwich grazie al quale un limite di rivelabilità 
sperimentale di 125 pM è stato raggiunto. La possibilità di monitorare la 
formazione di un legame di affinità in tempo reale ha permesso di 
ipotizzare un processo di impaccamento, dovuto alla formazione di 
aggregati tra i diversi nanotubi in dispersione, che impediva inizialmente 
la rigenerazione del sensore. Il processo è stato ripristinato servendoci di 
un passaggio di centrifugazione che abbattesse le nanostrutture più grandi 
in soluzione; ulteriori sviluppi, che permettano una selezione più fine dei 
nanotubi secondo la loro lunghezza, possono essere previsti.  
Altrettanto utile può essere l’utilizzo di CNTs direttamente immobilizzati 
sulla superficie del sensore in modo da sfruttare le residue proprietà 
Appendix I. Riassunto tesi dottorato - Italiano 
154 
dovute alla loro conducibilità, e di incrementare la capacità totale di 
cattura della superficie. 
La selezione è stata permessa da un processo di CE-Non-SELEX, che ha 
permesso con un volume estremamente ridotto di analita (circa 187 nL) e 
in pochi cicli di selezione (3), di arricchire il pool di sequenze, solo in 
quelle più affini per la proteina tau. Le caratteristiche del processo 
utilizzato sono sicuramente vantaggiose in termini di tempi necessari e 
costo globale, ma l’assenza di ripetuti passaggi di amplificazione ha 
portato ad una popolazione di sequenze altamente differenziata, messa in 
luce grazie a metodi di sequenziamento NGS.  
In questo senso lo sviluppo di aptameri per la proteina tau può ancora 
permettere enormi sviluppi grazie all’utilizzo di strumenti bioinformatici, 
attraverso i quali la grande variabilità dei pool ottenuti può essere 
completamente analizzata, e anche le sequenze più rare (ma più affini) 
possono essere mantenute. In questo lavoro l’analisi delle sequenze ha 
riguardato essenzialmente la ricerca di famiglie secondo motivi comuni a 
più aptameri del pool, ma la presenza di una stretta e univoca relazione tra 
sequenza e specificità per il target è stata recentemente messa in 
discussione. Infatti analisi QSAR
9
 sembrano dare maggiore importanza 
alla presenza di strutture secondarie, indipendentemente dalla successione 
delle basi presenti nella sequenza aptamerica. 
In conclusione, se ad oggi l’immunochimica gioca un ruolo predominante 
anche grazie alla combinazione con le nanotecnologie, la selezione degli 
aptameri, avendo ancora ampi margini di crescita, può sicuramente 
giocare un ruolo nell’affiancare e, in certi, casi sostituire l’uso dei recettori 
anticorpali nella diagnostica clinica. 
                                                 
 
9
 QSAR: quantitative structure activity relationship 
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A p p e n d i x  I I .  R é s u m é  d e  t h è s e  –  F r a n ç a i s  
Introduction 
La maladie d’Alzheimer (AD) a été découverte par Alois Alzheimer en 
1906, grâce à l’observation de plaques amyloïdes et d’agrégats 
neurofibrillaires localisés dans l’encéphale d’August Deter, une femme de 
50 ans qui a été le premier cas avéré de AD. Selon le World Alzheimer 
Report, environ 46 millions d’individus sont atteints de démence et parmi 
eux on estime une prévalence des cas d’Alzheimer à environ 60-70 % de 
la totalité. En ce qui concerne les plaques amyloïdes, leur composition 
révélée en 1985, montre l’existence de fortes concentrations de peptide 
bêta-amyloïde (Aβ), alors que pour les agrégats neurofibrillaires (1986), 
leur composition a montré essentiellement la présence de protéine tau. A 
l’heure actuelle, aucune technique existante ne s’est révélée efficace pour 
le diagnostic précoce de la maladie d’Alzheimer (ce qui serait fondamental 
pour intervenir dans les premières phases de la pathologie). Parmi les 
différentes techniques qui peuvent supporter le diagnostic in vivo nous 
pouvons énumérer les techniques d’imagerie médicale comme l’imagerie 
par résonnance magnétique (MRI en anglais), la tomographie par émission 
de positons (PET en anglais) ou les techniques basées sur des tests 
immunochimiques.  
Ces derniers se basent sur la variation des niveaux (reportés dans le 
Tableau 1) des biomarqueurs de certaines biomolécules dans le liquide 
céphalo-rachidien (LCR) : le peptide Aβ, la protéine tau (tau totale 
représentant le total des isoformes) et la protéine tau phosphorylée.  
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Tableau 3 : Niveaux de concentration et valeurs seuils correspondantes, obtenus à travers 
test ELISA, pour les biomarqueurs de l’Alzheimer. 
 
 
Ces biomarqueurs dérivent de l’hypothèse de la cascade amyloïde 
(représentée dans la Figura 1), développée entre les années 1990 et 2002 et 
selon laquelle l’agrégation de l’Aβ précède celle de la protéine tau.  
 
 
Figure 1 : Schéma représentant les voies suivies par la protéine tau et le peptide amyloïde 
selon l’hypothèse de la cascade amyloïde. 
 
Des développements dans l’étude des biomarqueurs ont ensuite décrit 
l’existence d’espèces oligomères qui, étant donné leur plus grande vitesse 
de diffusion, ont montré une toxicité plus élevée que les agrégats.  
Même si de nombreux travaux ont décrit la quantification de celles-ci ou 
d’autres espèces dans le LCR ou dans d’autres matrices biologiques, les 
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techniques immunochimiques de routine sont actuellement basées sur le 
dosage multiple des biomarqueurs telle que Aβ, tau-totale et tau 
hyperphosphorylée. L’utilisation de cette combinaison de biomarqueurs a 
démontré une sensibilité et une spécificité élevées, qui permettent de 
distinguer les sujets sains des sujets malades. De moins bonnes 
performances ont, en revanche, été rencontrées dans la distinction des 
différents types de démence.  
Dans les paragraphes suivants, nous présenterons les caractéristiques de 
plusieurs techniques immunochimiques et des approches innovantes 
basées sur des récepteurs synthétiques. 
 
Techniques immunochimiques adoptées dans les analyses de routine 
Suite à l’introduction d'anticorps commerciaux spécifiques pour les 
biomarqueurs de core, le test ELISA (Enzyme Linked Immunosorbent 
Assay) et le test xMAP ont été développés et utilisés dans la recherche 
biomédicale. Ils sont désormais adoptés dans les pratiques hospitalières 
(après l’introduction en 2007 des directives publiées par le NINCDS-
ADRDA
10
) dans le but de poser le diagnostic d’une probable maladie 
d’Alzheimer. Malgré les standards très élevés atteints en matière de 
répétabilité analytique et les excellentes performances en matière de 
sensibilité, avec des limites de détection (LOD) de l’ordre du picomolaire, 
ces deux techniques présentent encore plusieurs limites. La variabilité 
inter-laboratoires peut en effet atteindre des valeurs élevées, exprimées à 
travers le coefficient de variation (CV en %), qui peuvent atteindre 30%. 
De plus, l’utilisation de marqueurs fluorescents ou colorimétriques et de 
                                                 
 
10 NINCDS-ADRDA:  National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer's Disease and Related Disorders Association. 
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récepteurs comme les anticorps (fiables, mais sujets à une variabilité 
intrinsèque due au système de production des différents lots) peut 
fortement limiter l’application de ces tests. Pour cette raison, des 
techniques alternatives, basées notamment sur l’utilisation de biocapteurs, 
ont été développées. 
 
Biocapteurs d’affinité à base d’anticorps pour le diagnostic de la maladie 
d’Alzheimer 
Les principaux biocapteurs d’affinité (dont le principe sera explicité dans 
la section suivante) qui se servent des anticorps mono- ou poly-clonaux, 
utilisés pour le diagnostic sans marquage de la maladie d’Alzheimer, sont 
listés dans le Tabella 2. 
 
Tableau 4 : Techniques immunochimiques innovantes pour le diagnostic sans marquage 
de la maladie d’Alzheimer. Abréviations : SPR : résonance des plasmons de surface ; 
LSPR : SPR localisée ; SWV : voltamétrie à signaux carrés de potentiel ; EIS : 
spectrométrie d’impédance ; CNT-FET : transistors à effet de champ utilisant des 
nanotubes de carbone ; ADDL : oligomères dérivés du peptide amyloïde ; mAb : 
anticorps monoclonal. 
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Sans détailler les techniques développées, celles-ci, comme résumé dans le 
tableau, permettent l’obtention de limites de détection comparables ou 
supérieures à celles des techniques de routine. L’absence de marquage et 
la possibilité de détecter l’interaction en temps réel (dans la plupart des 
techniques présentées) augmentent la versatilité d’utilisation des 
biocapteurs, en simplifiant également l’interprétation des données 
obtenues. Par ailleurs, des possibilités élevées de miniaturisation 
instrumentale sont associées à l’utilisation de techniques telle que la LSPR 
et les techniques électrochimiques, ce qui les rend hautement adaptables à 
une utilisation sur le terrain (dans le cas d’analyses sur des matrices dont 
le prélèvement est moins invasif par rapport au LCR).  
La sensibilité des techniques immunochimiques peut être énormément 
améliorée à travers l’utilisation d’approches de type sandwich et grâce à 
l’utilisation de marqueurs de diverses natures (schématisés dans la            
Figura 2). 
 
Figure 2 : Représentation des classes de marqueurs utilisés dans les tests bioanalytiques 
pour l’analyse des marqueurs de l’Alzheimer (les dessins ne sont pas à l’échelle). De haut 
en bas : ADN, fluorophores, enzymes catalytiques et nanoparticules métalliques.  
 
Les oligonucléotides ont trouvé une application dans les méthodes qui 
permettent leur amplification à travers la réaction en chaîne par 
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polymérase (PCR en anglais) ou qui exploitent la possibilité de prédire les 
appariements entre les bases. La première propriété est exploitée par 
l’immuno-PCR, dans laquelle un des anticorps utilisés pour la 
reconnaissance de l’analyte est marqué avec un brin d’ADN et amplifié 
pour augmenter la sensibilité du test. Un exemple de l’association entre 
l’utilisation des oligonucléotides et des nanoparticules métalliques est 
décrit dans le test appelé biobarcode. Grâce à cette technique, la 
sensibilité de l’analyse a été abaissée jusqu’à des niveaux de l’ordre de 
attomolaire pour les oligomères issus du peptide amyloïde.  
Dans d’autres exemples, les nanoparticules métalliques ont trouvé une 
application dans l’amplification de phénomènes comme la diffusion 
Raman ou dans d’autres méthodes optiques, tandis que les fluorophores 
organiques ont été exploités pour l’étude de résonance Foster (FRET) ou 
pour des mesures traditionnelles de l’intensité de fluorescence.  
Les marqueurs enzymatiques, comme la phosphatase alcaline, sont adaptés 
pour une utilisation par des méthodes électrochimiques (électrodes 
conventionnelles ou SPE
11
), dont on trouve par contre un nombre inférieur 
d’exemples dans la littérature scientifique. 
En conclusion, les techniques émergentes semblent avoir besoin d’une 
attention particulière pour leur utilisation dans une matrice biologique. 
L’utilisation d’un marqueur ou tout du moins le développement de tests de 
type sandwich semble être favorisé et, à l’heure actuelle, la plupart des 
méthodes sont orientées vers l’analyse d’espèces dérivées de l’APP12 
(oligomères de l’amyloïde, Aβ). On s’aperçoit également qu’il est 
nécessaire d’accroitre le nombre de techniques pour le dosage de la 
protéine tau. 
                                                 
 
11
 SPE: Screen Printed Electrode 
12
 APP: amyloid precursor protein 
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Récepteurs biomimétiques 
On énumère dans la famille des récepteurs biomimétiques tous ceux qui 
ont des propriétés similaires (voire meilleures dans certains cas) aux 
récepteurs de type biologique (anticorps, enzymes, etc.) et qui proviennent 
d’un processus de synthèse chimique effectué in vitro grâce auquel on 
obtient une production contrôlée et reproductible. De manière générale, les 
aptamères, les peptides, les peptoïdes (oligo-glycines substituées à l’atome 
d’azote) et les MIP (polymères à empreinte moléculaire) sont assurément 
les récepteurs synthétiques les plus utilisés en bioanalyse. 
Dans le secteur des techniques bio-moléculaires appliquées au dépistage 
de la maladie d’Alzheimer (AD), on trouve de nombreux exemples de 
peptides. En particulier on exploite leur plus grande capacité de repliement 
sur eux-mêmes, par rapport à des récepteurs protéiques comme les 
anticorps. Cette caractéristique a été utilisée dans les méthodes 
d’impédance qui exploitent le processus de transfert de charge du peptide 
(marqué avec un médiateur chimique, tel que le ferrocène) à la surface 
d’une électrode. Au moment de l’interaction analyte-récepteur la 
conformation du peptide change, et une variation du signal analytique est 
détectée. 
En ce qui concerne les aptamères et les MIP, à ce jour on ne relève pas 
d’applications diagnostiques pour ces éléments de reconnaissance, même 
si un développement croissant a été enregistré à partir de 2002. Les deux 
classes de récepteurs sont connues pour garantir une reconnaissance 
sélective des cibles, à travers les structures tridimensionnelles qu’ils 
assument lors de l’interaction avec la molécule d’intérêt. Certains auteurs 
ont décrit, pour les aptamères, un manque substantiel de sélectivité envers 
les espèces dont l’agrégation se fait par la formation de feuillets bêtas 
Appendix II. Résumé de thèse – Français 
162 
(protéines prioniques, alpha-synucléine, amyloïde, tau, etc.). Toutefois, 
comme nous le décrirons dans les prochaines sections de la thèse, les 
résultats obtenus au cours de ce travail montrent une amélioration 
significative de l’affinité des séquences isolées par rapport à celle mesurée 
pour le pool de séquences initiales, suggérant ainsi un mécanisme de 
sélection vis-à-vis de la cible. 
D’autres récepteurs synthétiques ont été développés et utilisés dans des 
capteurs de type électrochimique en garantissant les limites de détection 
de l’ordre du picomolaire. 
En conclusion, même si l’aboutissement vers un diagnostic précoce de 
l’AD reste encore un défi difficile à relever, l’état de l’art indique que les 
développements dans le domaine des biocapteurs et de la bioanalyse, 
peuvent apporter une évolution positive dans cette direction. Toutefois, un 
rôle important est aussi à envisager pour tout ce qui concerne 
l’amélioration des techniques d’échantillonnage, le développement de 
matrices de référence, l’adoption de protocoles standardisés et enfin 
l’augmentation de la connaissance des aspects biochimiques associés au 
développement de la pathologie. Toutes ces améliorations pourraient 
aboutir à un diagnostic et un traitement plus précoce de la maladie 
d’Alzheimer. 
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Principes de Résonance des Plasmons de Surface et sélection des 
aptamères 
La Résonance des Plasmons de Surface (SPR en anglais) et 
l’Electrophorèse Capillaire (EC) ont été utilisées pendant le travail de 
thèse. 
Dans cette partie, les principes des techniques sont détaillés, notamment 
en portant une attention particulière aux principes physiques qui 
permettent la détection par SPR et aux différentes méthodes de sélection 
où l’EC est utilisée pour l’obtention des aptamères. 
 
Principes de base de SPR 
Parmi les phénomènes physiques exploités pour le développement d’un 
biocapteur, la SPR est sans doute un de ceux qui rencontre le plus de 
succès. Bien que de nombreux exemples de capteurs en milieu homogène 
aient été décrits dans la littérature scientifique, un biocapteur est composé 
d’un élément biologique, tel qu’un anticorps, un brin d’ADN etc., en 
contact direct avec un transducteur du signal. Ce dernier sert à transformer 
l’interaction biologique en un signal détectable analytiquement (Figure 3).  
 
Figure 3 : Principes et principaux composants d’un biocapteur. 
 
Appendix II. Résumé de thèse – Français 
164 
En SPR la transduction est assurée à travers le couplage entre les 
polaritons de surface, présents à l’interface métal-matériel diélectrique, et 
une radiation à longueur d’onde adaptée pour pouvoir résonner avec les 
électrons du métal.  
Dans des conditions favorables, qui varient en fonction des matériaux 
utilisés (type de film métallique, prisme) et de la configuration des 
éléments optiques dans l’espace (angle d’incidence de la source de 
radiation), les électrons sont excités collectivement et produisent, en 
conséquent, une onde évanescente qui traverse le film métallique jusqu’à 
ce qu’elle rejoigne la face en contact avec le matériel diélectrique. Pour 
cette raison, les phénomènes qui apportent des variations à l’indice de 
réfraction du diélectrique et qui sont produits dans les 500 nm de distance 
de la surface métallique (dans le cas des films d’or), sont immédiatement 
détectés de manière très sensible.  
Si l’on compare cette technique avec celle la plus couramment utilisée (la 
technique ELISA) nous pouvons mettre en avant plusieurs avantages : a) 
la révélation se fait en temps réel et sans avoir besoin du marquage avec 
des chromophores, ce qui facilite grandement l’analyse des paramètres 
cinétiques de l’interaction, b) la surface de la puce peut être utilisée 
pendant plusieurs cycles, grâce à des protocoles de régénération, c) 
l’amplification du signal peut-être réalisée à travers différentes stratégies, 
dont une des plus communes concerne l’utilisation de nanostructures d’or 
ou d’autres matériaux. 
Dans les paragraphes suivants les propriétés de la SPR qui ont été 
exploitées au cours du travail sont reportées de manière plus détaillée, en 
mettant en évidence la versatilité de la technique dans plusieurs domaines 
de la bioanalyse.  
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SELEX et Non-SELEX : avantages et inconvénients des techniques pour la 
sélection des aptamères  
Au cours de l’année 1990, deux groupes de recherches ont développé une 
technique appelée aujourd’hui SELEX13. Cette technique est divisée 
principalement en quatre passages fondamentaux : a) la banque d’ADN ou 
d’ARN est synthétisée et ensuite incubée avec la cible pour laquelle on 
veut obtenir l’aptamère (b). La séparation des séquences d’ADN affines de 
celles à faible affinité est effectuée à travers différentes méthodes, et elle 
est suivie par une amplification PCR (c) qui enrichit l’échantillon 
seulement avec les brins souhaités. A la fin de la méthode, le brin 
complémentaire qui est produit est éliminé (d) et le processus peut être 
répété jusqu’à 15 fois (comme résumé dans la Figure 4).  
 
 
Figure 4: Technique de sélection SELEX pour l’identification des aptamères. 
 
La forte résolution de l’EC a été exploitée durant ce travail. Cette 
technique est très avantageuse par rapport à d’autres méthodes de 
                                                 
 
13
 SELEX: Systematic Evolution of Ligands by EXponential enrichment 
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séparation habituellement employées. Par exemple, la cible n’a pas besoin 
d’être immobilisée sur un support adapté à la sélection, donc elle reste 
complètement accessible à la banque d’ADN en exposant tous les sites qui 
garantissent le mécanisme de reconnaissance moléculaire. De plus, avec 
l’EC il est également possible d’estimer l’affinité de la banque envers la 
cible, en calculant la surface du pic des espèces présentes dans le 
capillaire.  
Comme pour l’EC-SELEX, l’EC-Non-SELEX possède les mêmes 
propriétés. La différence principale entre les deux méthodes demeure au 
niveau de l’amplification PCR, qui, pour l’EC-Non-SELEX, n’est pas 
effectuée entre chaque cycle, mais uniquement lors du dernier cycle de 
séparation. Ceci permet une réduction très importante du temps de 
sélection, avec un processus réalisé en quelques heures. Cependant, elle 
fournit un échantillon très peu enrichi et qui est donc plus difficile à 
interpréter à cause de la présence d’une population très variée de brins 
d’ADN. 
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Objectif de la thèse 
 
Cette thèse a comme objectif principal le développement d’une méthode 
d’analyse de la protéine tau par voie SPR. Au début, des anticorps 
commerciaux ont été utilisés pour leur capacité à interagir sélectivement 
avec la cible, et les informations récoltées durant la mise au point de la 
méthode directe ont servi au développement de l’essai sandwich, avec ou 
sans nanostructures de carbone. Ces structures permettent une grande 
amplification du signal analytique dont le principe est décrit dans le 
paragraphe suivant.  
 
Afin d’étudier la faisabilité d’un processus de sélection des aptamères 
pour la protéine tau, deux techniques ont été comparées (EC-SELEX et 
EC-Non-SELEX) et les raisons qui ont permis le choix de l’une ou de 
l’autre sont analysées. Ici la SPR a été utilisée pour évaluer l’affinité des 
séquences obtenues, en montrant sa versatilité dans plusieurs domaines de 
la bioanalyse. 
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Immunocapteur pour la protéine tau 
Le développement de l’immunocapteur pour quantifier la protéine tau a 
été réalisé grâce à une étroite collaboration avec le groupe de recherche du 
professeur Cicchi, qui a fourni les nanotubes de carbone (CNTs) utilisés 
pour l’amplification du signal analytique (Figure 5) 
 
 
Figure 5 : Représentation de l’essai immunochimique. 1) Essai direct ; l’anticorps 
primaire est immobilisé sur la surface du capteur et sert pour assurer la reconnaissance 
moléculaire afin de capturer la cible. 2) Amplification du signal avec un anticorps 
secondaire marqué avec des nanotubes de carbone (CNTs).  
 
Les CNTs ont déjà été utilisés pour l’analyse de l’EPO14 par voie SPR et 
ils ont montré de fortes capacités d’amplification du signal analytique. Ces 
structures peuvent donc être proposées comme alternatives aux structures 
métalliques, qui sont plus souvent utilisées en SPR. Parmi les 
caractéristiques qui permettent l’amélioration du signal, on peut indiquer 
leur géométrie, à travers laquelle l’indice de réfraction du milieu est 
modifié de manière significative, et l’augmentation de la surface dont 
l’anticorps et l’analyte disposent pour établir leurs interactions. 
  
                                                 
 
14
 EPO : érythropoïétine, protéine du corps humain de 34 KDa. 
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Résultats et discussion 
Durant l’analyse, la protéine tau a été injectée à une concentration 
comprise entre 125 pM et 250 nM, et détectée tout d’abord avec un 
anticorps monoclonal qui reconnait la cible dans la région comprise entre 
l’acide aminé 189 et 195 (clone de l’anticorps 39E10). L’immobilisation 
du récepteur a été réalisée grâce à la technique du couplage-amino, qui 
permet l’exploitation des groupes aminés présents à la surface des 
protéines pour assurer la formation d’une liaison covalente entre la surface 
du capteur et la protéine elle-même. La valeur du pH (4,0, maintenu avec 
tampon acétate 10 mM) pour l’immobilisation a été définie grâce à un test 
de pré-concentration qui a permis d’identifier les conditions les plus 
adaptée à la fonctionnalisation de la surface à base de dextrane d’une puce 
d’or (CM5, commercialisé par GE Healthcare). La méthode ainsi 
développée permettait de quantifier la protéine tau dans un tampon et dans 
une solution conçue pour avoir une composition similaire à celle du 
liquide céphalorachidien (LCR). Dans ces conditions la sensibilité 
analytique reportée était de l’ordre du nM pour les deux milieux 
considérés, mais de meilleures performances en matière de répétabilité et 
d’amplitude du range linéaire ont été observées dans le LCR artificielle 
(aLCR) (Figure 6). 
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Figure 6: test direct avec l’anticorps primaire en aLCR 
 
Le résultat obtenu est prometteur si on le compare à ceux obtenus par 
d’autres auteurs en littérature, car une limite de détection de l’ordre du nM 
avait été précédemment reportée avec l’utilisation d’un essai sandwich, 
tandis qu’ici nous n’avons utilisé qu’un seul anticorps. Les raisons qui ont 
permis d’obtenir ces performances doivent être probablement recherchées 
dans la capacité de la surface de dextrane à capturer une quantité de cible 
plus importante grâce à sa conformation 3D. De plus, l’analyse du aLCR 
est sans doute plus adaptée pour le dépistage précoce de la maladie 
d’Alzheimer. Elle révèle aussi la nécessité de développer une matrice 
certifiée (CRM), qui pourrait améliorer les performances des méthodes 
conventionnelles. 
Le test sandwich, conçu en utilisant comme base l’essai direct décrit 
auparavant, a utilisé un anticorps secondaire (clone tau12, monoclonal) 
qui reconnait la protéine tau dans sa partie N-terminale. Comme pour le 
premier essai, la méthode développée a permis la détection en aLCR en 
améliorant les performances de l’essai jusqu’à une limite de 2,5 nM 
(Figure 7B), deux fois inférieure à la précédente, mais loin des niveaux 
atteints par l’analyte dans la matrice.  
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Figure 7 : A) absence d’interaction entre l’anticorps secondaire et la surface 
fonctionnalisée avec l’anticorps primaire ; B) signaux enregistrés pour des concentrations 
de protéine tau de 1 à 25 nM.  
 
L’injection du récepteur secondaire en absence d’analyte n’a pas montré 
de contributions aux signaux venants de l’interaction entre les deux 
anticorps (Figure 7A), et le même comportement a été observé pour 
l’interaction avec l’albumine humaine (HSA). 
Afin d’atteindre le niveau pM nécessaire, le groupe du professeur Cicchi a 
réalisé l’oxydation et l’activation des nanotubes, pour permettre à la fois 
leur dispersion dans une solution aqueuse et l’ancrage covalent de 
l’anticorps. Cette deuxième étape a été facilitée par l’activation des 
nanostructures avec des groupes fonctionnels O-succinimide, dont nous 
avons vérifié la présence par spectrométrie infrarouge (IR) et par analyse 
élémentaire. Ensuite, trois paramètres ont été considérés pour rendre plus 
efficace la conjugaison de l’anticorps et permettre également l’obtention 
d’une dispersion stable. En particulier, le temps de sonication sur les 
nanostructures sans l’anticorps, le milieu où nous avons effectué la 
réaction et la concentration globale de l’anticorps ont montré leur 
importance dans le processus de conjugaison (Figure 8). 
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Figure 8 : Optimisation des paramètres pour la conjugaison de l’anticorps secondaire. 1) 
temps de sonication ; 2) milieu de conjugaison ; 3) rapport entre les concentrations de 
CNTs et la cible.  
 
Une amélioration significative du signal a été obtenue dans l’essai réalisé 
dans le tampon (Figure 9A). Toutefois, la régénération de la puce, avec 
des injections de courte durée de NaOH (24-48’’, 10 mM – 50 mM), n’a 
pas été possible, à cause de la présence des CNTs. 
 
 
Figure 9 : A) amplification du signal en tampon à travers l’utilisation des CNTs, comparé 
avec le signal d’une concentration équivalente de l’anticorps secondaire non marqué ; B) 
utilisations de CNTs centrifugés pour l’amplification des signaux de la protéine tau dans 
la région du pM. 
 
Parmi toutes les causes pouvant affecter le processus de régénération du 
capteur, la dispersion des nanotubes en structure de différentes longueurs 
semble la plus probable. Il est connu que les CNTs sont composés de 
fractions dont la taille varie beaucoup, pouvant arriver à des valeurs de 
l’ordre du µm. Ces derniers ont une tendance à interagir de manière très 
forte avec eux-mêmes et peuvent donc produire une couche très épaisse de 
CNTs qui n’est pas accessible à la solution de régénération. En 
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introduisant une étape de centrifugation, réalisée à faible régime de 
rotation (3000 rcf) et pour une courte durée (3 minutes), nous avons réduit 
la présence en dispersion de la fraction de plus grande taille. De cette 
manière, la régénération de la puce a été rétablie. Grâce à cela, le 
comportement de l’interaction cible-anticorps à des concentrations de 
l’ordre du pM a pu être étudié (Figure 9B). Une relation linéaire entre la 
concentration de l’analyte et le signal a été observée, jusqu’à des valeurs 
de tau de l’ordre du nM. Au-delà, une déviation de la linéarité vers une 
relation de type exponentielle a été montrée, probablement due à une 
augmentation des interactions entre les différents nanotubes.  
 
Conclusions – immunocapteur  
Dans cette partie du travail, l’utilisation des CNTs pour augmenter le 
signal d’un immunocapteur SPR conçu pour la détection de la protéine tau 
a été décrite. Grâce à l’utilisation de ces nanostructures, le signal 
analytique a été amplifié de deux ordres de grandeur par rapport à la 
méthode directe. Ceci permet ainsi d’atteindre une limite de détection pour 
la protéine tau de l’ordre du pM avec une répétabilité acceptable (CV 
14%) entre les différents lots de nanotubes testés.  
Une optimisation de la méthode pourrait porter sur une sélection plus fine 
des longueurs des nanotubes afin d’obtenir un processus globalement plus 
contrôlable, mais, même en l’état actuel des choses, ces nanostructures 
peuvent être considérées comme une nouvelle étape pour le dépistage de 
la maladie d’Alzheimer.  
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Sélection d’un élément de reconnaissance de type aptamère pour la 
détection de la protéine tau 
La deuxième partie des travaux de recherche a été réalisée au sein du 
département de pharmaco-chimie moléculaire (DPM) de l’Université 
Grenoble Alpes. Le but de cette partie du travail était de se consacrer au 
développement d’un élément de reconnaissance moléculaire de type 
aptamère, capable, par ses propriétés de stabilité et de reproductibilité dans 
la production des différents lots, de rivaliser avec les anticorps comme 
outil d’analyse de la protéine tau. La technique qui permet l’obtention des 
aptamères prend le nom de SELEX et se base sur l’enchaînement d’étapes 
de séparations, suivies par des étapes d’amplification, qui sont répétées en 
boucle jusqu’à environ 15 fois afin d’atteindre des résultats optimaux. 
Dans la méthode, moins répandue, appelée EC-Non-SELEX, les étapes 
séparatives sont effectuées consécutivement, avant de procéder à une seule 
amplification par PCR.  
Après avoir comparé les résultats de ces deux méthodes, nous avons isolé 
un nombre limité de séquences d’ADN pour déterminer leur affinité 
envers la cible via Anisotropie de Fluorescence (FA) et par SPR.  
 
Résultats et discussion 
Avant de pouvoir commencer la sélection, des étapes préliminaires ont été 
réalisées pour assurer la séparation entre la banque d’ADN (marquée avec 
de la fluorescéine et constituée de 77 nucléotides, dont 30-mer sont 
obtenues d’une manière aléatoire afin d’obtenir un nombre de séquences 
différentes de l’ordre de 1015) et la protéine tau. Cette étape a permis 
d’identifier la zone de l’électrophérogramme où les séquences d’intérêt 
ont été récoltées. A cause de la présence de plusieurs pics dans le tracé 
électrophorétique, nous avons mesuré la mobilité des espèces présentes à 
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des valeurs de pH différentes (3,0 ; 5,5 ; 7,4). Seule la mobilité de la 
protéine tau était sensible à ces types de variations : cela nous a permis 
d’identifier la fenêtre de collection (Figure 10).  
 
 
Figure 10 : a) fenêtre de collection pour le CE-SELEX et b) pour le CE-Non-SELEX. Le 
pic de la protéine tau (trait en pointillé) migre plus rapidement par rapport aux molécules 
d’ADN libre (trait continu), qui sont éliminées. Les tracés électrophorétiques sont 
obtenus dans les mêmes conditions à 20 kV, 25°C et les molécules sont détectées par UV, 
en mesurant l’absorbance à 200 nm. 
 
Ensuite, une analyse de PCR quantitative (qPCR) a permis de mettre au 
point la concentration initiale de cible à incuber avec la banque et les 
nombres de cycles PCR optimaux pour ne pas amplifier des « primer 
dimer ». En effet, en ce qui concerne le premier aspect, la concentration de 
cible doit être de deux ordres de grandeur plus faibles que la constante de 
dissociation Kd estimée lors de l’interaction avec la banque. Nous avons 
estimé une concentration de tau initiale de 0,750 µM en se basant sur les 
tracés électrophrétiques ; cependant, l’analyse en qPCR a révélé la 
formation d’une quantité de complexe très faible, qui ne permettait pas 
une amplification sélective des brins les plus affins. En augmentant la 
concentration de protéine en contact avec la banque à 7,5 µM, la qPCR a 
permis de montrer qu’il y avait formation de complexe entre la banque et 
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la protéine tau. En effet, la fraction collectée en présence de la cible a 
montré des Ct (nombre de cycles seuils à partir desquels il y a 
amplification) inférieurs à la fraction collectée sans cible (Ct= 6 contre Ct= 
18 ; plus la valeur est faible, plus le nombre d’amplicons est important). 
Bien que la sélection par voie SELEX ait été réalisée dans ces conditions, 
l’évaluation du complexe par EC, n’a pas montré une évolution vers des 
brins plus affins pour la tau. Par contre, l’utilisation de la méthode        
EC-Non-SELEX, a montré une évolution après seulement trois cycles de 
sélection  
 
 
Figure 11 : Complexe d’affinité issu de deux processus de sélection. a) EC-Non-SELEX ; 
augmentation des aires qui représentent le complexe d’affinité stable (observé avec un 
temps de migration de 9,8 minutes) durant les trois rounds. Les aires dérivées de la 
formation du complexe avec la banque et celle en présence du premier round ont montré 
les mêmes valeurs, donc seulement la deuxième est représentée dans la figure. b) EC-
SELEX ; aire du complexe d’affinité avec la banque (trait pointillé) et avec le pool 
sélectionné après le round 2 (trait continu).  
 
La formation de sous-produits, dérivants de l’amplification PCR, est peut-
être une des causes qui ont empêché au SELEX conventionnel de produire 
l’augmentation d’affinité recherchée. En effet, lors de la formation du 
double brin, une température de fusion (Tm de l’anglais Temperature of 
Melting) plus faible par rapport à celle de la banque a été observée pour 
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l’EC-SELEX, indiquant, probablement, l’amplification prépondérante de 
brins plus courts que la banque (que l’on peut associer à des sous-
produits). 
L’échantillon collecté du processus d’EC-Non-SELEX a été retenu et 
envoyé à l’étape de séquençage, qui a été réalisé par NGS15. Dans cette 
méthode, l’absence de l’étape de clonage et l’utilisation d’un système 
d’analyse très rapide ont permis d’avoir des milliers de séquences (4792), 
toutes potentiellement capables d’interagir avec la protéine tau avec la 
même affinité. Une analyse des séquences par logiciels bio-informatiques 
(PATTERNITY – Seq et MEME16) a montré une très grande diversité de 
la population des séquences récoltées. Cependant, cinq brins ont été isolés 
afin d’effectuer une caractérisation de l’affinité par voie expérimentale 
(FA et SPR). L’anisotropie de fluorescence permet, en utilisant des 
volumes d’échantillon très petits (10 µL), d’estimer l’affinité dans des 
conditions qui reflètent celles de la sélection. Suite aux résultats obtenus 
en FA, les séquences 4133, 3146 et 433 ont montré une meilleure affinité 
par rapport à celle de deux autres testées et de la banque (Figure 12a et b). 
  
                                                 
 
15
 NGS: Next Generation Sequencing 
16
 MEME: Multiple Em for Motifs Elicitation 
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Figure 12 : a) Variations d’anisotropie de fluorescence des aptamères 3146 (triangles), 
4618 (carrés) et pour la banque (cercles) à des concentrations de tau croissantes (entre 
0.02 et 0.7 µM). b) valeurs de mêmes séquences à faible (0.04 µM) et haute 
concentration (0.3 µM) de cible. 
 
L’analyse par SPR se fait en immobilisant la protéine tau sur la surface à 
base de dextrane d’un capteur CM5 commercial, en exploitant les groupes 
carboxyles présents sur le capteur pour le couplage-amino. Les courbes 
dérivantes de l’interaction sont reportées en Figure 13. 
 
 
Figure 13 : Signaux des séquences isolées mesurées par SPR. 
 
Les résultats obtenus lors de l’analyse par SPR concordent avec les 
mesures d’anisotropie, ce qui est très encourageant si l’on considère la 
diversité des deux techniques. Les séquences ont été injectées à la même 
concentration (1 µM) sur la puce fonctionnalisée avec la tau. L’aptamère 
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3146 possède une meilleure affinité par rapport aux autres. Si l’on 
considère le signal obtenu du brin 3146 comme Rmax, il est possible 
d’estimer une Kd autour du nM, bien que cette valeur ait besoin d’analyses 
supplémentaires afin de la confirmer. 
 
Conclusions 
La sélection rapide d’aptamères pour la protéine tau a été décrite dans ce 
travail de recherche, où la méthode conventionnelle de l’EC-SELEX a 
montré des limites par rapport à l’EC-Non-SELEX, qui a en revanche 
permis d’accomplir la tâche que nous nous étions fixée.  
Même si les rounds de sélection ont été fortement réduits par rapport à 
d’autres techniques reportées dans la littérature scientifique, une grande 
variabilité des séquences a été observée. 
Des techniques issues de la bio-informatique ont été appliquées pour 
surmonter cette difficulté, en s’appuyant sur l’utilisation de logiciels 
préalablement développés (PATTERNITY-Seq et MEME). Ces derniers 
n’ont pas réussi à identifier des séquences consensus aptes à limiter la 
variabilité observée ; il reste donc un grand potentiel inexploré, qui 
pourrait conduire à des aptamères plus fortement affins pour la tau, par 
rapport à ceux qui ont été décrits dans cette thèse.  
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Conclusions Générales 
Dans cette thèse, la détection de la protéine tau dans un but de diagnostic a 
été évaluée en considérant deux aspects différents. En premier lieu, le 
travail a concerné le développement d’un test immunochimique avec des 
anticorps monoclonaux commerciaux. Dans un deuxième temps, nous 
avons développé une méthode de sélection pour obtenir un ou plusieurs 
aptamères spécifiques de la protéine tau. 
Dans ces deux approches, l’utilisation de la technique SPR, grâce à ses 
propriétés et à sa versatilité, a permis de quantifier la cible 
(immunodosage) ou d’estimer les affinités des récepteurs sélectionnés. 
Pendant le développement de l’immunocapteur, une partie importante du 
temps a été consacrée à la conception de stratégies d’amplification 
innovantes pour atteindre une sensibilité suffisante et adaptée aux niveaux 
de la protéine tau (pM) généralement présents dans le CSF, aussi bien 
chez les sujets sains que chez les sujets atteints de démence.  
Pour atteindre ces objectifs, l’utilisation de nanostructures de carbone 
(CNTs), comme marqueurs d’anticorps secondaire, a permis le 
développement d’un test sandwich grâce auquel nous avons obtenu une 
limite de détection expérimentale de 125 pM. La formation d’agrégats 
entre les différents nanotubes en dispersion a initialement empêché la 
régénération du capteur. Le système a pu être à nouveau régénéré en 
utilisant une étape de centrifugation qui a abattu les nanostructures de plus 
grande taille. Ainsi, des développements ultérieurs, qui permettraient une 
sélection plus fine des nanotubes selon leur longueur, pourraient être 
envisagés. L’utilisation de CNTs directement immobilisés à la surface du 
capteur pourrait être tout autant utile, car elle permettrait d’exploiter les 
propriétés résiduelles de conductivité des nanostructures et aussi 
d’augmenter la capacité totale de capture du récepteur immobilisé. 
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La sélection d’aptamères anti-tau a été effectuée grâce au processus d’EC-
Non-SELEX qui a permis, en peu de rounds de sélection (3), de 
sélectionner un pool de séquences affines vis-à-vis de la protéine tau. Si 
les caractéristiques du processus utilisé sont assurément avantageuses en 
matière de temps nécessaire et de coût global, l’absence de passages 
répétés d’amplification, combinée au nombre limité de séquences qu’il est 
possible d’introduire dans le capillaire pour la séparation 
électrophorétique, a conduit à l’obtention d’une population de séquences 
très diversifiée. Cet aspect a été mis en évidence grâce au séquençage 
NGS qui a abouti à un séquençage très rapide de la population entière. 
Dans ce travail, l’analyse des séquences a concerné essentiellement la 
recherche de familles sur la base de motifs communs à plusieurs 
aptamères du pool, mais la présence d’une relation étroite et univoque 
entre séquence et spécificité pour la cible a été récemment mise en 
discussion. En effet, des analyses QSAR
17
 semblent attribuer plus 
d’importance à la présence de structures secondaires, indépendamment de 
la succession des bases présentes dans la séquence aptamérique. Des tests 
bioinformatiques plus poussés, ou sur des critères différents de ceux 
utilisés, pourraient être envisagés. 
En conclusion, si à ce jour, grâce également aux techniques qui permettent 
le couplage des anticorps avec les nanotechnologies, l’immunochimie joue 
un rôle prédominant, la sélection des aptamères, ayant encore une grande 
marge de croissance, peut assurément permettre à ce type de récepteurs 
d’être utilisés voire même de remplacer les récepteurs conventionnels dans 
le domaine du diagnostic clinique. 
 
                                                 
 
17
 QSAR: quantitative structure activity relationship 
